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ABSTRACT 
Pygopus plays an important role in canonical Wnt signaling by functioning in 
complex with T cell factor (TCF), B Cell Lymphoma 9 (BCL9) and ~-catenin to activate 
target gene transcription. Many cancers show mutational defects in components of the 
Wnt pathway, leading to ~-catenin overexpression and increased TCF-mediated 
transcription of the target genes. Pygopus is crucial to this target gene overexpression in 
that it is a required protein in the transcription complex. As such, we show pygopus is 
overexpressed in Epithelial Ovarian Cancer (EOC) cell lines and is required for their 
proliferation. To date pygopus function has only been studied in relation to its canonical 
Wnt signaling activity. However, we also demonstrate that pygopus functions outside the 
canonical Wnt pathway as a transactivator and that its presence is required for EOC 
proliferation regardless of whether it functions in the canonical Wnt signaling pathway. 
.------------ ---------------- -- -
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CHAPTER! 
INTRODUCTION 
1.1 Ovarian Cancer 
1.1.1 Incidence and Epidemiology 
Ovarian cancer is the second most common cancer, but the leading cause of death 
from gynecologic malignancies (Jemal et al, 2008). The American Cancer Society 
estimates ovarian cancer will account for 21650 or 3% of new cancer cases in American 
women in 2008, whereas they estimate 15520 or 6% of deaths from cancer in American 
women (Jemal et al, 2008). That makes ovarian cancer the 71h leading cause of a new 
diagnosis of cancer in women and the 5th leading cause of death from cancer in American 
women. 
Ovarian cancer incidence rates have slightly decreased over the past 30 years 
(Jemal et al, 2008). The lifetime risk of ovarian cancer in the general population is 
1.39%. This number can be expressed as 1 woman in 72 who will be diagnosed with 
ovarian cancer sometime in their lifetime (www.seer.cancer.gov accessed September 23, 
2008). The age-adjusted incidence rate is 13.3 cases per 100,000 women 
(www.seer.cancer.gov accessed September 23, 2008). The median age of diagnosis is 63 
years old and the median age of death from ovarian cancer is 71 years. The incidence of 
both diagnosis and death increased with age up to the age of 85 and then declined 
(www.seer.cancer.gov accessed September 23, 2008). The mean age of diagnosis is 
younger among women with hereditary or familial disease. 
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1.1.2 Histopathology 
Ovarian tumours display histologic heterogeneity. The World Health 
Organization (WHO) classifies ovarian tumours based on their histogenesis from the 
normal ovary. Ovarian cancers can broadly be divided into epithelial and non-epithelial 
types (see Figure 1.1 ). The majority of primary ovarian cancer tumours are Epithelial 
Ovarian Cancers (EOC). They constitute about two thirds of all ovarian neoplasms and 
an even greater proportion of ovarian malignant neoplasms. They occur predominantly 
in adults, with the malignant forms generally appearing later in life. They are derived 
from neoplastic transformation of coelomic epithelial cells on the surface of the ovary 
and the adjacent ovarian stroma. Nonepthelial ovarian cancers include sex-cord stromal 
tumours, which are derived from the nongerm cell components of the gonads; germ cell 
tumours, which are derived from the germ cells; and small cell tumours, which have an 
unknown origin and are associated with hypercalcemia (Kaku, 2003; Harrison et al, 
2006). 
Epithelial tumors are classified according to the predominant pattern of 
differentiation of the tumor cells (Table 1.1). The main histologic types are serous, 
mucinous, endometrioid, clear cell, transitional cell tumors (Brenner tumors), 
carcinosarcoma, mixed epithelial tumor, undifferentiated carcinoma, and others (Serov et 
al, 1973; Kaku et al, 2003). The different histologic types may be associated with 
different risk factors (Kurian et al, 2005). Stage distribution varies among the types of 
Epithelial Ovarian Cancer (see Figure 1.2). Serous carcinoma is predominantly found in 
stage III or IV. On the contrary, clear cell (63%), endometrioid (48%), and mucinous 
(71 %) carcinomas tend to remain confined to the ovary (stage I). The association 
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Table 1.1 
World Health Organization histological classification of ovarian tumors: surface 
epithelial-stromal tumors (Kaku et al, 2003). Epithelial tumors are classified according 
to the predominant pattern of differentiation of the tumor cells. 
Chapter 1 : Introduction 
I. Serous tumors 
(I) Benign 
I. Cystadenoma and papillary cystadenoma 
2. Surface papilloma 
3 Adenofibroma and cystadenofibroma 
(2) Of borderline malignancy (oflow malignant potential) 
I. Cystic tumor and papillary cystic tumor 
2. Surface papillary tumor 
3. Adenofibroma and cystadenofibroma 
(3) Malignant 
I. Adenocarcinoma, papillary adenocarcinoma, and papillary cystadenocarcinoma 
2. Surface papillary adenocarcinoma 
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3. Adenocarcinofibroma and cystadenocarcinofibroma (malignant adenofibroma and cystadenofibroma) 
2. Mucinous tumors, endocervical-like and intestinal types 
(I) Benign 
I. Cystadenoma 
2. Adenofibroma and cystadenofibroma 
(2) Of borderline malignancy (oflow malignant potential) 
I. Cystic tumor 
2. Adenofibroma and cystadenofibroma 
(3) Malignant 
I. Adenocarcinoma and cystadenocarcinoma 
2. Adenocarcinofibroma and cystadenocarcinofibroma (malignant adenofibroma and cystadenofibroma) 
3. Endometrioid tumors 
(I) Benign 
I. Cystadenoma 
2. Cystadenoma with squamous differentiation 
3. Adenofibroma and cystadenofibroma 
4. Adenofibroma and cystadenofibroma with squamous differentiation 
(2) Of borderline malignancy (of low malignant potential) 
I. Cystic tumor 
2. Cystic tumor with with squamous differentiation 
3. Adenofibroma and cystadenofibroma 
4. Adenofibroma and cystadenofibroma with squamous differentiation 
(3) Malignant 
I. Adenocarcinoma and cystadenocarcinoma 
2. Adenocarcinoma and cystadenocarcinoma with squamous differentiation 
3. Adenocarcinofibroma and cystadenocarcinofibroma (malignant adenofibroma and cystadenofibroma) 
4. Adenocarcinofibroma and cystadenocarcinofibroma with squamous differentiation (malignant adenofibroma 
and cystadenofibroma with squamous differentiation) 
( 4) Epithelial-stromal and stromal 
4. Clear cell tumors 
(I) Benign 
I. Adenosarcoma, homologous and heterologous 
2. Mesodermal (mullerian) mixed tumor (carcinosarcoma), homologous and heterologous 
3. Stromal sarcoma 
I. Cystadenoma 
2. Adenofibroma and cystadenofibroma 
(2) Of borderline malignancy (oflow malignant potential) 
I. Cystic tumor 
2. Adenofibroma and cystadenofibroma 
(3) Malignant 
I. Adenocarcinoma 
2. Adenocarcinofibroma and cystadenocarcinofibroma (malignant adenofibroma and cystadenofibroma) 
5. Transitional cell tumors 
(I) Brenner tumor 
(2) Brenner tumor of borderline malignancy (proliferating) 
(3) Malignant Brenner tumor 
(4) Transitional cell carcinoma (non-Brenner type) 
6. Squamous cell tumors 
7. Mixed epithelial tumors (specific types) 
(I) Benign 
(2) Of borderline malignancy (of low malignant potential) 
(3) Malignancy 
8. Undifferentiated carcinoma 
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Figure 1.1 
Stage distribution of various types of Epithelial Ovarian Cancers (adapted from 
Kaku et al, 2003). 
A. Staging of ovarian cancer is surgical and based on operative findings. B. Serous 
carcinoma is predominantly found in stage III or IV, whereas clear cell (63%), 
endometrioid ( 48% ), and mucinous (71%) carcinomas tend to remain confined to the 
ovary (stage 1). P < 0.0001 , x.2-test 
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A. 
Stage I: 
Stage II: 
Stage III: 
Stage IV: 
B . 
... ·-
Growth limited to the ovary 
Growth involving one or both ovaries with pelvic extension 
Tumor involving one or both ovaries with peritoneal implants outside the 
pelvis and/or positive retroperitoneal 
or inguinal nodes; the tumor is limited to the true pelvis but with 
histologically varified malignant extension to small bowel or omentum 
Growth involving one or both ovaries with distant metastasis; 
if pleural effusion is present, there must be positive cytological test results 
to allot a case to stage IV; 
parenchymal liver metastasis equals stage IV 
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between endometriosis and EOC varies among the histologic types. Clear cell and 
endometrioid carcinomas are highly associated with endometriosis (Kaku et al, 2003). 
Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a rare tumor 
typically affecting young women. It is an aggressive malignancy with a poor prognosis 
and few long-term survivors. The histogenesis ofSCCOHT and the mechanism of the 
development of the hypercalcemia are unknown (Harrison et al, 2006). 
1.1.3 Pathogenesis 
The molecular events leading to the development of epithelial ovarian cancer are 
unknown. However, there are two main hypotheses that have been proposed. The first is 
the "incessant ovulation" hypothesis (Fathalla, 1971). It postulates that the ovulation 
causes repeated minor trauma and repair of the covering epithelium as well as repeated 
exposure of the ovarian surface to the estrogen rich viscous follicular fluid. This affords 
an opportunity for genetic mutation and cellular neoplasm. This theory is supported by 
the total ovulatory years or cycles directly correlating with ovarian cancer risk 
(Casagrande et al, 1979; Purdie et al, 2003; Moorman et al, 2002; Tung et al, 2005). 
Risk for ovarian cancer is inversely related to number of pregnancies and lengths of 
breast-feeding and oral contraceptive use. These events, which interrupt ovulation, are 
protective factors against developing ovarian cancer. 
The second main hypothesis involves persistent exposure of the ovaries to high 
gonadotropin levels, promoting high estrogen concentrations, leading to epithelial 
differentiation, proliferation and possibly malignant transformation (Cramer, 1983). The 
increased gonadotropin levels could be produced by a nwnber of common chemicals and 
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drugs that may increase gonadotropins by enhancing estrogen degradation in the liver or 
by directly stimulating production by the pituitary. Alternatively elevated gonadotropins 
may result from primary ovarian failure, that can result from pelvic irradiation, exposure 
to chemicals or metabolites toxic to follicles, or ovarian infections such as mumps. 
Several other theories have been proposed with varying degrees of supporting 
evidence. In 1998, Risch proposed a hypothesis for the pathogenesis of ovarian cancer 
relating to the role of androgens in stimulating epithelial cell proliferation and the 
protective effects of progesterone. In 2008, a group of Australian scientists studied this 
hypothesis (Olsen et al, 2008). Using data from an Australia-wide population-based 
case-control study, they conducted a detailed analysis of ovarian cancer rates in women 
who used testosterone supplements or the androgenic medication Danazol and in women 
with factors possibly associated with high circulating levels of androgens, including 
polycystic ovary syndrome (PCOS), hirsutism and acne. Their results did not support the 
hypothesis that androgen-related disorders increase the risk of ovarian cancer, with the 
exception of an increased risk of serous borderline tumours in women who had PCOS. 
Women who had ever used testosterone supplements had an increased risk of ovarian 
cancer (OR 3.7; 95% CI 1.1-12.0); however, use of the androgenic medication Danazol 
did not increase risk (OR 1.0; 95% CI 0.4-2.9). 
Another hypothesis is that ovarian inflammation, with rapid DNA turnover, 
oxidative stress, and increased cytokine production, may play a role in ovarian cancer 
pathogenesis (Ness RB, Cottreau C., 1999; Ness et al, 2000). Several risk factors for 
ovarian cancer have some association with inflammatory changes: ovulation entails 
ovarian epithelial inflammation; talc, endometriosis, cysts, and hyperthyroidism may be 
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associated with inflammatory responses of the ovarian epithelium. The protective effect 
of hysterectomies and tubal ligations may be secondary to these gynecologic surgeries 
precluding irritants from reaching the ovaries via ascension from the lower genital tract. 
Using TNF-a deficient mice, Balkwill (2000) demonstrated that this proinflammatory 
cytokine was required for de novo carcinogenesis and that TNF-a is important to the 
early stages of epithelial tumor promotion. Therefore inflammatory cytokines may not 
contribute to the genetic damage that initiates the cancer but they may provide the driving 
force. 
1.1.4 Risk and Protective Factors 
1.1.4.1 Race and Ethnic Factors 
The incidence of EOC varies based on race and geographical location. The 
incidence rate of ovarian cancer is highest among white and Hawaiian women, 
intermediate among African-American, Hispanic and Asian-American women, and 
lowest among Native American women (Daly and Obrams, 1998). From 1986 to 1990, 
the incident rate among Caucasians was 50% higher than among African American 
women, both in pre- and post-menopausal populations. 
Western countries, including Canada, have high rates of ovarian cancer, 
approximately three to seven-fold greater than Asian countries and approximately double 
that of Central/South American countries (Petitti and Potterfield, 1992; Whittemore, 
1992; Whittemore et al, 1994). However, the rate of ovarian cancer is higher in Asian 
immigrants to the Western countries as compared to the rates in Asians overall. This 
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speaks to the socioeconomic factors that also may play a role in ovarian cancer 
pathogenesis. 
1.1.4.2 Reproductive and Hormonal Factors 
In keeping with the "incessant ovulation" and excess gonadotropin theories of 
pathogenesis, women with a greater number of ovulatory years or cycles are at greater 
risk of developing ovarian cancer (Casagrande et al, 1979; Purdie et al, 2003; Moorman 
et al, 2002; Tung et al, 2005). Nulliparity, infertility (RR = 1.36, 95% CI: 1.07, 1.75; 
Tworoger et al, 2007, see Table 1.2), early age of menarche (before age 12) or late age of 
menopause (after age 50) increase the number of ovulatory cycles and increase a 
woman's risk of ovarian cancer. Whereas risk for ovarian cancer is inversely related to 
things that inhibit ovulation, such as number of pregnancies, length of breast-feeding and 
length of oral contraceptive use (Adami et al, 1994; Hankinson et al, 1995; Risch et al, 
1983; Rosenblatt et al, 1993; Whittemore, 1992; Whittemore et al, 1994; see Figure 1.3). 
For women using oral contraceptives for >5 years, the risk ratio for ovarian cancer for 
~20 years since last use was 0.58 (95% confidence interval (CI): 0.39, 0.87), with no 
association found for >20 years since last use (rate ratio (RR) = 0.92, 95% CI: 0.61, 1.39) 
(Tworoger et al, 2007). 
Low dose OCPs are as or more effective than higher dose OCPs (Lurie et al, 
2007). When compared with women who never used hormonal contraception, users of 
OCPs with low estrogen (equal to or less than 0.035 mg ethinyl estradiol) and low 
progestin (less than 0.3 mg norgestrel) were at significantly reduced risk of ovarian 
carcinoma (odds ratio 0.19; 95% confidence interval 0.05-0.75). The risk among these 
~ ----~----------------------------------
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Figure 1.2 
Risk of Invasive Epithelial Ovarian Cancer in US White Women (adapted from 
Whittemore, 1994; Whittemore et al, 1992). Data sorted according to (A) Number of 
Term Pregnancies, (B) months ofbreastfeeding, (C) failed pregnancies (ectopic 
' 
pregnancies, abortions, miscarriages, and stillbirths), and (D) years of oral contraception 
(OC) use. Data based on six hospital-based studies and six population-based studies. 
Odds ratios are adjusted for age (A, B, C, D) , parity (B, C, D), and oral contraception use 
(A, B, C). 
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Table 1.2 
Ovarian Cancer Risk with respect to Contraception use and Infertility (Tworoger et 
al, 2007). Multivariate relative risk of invasive ovarian cancer among premenopausal 
Nurses' Health Study participants between 1976 and 2004 (United States), according to 
history of contraceptive method, other than oral contraceptive pills, and history of 
infertility. 
----------------- ---------------------
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No. 
Multivariate adjusted 
of No. of Age-person-years adjusted RR 
cases 
RR 95%CI 
Contraceptive type 
No tubal ligation 566 2,041,819 1.00 (ref) 1.00 (ref) 
Tubal ligation 59 457,308 0.63 0.66 0.50, 0.87 
No rhythm method 608 2,395,8I5 1.00 (ref) 1.00 (ref) 
Rhythm method 17 103,313 0.86 0.77 0.47, 1.26 
No diaphragm 601 2,4IO,l1I 1.00 (ref) 1.00 (ref) 
Diaphragm 24 89,0I6 1.50 1.27 0.83, I .92 
No condoms 588 2,340,962 1.00 (ref) I.OO (ref) 
Condoms 37 158,165 1.27 l.IO 0.78, 1.55 
No IUD 607 2,434,28I 1.00 (ref) 1.00 (ref) 
IUD 18 64,847 1.95 1.76 1.08, 2.85 
No foam 609 2,408,854 1.00 (ref) 1.00 (ref) 
Foam 16 90,273 0.92 0.82 0.50, 1.36 
No vasectomy 579 2,237,864 I.OO (ref) 1.00 (ref) 
Husband's 
46 26I,264 0.97 0.87 0.63, l.I9 
Vasectomy 
Infertility 
No 487 I ,870,756 I.OO (ref) 1.00 (ref) 
Yes (Female) 75 196,506 1.50 1.36 1.07, 1.75 
Yes (Male) II 29,8I5 1.39 1.23 0.68, 2.25 
-- ------------------------------------
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women was lower than among users of estrogen or progestin of high potency, but the 
difference was not statistically significant. 
With OCP being protective, Tworoger et al (2007) studied the effect of other 
methods of contraception in a large prospective epidemiologic study (US Nurses' Health 
Study, n=107,900). Intrauterine device use increased the risk of ovarian cancer (RR = 
1.76, 95% CI: 1.08, 2.85). Their results suggested other methods of birth control, 
including the rhythm method, diaphragm, condoms, foam, and vasectomy, did not 
increase or decrease ovarian cancer risk (see Table 1.2). 
Other protective factors include tubal ligations and hysterectomies (Whittemore, 
1994; Whittemore et al, 1992). Tubal ligation reduced the risk of ovarian cancer 
significantly when adjusted for age, oral contraceptive use, parity, and other ovarian 
cancer risk factors (multivariate relative risk [RR], 0.33; 95% confidence interval [CI], 
0.16 to 0.64) (Hankinson et al, 1993). There was a weaker inverse association between 
simple hysterectomy and ovarian cancer (RR, 0.67; 95% CI, 0.45 to 1.00) (Hankinson et 
al, 1993 ). Tubal ligations were found to decrease the rate of ovarian to an even greater 
extent, by 60% (odds ratio 0.39), in women who carried the BRCA1 Gene (Narod et al, 
2001 ). The protective effect has been postulated to be secondary these procedures 
limiting the upward migration of irritants and carcinogens through the vagina, cervix, 
uterus, and fallopian tubes to the ovaries and into peritoneal cavity (Whittemore et al, 
1992). Another potential mechanism is that both procedures can impair ovarian blood 
supply. 
With oral contraceptive use being a protective factor prior to the menopause, it 
might be presumed that postmenopausal hormone replacement the~apy may also provide 
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some protection. However postmenopausal estrogen replacement therapy may increase 
the risk of ovarian cancer. The American Cancer Society Cancer Prevention Study 
(Rodriguez et al, 1995) based on mortality data of 224 307 woman-years found an RR of 
1.7 (95% CI 1.1-2.8). A 14-year follow-up ofthis study confirmed these findings with 
an RR of 1.5 (95% CI 1.2-2.0) for every user and 2.2 (95% CI 1.5-3.2) for use of 10 
years or more (Rodriguez et al, 2001 ). Among former users, the RR decreased with time 
since last use. The addition of progesterone with estrogen in the hormone replacement 
therapy regimen has a protective effect and decreases the risk of ovarian cancer to near 
normal levels. The hazard ratio (HR) for invasive ovarian cancer in women assigned to 
estrogen plus progestin compared with placebo was 1.58 (95% confidence interval [CI], 
0.77-3.24) (Anderson et al, 2003). No appreciable differences were found in the 
distributions of tumor histology, stage, or grade for either cancer site. The authors 
concluded that their randomized trial suggested continuous combined estrogen plus 
progestin therapy may increase the risk of ovarian cancer (Anderson et al, 2003). 
A large cohort study suggested that endometriosis is an independent risk factor for 
epithelial ovarian cancer (van Gorp et al, 2004). They demonstrated a link between 
endometriosis and endometrioid and clear cell-carcinomas, which could not be explained 
by shared risk factors alone. The prevalence of endometriosis in mucinous, serous, 
endometriod, and clear cell ovarian carcinoma was 1.4, 4.5, 19.0, and 35.9%. The risk of 
malignant transformation of ovarian endometriosis was estimated to be 2.5%. Since 
endometriosis is a common cause of infertility, this may explain why infertile women are 
at increased risk of ovarian cancer. 
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1.1.4.3 Social and Environmental Factors 
Cigarette smoking, whether current or in the past, appears to be a risk factor for 
mucinous ovarian cancer, but not other types of EOC (Jordan et al, 2006; Tworoger et al, 
2008). In a meta-analysis of eight population-based case-control studies, one pooled 
analysis of case-control studies, and one cohort study, Jordan et al (2006) found that the 
risk of mucinous ovarian cancer doubled in current smokers compared to women who 
had never smoked (summary RR 2.1, 95% CI 1.7-2.7). There was no increased risk of 
serous (1.0, 95% CI 0.8-1.2) or endometrioid (0.8, 95% CI 0.6-1.1) cancers and a 
significant risk reduction for clear cell cancers (0.6, 95% CI 0.3-0.9). The risk of 
mucinous cancer increased with increasing levels of cigarette smoking. Risk of 
mucinous ovarian cancer in ex-smokers was 2.02 (CI 1.15-3.55; Tworoger et al, 2008), 
but returned to that of never smokers within 20-3 0 years of stopping smoking (Jordan et 
al, 2006). 
A proposed hypothesis for pathogenesis of ovarian cancer is upward migration of 
a carcinogenic or etiologic agent through the vagina, cervix, uterus and fallopian tubes 
and into the peritoneal cavity. This is the proposed mechanism of perineal talc increasing 
the risk of ovarian cancer. There is some data that indicates that talc may be transported 
retrograde through the fallopian tubes to the ovaries (Wehner, 1994). Some studies have 
shown an increased risk of ovarian cancer in women exposed to talc (Ness et al, 2000; 
Harlow et al, 1992), whereas some have not (Gertig et al, 2000). One explanation for the 
association between talc use and ovarian cancer is that in the past talc has been 
contaminated with significant amounts of asbestos, a known carcinogen (Cramer et al, 
1982). 
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The role of diet in ovarian cancer pathogenesis is unsettled. Significant 
heterogeneity and potential biases, even when prospective and controlled, limit 
interpretation of results. There is no high quality evidence that consumption of any 
macro- or micro-nutrient, supplement, tea, coffee, or alcohol significantly affects a 
woman's risk of developing ovarian cancer (Shu et al, 1989; Tworoger et al, 2006; 
Tworoger et al, 2008; Vainio and Bianchini, 2003; Huncharek and Kupelnick, 2001; 
Zhang et al, 2002; McCann et al, 2001; McCann et al, 2003; Bosetti et al, 2001; Kushi et 
al, 1999; Fairfield et al, 2001; Salazar-Martinez et al, 2003; Larsson et al, 2004; Larsson 
et al, 2006; Bidoli et al, 2001; Giovannucci and Wolk, 2004; Mommers et al, 2006; 
Koushik et al, 2006; Chang et al, 2007; Prentice et al, 2007; Steevens et al, 2007). There 
was a slightly increased risk of ovarian cancer in women who had not used oral 
contraception or post-menopausal hormones (Tworoger et al, 2008). Alcohol intake was 
not associated with ovarian cancer risk (Tworoger et al, 2008). More data is needed on 
any potential association between diet and ovarian cancer before any dietary 
recommendations can be made. 
The association between exercise and ovarian cancer is unclear. Multiple case-
control studies (Pan et al, 2005; Tavani et al, 2001; Bertone et al, 2002; Bain et al, 1996) 
and cohort studies (Bertone et al, 2001; Patel et al, 2006; Biesma et al, 2006; Hannan et 
al, 2004; Weiderpass et al, 2006) have assessed the association of recreational physical 
activity and ovarian cancer. Two case-control studies (Pan et al, 2005; Bain et al, 1996) 
showed larger risk reductions in obese women who exercised vigorously. The other 
studies found no significant effect of physical activity on risk of ovarian cancer. The 
non-recreational physical activity and epithelial ovarian cancer was assessed in three of 
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those studies (Pan et al, 2005; Tavani et al, 2001; Patel et al, 2006). Two of the studies 
(Pan et al, 2005; Patel et al, 2006) found no relationship with risk of ovarian cancer. The 
other reported a modest inverse association with higher levels of occupational physical 
activity (Tavani et al, 2001). One study (Anderson et al, 2004) found a positive 
relationship between vigorous activity and EOC, whereas others have reported no 
significant association or a small inverse association (Pan et al, 2005; Bertone et al, 2001; 
Weiderpass et al, 2006; Bertone et al, 2002). Patel et al (2006) reported a significantly 
increased risk of ovarian cancer with the highest number of hours sitting each day, 
whereas two other studies (Zhang et al, 2004; Dosemeci et al, 1993) demonstrated no 
relationship between sedentary activity and EOC. 
There appears to be increased risk of ovarian cancer with a high body mass index 
(BMI). A meta-analysis looked at 28 studies (Olsen et al, 2007). 24 of the 28 studies 
demonstrated an increased risk of ovarian cancer with obesity, 10 of which reached 
significance. When averaged in the meta-analysis, the pooled effect estimated for adult 
obesity was 1.3 (95%, CI 1.1-1.5) with a smaller increased risk in overweight individuals 
(OR1.2; 95%CI1.0-1.3). There was no evidence that the association varied for the 
different histological subtypes of ovarian cancer. However other papers have the risk as 
different among different histologic subtypes (Olsen et al, 2008). Obesity was positively 
associated with clear cell tumors (Odds Ratio 2.3; 95% CI 1.2-4.2) and serous peritoneal 
tumors (2.9; 1.7-4.9) but not invasive endometrioid, mucinous, or invasive serous tumors 
overall (0.9; 0.7-1.2). Of the borderline subtypes, obesity was positively associated with 
serous (1.8; 1.1-2.8) but not mucinous tumors (1.1; 0.7-1.7). 
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1.1.4.4 Genetic Factors 
Genetic factors are estimated to account for 10 to 15% of ovarian cancer cases 
(Boyd et al, 2003; Li and Karlan, 2001; Risch et al, 2001; Pal et al, 2005). A personal 
history of breast cancer, especially at a young age, or a family history of breast or ovarian 
cancer is one of the strongest risk factors for ovarian cancer, increasing a woman's risk of 
EOC two- to six-fold (Schildkraut and Thompson, 1988; Kerlikowske et al, 1992; 
Bergfeldt et al, 2002). 
It is clinically important to distinguish between familial and hereditary EOC. 
Familial EOC represents a cluster ofEOC that occurs based on a combination of 
environmental and genetic factors. No single gene mutation is responsible. Women with 
a single family member with ovarian cancer have a 4-5% risk of ovarian cancer, whereas 
women with two affected relatives have a 7% risk (Daly and Obrams, 1998). Hereditary 
EOC, defined as having two first-degree relatives with EOC, is caused by a single gene 
mutation that strongly contributes to the pathogenesis of the EOC. The lifetime risk of 
developing ovarian cancer in women with a family history of hereditary EOC is 20-50% 
(Boyd, 2003). 
Three hereditary ovarian cancer syndromes exist: the breast and ovarian cancer· 
syndrome; "site-specific" ovarian cancer; and the Hereditary Nonpolyposis Colorectal 
Cancer (HNPCC) syndrome, also known as Lynch Syndrome. The first two are 
associated with the BReast CAncer susceptibility proteins (BRCA1 and BRCA2) whereas 
the HNPCC is associated with a number of germline mutations involving the DNA 
Mismatch Repair Pathway, primarily MSH2 and MLHl. 
------~---------------------------------------
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1.1.4.4.1 Site-Specific Ovarian Cancer 
This syndrome is generally recognized in individuals with two or more first or 
first and second degree relatives affected with EOC. The lifetime risk is 5%, 
approximately three fold higher than the general population (Stratton et al, 1998). No 
specific susceptibility gene has been identified for ovarian cancer. Therefore site-specific 
ovarian cancer and breast ovarian cancer syndrome are considered to be part of the same 
spectrum (Pharoah and Ponder, 2002). 
1.1.4.4.2 Breast Ovarian Cancer Syndrome 
Genetic studies of breast-ovarian cancer syndromes led to the discovery of BReast 
CAncer susceptibility gene 1 and 2 (BRCA1 and BRCA2). Mutations to either of these 
genes cause a highly penetrant, autosomal dominant genetic predisposition to ovarian and 
breast cancer. Founder effects of BRCA1 and BRCA2 mutations have been found in 
several populations, most notably Ashkenazi Jewish individuals, where 2.5% (1 in 40) 
carry one of the BRCA mutations (Struewing et al, 1995; Abeliovish et al, 1997). In 
comparison, 1 in 280 individuals in the general population carry a mutation (Ford et al, 
1995). 
Mutations to BRCAI and BRCA2 are responsible for 90% of hereditary ovarian 
cancer and 10-15% of all ovarian cancer. A meta-analysis of six studies (Takahashi et al, 
1995; Matsushima et al, 1995; Stratton et al, 1997; Berchuck et al, 1998; Khoo et al, 
2000; Risch et al, 2001) of unselected series of ovarian cancers indicates that 5. 7% 
(70/1236) of all ovarian cancers are associated with germline mutations of BRCAJ, while 
four such studies (Khoo et al, 2000; Risch et al, 2001; Takahashi et al, 1996; Foster et al, 
-~--------~----- -----~-------- --------------------------·------------~ --
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1996) indicate that 3.8% (28/738) of all ovarian cancers are associated with gennline 
mutations inBRCA2. The combined figure of9.5% is likely an underestimate, as all of 
these studies utilized indirect methods for mutation screening. Subsequent studies, that 
have used full sequencing of the BRCA genes, have shown BRCA mutations accounting 
for 15.3% (Pal et al, 2005) and 13.2% (Risch et al, 2006) of ovarian cancer. 
The absolute risk of ovarian cancer associated with the presence of BRCA 
mutations has been investigated by studies worldwide, with the reported estimates 
varying. A meta-analysis performed in 2007 provides the best estimate of the penetrance 
of the BRCA mutations (Chen and Parmigiani, 2007). Meta-analytic mean cumulative 
ovarian cancer risk for mutation carriers at age 70 years was 40% (95% CI, 35% to 46%) 
for BRCAJ and 18% (95%CI, 13% to 23%) for BRCA2 mutation carriers. The lifetime 
risk in the general population was 1.5%. In a population-based study in Ontario, Canada, 
the estimated penetrance by age 80 years for carriers ofBRCA1 mutations was 36% for 
ovarian cancer and 68% for breast cancer (Risch et al, 2006). 
The risk of ovarian cancer among BRCA heterozygotes is modified by 
environmental and genetic factors. A rare gene, HRAS 1 variable number of tandem 
repeat (VNTR) locus, has been shown to increase penetrance in BRCA1 carriers (Phelan 
et al, 1996). In terms of nongenetic risk modifiers, oral contraceptives and tubal ligation 
appear to significantly lower the risk of ovarian cancer in BRCA mutation carriers (Narod 
et al, 1998; Narod et al, 2001), consistent with their protective effect in the general 
population. The protective effects of tubal ligation and oral contraceptive use appear to 
be additive (Narod et al, 2001). 
------ ~------------------------------------------
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In women with BRCA mutations who develop cancers, breast cancer is normally 
diagnosed first (Metcalfe et al, 2005; Liou et al, 2006). The onset of ovarian cancer is 
related to the mutation type with BRCAI-associated ovarian cancers generally occurring 
in the fourth decade and BRCA2-associated ovarian cancer occurring in the sixth decade 
(Karla et al, 2003). In addition to breast and ovarian cancer, BRCA mutation 
heterozygotes have increased risk of other cancers including prostate cancer in male 
carriers. However, they do not have an increased risk of developing ovarian tumours of 
low malignant potential. 
Some studies have shown a better prognosis for hereditary ovarian cancer than for 
the sporadic type (Boyd et al, 2000). In a retrospective cohort study of a consecutive 
series of 933 ovarian cancers, the hereditary group had a longer disease-free interval 
following primary chemotherapy in comparison with the nonhereditary group, with a 
median time to recurrence of 14 months and 7 months, respectively (P<.OO 1) (Boyd et al, 
2000). Those with hereditary cancers had improved survival compared with the 
nonhereditary group (P=.004). For stage III cancers, BRCA mutation status was an 
independent prognostic variable (P=.03). It has been proposed that this reflects a higher 
cisplatin sensitivity relative to sporadic cases (Taniguchi et al, 2003; Cass et al, 2003). 
Research indicates prophylactic bilateral salpingo-oophorectomy reduces the risk 
of ovarian and breast cancer (Llort et al, 2007; Finch et al, 2006). The overall (adjusted) 
reduction in cancer risk associated with bilateral oophorectomy is 80% (multivariate 
hazard ratio = 0.20; 95% confidence interval, 0.07-0.58; P = .003) (Finch et al, 2006). 
Bilateral prophylactic mastectomy reduced the risk of breast cancer by approximately 
-----------------------
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95% in women with prior or concurrent bilateral prophylactic oophorectomy and by 
approximately 90% in women with intact ovaries (Rebbeck eta/, 2004). 
1.1.4.4.3 Hereditary Nonpolyposis Colorectal Cancer 
Hereditary nonpolyposis colorectal cancer (HNPCC) accounts for 4-6% of 
colorectal cancer. It can be divided into two categories, Lynch syndromes I and II 
(Lynch et al, 1991; Watson and Riley, 2005; Watson et al, 2008). Lynch syndrome I is 
an autosomal-dominant condition characterized by a high risk of early-onset colonic 
cancer, often proximal and with multiple primaries. Lynch syndrome II includes all the 
features of Lynch syndrome I along with the addition of other cancers, including 
endometrial, ovarian, urogenital, and other gastrointestinal primaries. Cumulative risks 
were highest for colorectal (78%) and endometrial cancers (43%, women only), but 
ovarian cancer also had an increased lifetime risk (9-12%) (Aarnio et al, 1995). HNPCC 
cancers account for 1% of ovarian cancers (Rubin et al, 1998). 
Lynch syndrome is caused by germline mutations in DNA-mismatch-repair 
(MMR) genes, predominantly in Mut L Homologue 1 (MLHI), Mut S Homologue 2 
(MSH2), and Mut S Homologue 6 (MSH6) and rarely in Postmeiotic segregation 
increased 1 and 2 (PMS 1 and PMS2) (Peltomaki and Vasen, I 997). All these genes are 
involved in the most important DNA repair mechanisms and are responsible for the repair 
of the nucleotide mismatch during DNA replication (Arzimanoglou et al, 1996). The 
MMR genes are located in five different chromosomes and work as heterodimers. The 
complex, made up of the protein MSH2 with MSH6 or MSH3, recognizes and binds the 
mismatch during S or G2 phases of cell cycle. MLH1 with PMS 1 or PMS2 are involved 
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in the resynthesis of the DNA strand (Buermeyer et al, 1999). The alteration of this 
pathway brings about an increased rate of mutations, leading ultimately mutations and 
dysfunction of growth-regulating genes (Thibodeau et al, 1993). 
The recommendations for OC include transvaginal pelvic ultrasound with color 
Doppler and serum CA125 every 6 months. Hysterosalpingo-oophorectomy should be 
considered in HNPCC women who undergo surgery for colorectal carcinoma. 
Prophylactic hysterectomy with bilateral salpingo-oophorectomy is an effective strategy 
for preventing endometrial and ovarian cancer in the Lynch Syndrome cohort (Schmeler 
et a/, 2006). Schmeler et a/ (2006) performed a case-control study of 315 women from 
1973 to 2004, and found there were no occurrences of endometrial, ovarian, or primary 
peritoneal cancer among the women who had undergone prophylactic surgery, whereas 
endometrial cancer was diagnosed in 69 women in the control group (33 percent) and 
ovarian cancer was diagnosed in 12 women in the control group (5 percent). The main 
disadvantages of prophylactic hysterectomy and bilateral salpingo-oophorectomy 
included the surgical complications and premature menopause. 
1.1.5 Clinical Manifestations 
Most of the Epithelial Ovarian Cancers (EOCs) are diagnosed between 40 to 60 
years of age, while non-epithelial ovarian cancers are more common in girls and younger 
women. Symptoms (the subjective evidence of disease as perceived by the patient) and 
signs (objective evidence of disease) are similar for all types. 
Ovarian cancer is called the "silent killer" because often signs and symptoms are 
vague and sometimes nonexistent until late in the course of the disease. As well, the 
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early signs and symptoms are common complaints in the population and have many 
possible causes, including some benign explanations. This contributes to the difficulty in 
recognizing and diagnosing ovarian cancer in its early stages. Because of this, clinicians 
often require a high index of suspicion to make a prompt diagnosis. Ovarian cancer 
should be considered in the differential diagnosis of any woman presenting with recent 
onset of abdominal or pelvic complaints, such as bloating, increase abdominal size, 
urinary urgency or frequency, difficulty eating or feeling full, abdominal pain or pelvic 
pain. Acute symptoms due to ovarian rupture or ovarian torsion are unusual. 
Goff et al (2000) surveyed 1725 women with ovarian cancer. The median age of 
the women was 52 and 70% had stage III or IV disease. 95% reported symptoms prior to 
their diagnosis. These symptoms were categorized as abdominal (77% ), gastrointestinal 
(70%), pain (58%), constitutional (50%), urinary (34%), and pelvic (26%). Only 11% of 
women with Stage IIII and 3% with Stage III/IV reported no symptoms before their 
diagnosis. The time required for a health care provider to make the diagnosis was 
reported as less than 3 months by 55%, but greater than 6 months by 26% and greater 
than 1 year by 11 %. 
Advanced disease was typically associated with abdominal distension, nausea, 
anorexia or early satiety due to the presence of ascites and omental or bowel metastases 
(Eitan et al, 2005). Dyspnea was occasionally present secondary to pleural effusion. 
Paraneoplastic syndrome and Trousseau's syndrome are possible, but uncommon. 
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1.1.6 Physical Exam 
With any patient, a thorough physical exam is a necessity. Particular focus must 
be paid to the abdominal and pelvic exams. Pelvic examination is an extremely sensitive 
method to detect ovarian cancer; 93% of women with ovarian cancer had palpable masses 
(Schutter et al, 1998). Therefore it follows that palpitation of an adnexal mass is the 
usual initial physical sign in a diagnosis of ovarian cancer. However pelvic masses are 
not specific for ovarian cancer. There are many causes of adnexal masses, including 
ovarian pathologies such as ovarian cysts, endometriomas, and metastatic carcinomas 
such as breast, colon and endometrial. Extraovarian masses include ectopic pregnancy, 
abscesses, cysts, fibroids, inflammatory bowel disease and pelvic kidney. 
In premenopausal women only 5-10% of adnexal masses will be malignant. 30-
60% of adnexal masses in postmenopausal women are malignant (Roman et al, 1997; 
Schutter et al, 1998). However, the presence of a solid, fixed pelvic mass is highly 
suggestive of an ovarian malignancy, with the diagnosis of malignancy almost certain if 
this fixed, irregular pelvic mass is associated with an upper abdominal mass or ascites. 
1.1. 7 Laboratory Evaluation 
CA-125 is the most well-known ovarian cancer biomarker. It consists of two 
major domains, A and B, which bind the monoclonal antibodies OC125 and M11, 
respectively (Nustad et al, 1996). The original clinical assay for CA-125 utilized only the 
OC125 antibody. The current CA-125 II assay, quantitfies CA-125 using both the OC-
125 and M 11 antibodies (Lloyd et al, 1997). 
Chapter 1: Introduction Wells; page 28 
Table 1.3 
Summary of Selected Screening Tools for Ovarian Cancer (Nossov et al2008). To 
be an effective screening test for ovarian cancer would require a minimum positive 
predictive value of 10% and a specificity of99% (Jacobs et al, 1993; Jacobs et al, 2004; 
National Institutes of Health consensus Conference, 1995). Currently no screening test 
meets those requirements. The John Hopkins group studied the combination ofCA-125, 
apolipoproteinA1 (down-regulated in cancer), a truncated form oftransthyretin(down-
regulated) and a cleavage fragment of inter-a-trypsin inhibitor heavy chain H4 (up-
regulated) (Zhang et al, 2004). The Yale group analyzed the combination of biomarkers 
that included leptin, prolactin, osteopontin, insulin-like growth factor II, macrophage 
inhibitory factor, and CA-125 (Lester et al, 2007; Visintin et al, 2008). The UCLA group 
studied four biomarkers (Su et al, 2007). 
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Screening Sensitivity, Specificity, Positive Negative 
modality Stage % % predictive predictive Special issues 
value,% value,% 
Early Cheap and available in most CA-125 50-62 95 57 70.6 laboratories. Poor sensitivity in early-
stage 
stage disease. 
Late 90 
stage 
Arbitrary cutoff of 3 em. Low 
Ultrasound All 96.8 77 29.4 99.6 specificity Better suited for 
stages differentiation of malignant and 
benign masses but not for screening. 
Ultrasound with All 98 87 94 95 Operator dependent. Poor Doppler stages reproducibility. Low specificity. 
Combination Better results compared with UIS and CA- All 
125 (ROC stages 78 99.9 20.7-26.8 99.9 ultrasound alone or single value of 
model) CA-125 with ultrasound. 
Early Nonspecific elevation in ovarian LPA 90 86.2 93.3 91.8 cancer and other gynecologic cancers. 
stage No correlation with disease status. I 
Late 98 
stage 
Panel of 4 serum tests, not all 
Johns Hopkins Early 83 94 60 14 available at most laboratories. Still group stage below the desired threshold for 
screening the general population. 
Yale group ( 6 Early Panel of 6 serum tests, not all biomarker 91.6 99.4 97.6 98.9 
panel) stage available at most laboratories. 
All 95.3 
stages 
Panel of 4 serum tests, all available at 
UCLA group (4 most laboratories. Sensitivity and 
biomarker Early 89 97 97.7 85 specificity even greater for mucinous 
panel) stage ovarian tumors. Still below the desired threshold for screening the 
general population. 
Late 97 99 98.6 98.1 
stage 
----------
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CA-125 is the most studied ovarian cancer biomarker. The research was initiated 
by the initial findings in the early 1980's, demonstrating that CA-125levels greater than 
35 U/ml was seen in 83% of patients with epithelial ovarian cancer (East et al, 1983; 
Canning et al, 1984)., whereas the surface epithelium of normal ovaries does not express 
CA-125 (Kabawat et al, 1983). Further research has revealed that elevated levels of CA-
125 were found in greater than 90% of patients with advanced ovarian cancer, but in only 
50% of patients with stage I disease (Nustad et al, 1996). 
CA-125 has also been shown to have a strong association with serous, rather than 
mucinous, endometroid and other subtypes of borderline ovarian tumours and ovarian 
cancers (Hogdoll et al, 2007). 
To be an effective screening test for ovarian cancer would require a minimum 
positive predictive value of 10% and a specificity of99% (Jacobs et al, 1993; Jacobs et 
al, 2004; National Institutes of Health consensus Conference, 1995). As a screening tool 
in the asymptomatic population, CA-125 has inadequate sensitivity (Helzisouer et al, 
1993; Skates et al, 2003). In a case-control study in 1993, Helzisouer et al found that the 
sensitivity of a CA-125 level greater than 35 U/mL within the first 3 years prior to 
diagnosis of ovarian cancer was 57% (95% confidence interval, 20% to 88%) and the 
specificity was 100% (95% confidence interval lower limit, 73%). Sensitivity and 
specificity decreased with increasing time to diagnosis. 
There are also a large number of false positive values due to CA-125 serum levels 
being elevated by another means. A wide variety of conditions elevating serum levels 
including other cancers (pancreatic, breast, lung, liver, bladder), diverticulosis, liver 
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cirrhosis, endometriosis, uterine fibroids, benign ovarian lesions, and physiologic 
conditions such as menstruation and pregnancy. CA-125 is not a useful screening test in 
premenopausal women because ovarian malignancy is rare at this age and the other 
causes ofCA-125 elevation listed above would be higher in the differential diagnosis. 
CA-125 is more useful in postmenopausal women, having a 97% positive predictive 
value (Brooks, 1994; ACOG Committee Opinion Number 280, 2002). 
Several studies have looked at the possibility of adding additional novel 
biomarkers to CA-125 to improve the sensitivity and specificity towards ovarian cancer. 
A group from John Hopkins studied the combination ofCA-125, apolipoproteinA1 
(down-regulated in cancer), a truncated form oftransthyretin(down-regulated) and a 
cleavage fragment of inter-a-trypsin inhibitor heavy chain H4 (up-regulated) (Zhang et 
al, 2004). The Yale group analyzed the combination ofbiomarkers that included leptin, 
prolactin, osteopontin, insulin-like growth factor II, macrophage inhibitory factor, and 
CA-125 (Lester et al, 2007; Visintin et al, 2008). The UCLA group studied four 
biomarkers (Suet al, 2007). No combination proved to be a sufficient screening test for 
the general public. 
1.1.8 Diagnostic Tests 
Ultrasound is the most useful non-invasive diagnostic test in women with adnexal 
masses. It is commonly the first diagnostic imaging performed as it can provide detailed 
imaging of the ovaries and allows for the detection of so no graphic morphologic features 
of an ovarian mass that may aid in differentiating between benign and malignant ovarian 
disease. Features suggestive of a malignant diagnosis include: a solid component that is 
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often nodular or papillary; septations that are greater than 2-3 mm thick; Doppler 
demonstration of blood flow into the solid component; presence of asci ties; peritoneal 
masses; enlarged nodes; and matted bowel. 
Computerized tomography (CT) or magnetic resonance imaging (MRI) are useful 
in determining local, distant and lymphatic spread of any ovarian cancer and is important 
in planning appropriate surgery. Choosing between these two modalities involves taking 
into account availability, cost, patient comfort, and radiation exposure. 
An ovarian mass may be the result of an extraovarian primary cancer. Therefore 
preoperative evaluation would include diagnostic modalities to evaluate the possibility of 
cancers that commonly metastasize to the ovary. These include breast, endometrial, 
colorectal, gastric, peritoneal and fallopian. Any patient with signs or symptoms of a 
gastrointestinal cancer, fecal occult blood or intestinal obstruction should undergo a 
barium enema or colonscopy. Both are more sensitive than CT scanning. Upper GI 
series is indicated if there are signs or symptoms of an upper GI malignancy. 
Mammography should be performed in the presence of any breast mass (Tserkezoglou et 
al, 2006). 
Image-guided biopsy is a diagnostic option when there is uncertainty as to 
whether an ovarian mass has an extraovarian origin or when neoadjuvant chemotherapy 
is being considered. Similarly, in patients with ascites, a pathologic diagnosis can often 
be made via paracentesis or thoracocentesis. 
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1.1.9 Management 
1.1.9.1 Surgical Management 
The initial management of ovarian cancer is almost always surgical. A surgical 
approach is necessary to obtain tissue to confirm the diagnosis, surgical stage the disease, 
and attempt optimal cytoreduction. To confirm the diagnosis the abdomen is explored to 
rule out other primary cancers that have potentially metastasized to the ovary. Surgeons 
examine the peritoneum, endometrium, fallopian tubes, colon, stomach (for gastric cancer 
with Krukenberg ovarian metastasis) and breasts. 
The stage (see Figure 1.2 for stages) of the disease is assessed surgically. Patients 
with stage I (confined to the ovary) and Stage II (confined to the pelvis) disease are 
managed with optimal surgical debulking Young et al, 1983; Young et al, 1990). 
Systemic chemotherapy may or may not be recommended. Patients with Stage III 
(disease spread throughout the peritoneal cavity or involving the paraaortic or inguinal 
lymph nodes) and Stage IV metastatic disease requires aggressive surgical cytoreduction 
followed by aggressive chemotherapy (Young et al, 1983). 
Clinical practice guidelines lay out the procedure for optimal de bulking (Morgan 
et al, 2008). This includes a vertical-incision laparotomy; collection of ascites or 
peritoneal washings; peritoneal biopsies from the pelvis, paracolic gutters, and suspicious 
areas from the undersurfaces of the hemidiaphragms; bilateral pelvic and periaortic 
lymph node dissection if evidence of disease outside the pelvis; omentectomy; total 
abdominal hysterectomy (TAH); unilateral salpingo-oophorectomy (USO) for stage I 
disease or bilateral salpingo-oophorectomy (BSO) for higher stage disease; and every 
attempt to achieve a cytoreduction to less than 1 em residual disease including a possible 
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radical pelvic dissection, bowel resection, appendectomy, diaphragm stripping and/or 
splenectomy. 
Many women with ovarian cancer are not receiving recommended comprehensive 
surgery (Goff et al, 2006; Goff et al, 2007). In a study of 10,432 women with a primary 
diagnosis of ovarian cancer who underwent at least an oophorectomy, almost half of 
women with early stage disease were not adequately staged with 21.4% of women 
receiving no additional staging procedures and 46.8% not have nodal sampling (Goff et 
al, 2006). In women with advanced disease, the percentage that had additional surgical 
procedures such as bowel resections was much lower than in institutions that report high 
optimal cytoreduction rates (Goff et al, 2006). The poor, elderly and minorities were 
especially susceptible to not receiving recommended comprehensive surgery (Goff et al, 
2007). Outcome varying with surgeon specialty (gynecologic oncologists vs obstetrician 
gynecologists or general surgeons). Patients with stage III ovarian cancer who received 
surgical treatment by gynecologic oncologists had a 25% reduction in 5-year mortality 
risk (Junor et al, 1999). 
1.1.9.2 Adjuvant Chemotherapy 
Therapy for newly diagnosed EOC is dependent on the extent of the disease. The 
majority of patients, approximately 75%, are diagnosed with stage III (disease that has 
spread throughout the peritoneal cavity or to neighbouring lymph nodes) or stage IV 
(metastatic disease). The standard of care for these patients are aggressive surgical 
debulking followed by systemic chemotherapy (Young eta/, 1983). 
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For the remaining 25% of patients, those with stage I (disease confined to the 
ovary) and stage II disease (disease outside the ovary, but confined to the pelvis), 
management begins with surgical cytoreduction (Heintz eta/, 2001; Young eta/, 1983; 
Young eta/, 1990). No further treatment is recommended for patients with well or 
moderately differentiated stage I disease (Young eta/, 1990). Women with high risk 
stage I or II EOC benefit from adjuvant chemotherapy. Patients with stage I or II EOC 
are recommendedto have chemotherapy if they have one or more of the following 
adverse features: 
• Stage IA or lB disease with poorly differentiated histology; 
• Tumour present on the external surface of the ovary; 
• Ruptured tumour capsule; 
• Ascites or positive peritoneal washings; 
• Stage II disease 
The current standard in chemotherapy is paclitaxel plus a platinum-based agent 
(Bolis et al, 1995; Young, 1975). This has not always been the case, as therapies have 
and continue to evolve. Platinum compounds, which include cisplatin and carboplatin, 
are proposed mechanism of action is DNA methylation and disruption of its binding 
(Taniguchi eta/, 2003). In an early study, women with advanced EOC were treated with 
cyclophosphamide (a mustard alkylating agent), doxorubicin (topoisomerase type II 
inhibitor and DNA intercalator) plus or minus cisplatin demonstrated the addition of 
cisplatin increased complete response rate (CR; 51% of patients treated with cisplatin had 
a normal physical exam, normal radiographic exams and normalization of tumour 
markers, versus 26% who did not receive cisplatin) and progression-free survival (PFS; 
Chapter 1 : Introduction Wells; page 36 
13.1 vs 7.7 months) (Omura et al, 1986). Therefore cyclophosphamide, doxorubicin and 
cisplatin (CAP) became the standard of care for advanced disease in the 1980's. A meta-
analysis concluded that median survival was improved by 1.91 months with the addition 
of doxorubicin to the cisplatin/cyclophosphamide regimen, but there was significantly 
added toxicity (West and Zweig, 1997). 
Paclitaxel (Taxol®) was found to be highly active in patients with advanced 
recurrent EOC clinically resistant to platinum-based chemotherapy (Einzig et al, 1992; 
Kohn et al, 1994); McGuire et al, 1989; Thigpen et al, 1994). It is proposed to act by 
promoting microtubule assembly by enhancing the action of tubulin dimers, stabilizing 
existing microtubules, and inhibiting their disassembly, thus interfering with the late G2 
mitotic phase, and inhibiting cell replication. In addition, the drug can distort mitotic 
spindles, resulting in the breakage of chromosomes. Paclitaxel may also suppress cell 
proliferation and modulate immune response. The major side effect of paclitaxel was that 
it produced frequent and severe, albeit manageable, myelosuppression (McGuire et al, 
1989; Thigpen et al, 1994). This data led to multiple randomized trials of platinum plus 
paclitaxel combination chemotherapy versus platinum plus cyclophosphamide. The 
GOG Ill (McGuire et a!, 1996) and OV -10 (Piccart eta!, 2000) studies demonstrated 
significant improvements in overall response, clinical CR, PFS, and overall survival. 
Eventually in the mid 1990's, paclitaxel plus a platinum-based chemotherapy became the 
first line chemotherapeutic treatment. 
Phase III trials have failed to demonstrate survival benefit from the addition of a 
third agent (gemcitabine, liposomal doxorubicin, epirubicin, topotecan, interferon 
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gamma) to the paclitaxel/carboplatin backbone ( du Bois eta/, 2006; Bookman, 2006; 
Scarfone eta/, 2006; Alberts eta/, 2008). 
The choice of second line medical therapy depends on whether the disease was 
sensitive or resistant to platinum-based chemotherapy. The generally accepted 
recommendation for women with platinum-sensitive relapse (defined as an objective 
response to previous platinum-based therapy and a significant relapse-free interval) is a 
platinum (either cisplatin or carboplatin) plus paclitaxel combination (National 
Comprehensive Cancer Network guidelines at 
http://nccn.org/professionals/physician_gls/default.asp). In the management of women 
with chemoresistant disease single agent therapy is usually chosen. Paclitaxel is the 
treatment of choice when an objective response has not been achieved with an initial 
platinum-based regimen (assuming paclitaxel was not part of the regimen). The drugs 
with the highest response rates in platinum- and paclitaxel-resistant disease are liposomal 
doxorubicin, oral etoposide, and topotecan (Rose eta/, 1998; Muggia eta/, 1997; Gordon 
eta/, 2000). Thus, these agents should be considered for initial salvage therapy in 
women with platinum-refractory disease. Since the reported response rates with all of 
these drugs is similar, the choice of agent is often driven by the side effect profile and the 
convenience of administration (Cannistra, 2004). 
Because of its relative lack of toxicity, tamoxifen is a reasonable choice in women 
for whom toxicity is a major concern. Gemcitabine, vinorelbine, leucovorin-modulated 
5-FU, and ifosfamide have similar response rates in platinum-resistant patients, but all 
have a side effect profile that is worse than tamoxifen. Altretamine and oxaliplatin have 
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minor activity in platinum-resistant disease, but can be considered fourth or fifth-line 
salvage regimens. 
1.1.9.3 Neoadjuvant Chemotherapy 
Aggressive cytoreductive surgery followed by adjuvant chemotherapy is the 
standard of care for advanced-stage ovarian cancer patients. The greatest survival benefit 
is seen in those with no gross disease left after the initial surgical cytoreduction. 
However, this represents only 23% of stage III patients and 8% of stage. IV patients. 
Neoadjuvant chemotherapy can decrease tumour load prior to surgery in patients with 
advanced disease that does not allow for optimal debulking (Schwartz et a/, 2008). 
Neoadjuvant chemotherapy may also be an option for patients with significant 
comorbidities that prevent or limit surgery or for women who present with massive 
ascites or poor performance status that may place them at high risk ofperioperative 
mortality. 
1.1.10 Prognosis 
The prognosis of endothelial ovarian cancer is generally poor. This is 
primarily due to nature of the symptomatology (symptoms are vague and often absent) 
and the late presentation of the disease. The majority of patients, approximately 75%, are 
diagnosed with stage III (disease that has spread throughout the peritoneal cavity or to 
neighbouring lymph nodes) or stage IV (metastatic disease). Five year survival for these 
patients who present with stage III or IV disease is less than 50%, dipping to less than 
one-in-eight patients with stage IV disease surviving 5 years (Heintz eta/, 2003). This 
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Table 1.4 
Survival by FIGO stage for patients with ovarian cancer, 1996-98 FIGO statistics 
(Heintz et al, 2003). 
.---------------------------~---·---
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Overall survival, percent 
FIGO stage Number of patients 
1 year 2 years 5 years 
IA 467 98.5 97.8 89.3 
IB 58 94.7 85.8 64.8 
IC 560 96.2 89.9 78.2 
IIA 73 93.1 88.9 79.2 
liB 105 91.4 82.7 64.3 
IIC 206 92.1 83.9 68.2 
IliA 120 86.6 76.1 49.2 
IIIB 251 86.1 65.5 40.8 
nrc 1653 81.5 61.1 28.9 
IV 511 64.7 39.3 13.4 
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denotes the importance of early diagnosis and the importance of finding diagnostic and 
therapeutic targets. 
1.2 The Wnt Signaling Pathway 
The Wnt extracellular signaling pathway (wingless in Drosophila) is one of a 
handful of evolutionarily-conserved signal transduction pathways throughout all of 
animal development (Cadigan and Nusse, 1997; Wodarz and Nusse, 1998; Hobmayer et 
al., 2000; Peifer and Polakis, 2000). It functions very similarly in many species, ranging 
from Hydra, a member of the evolutionarily old metazoan phylum Cnidaria (Hobmayer 
et al., 2000) to Drosophila, fruit flies, to the worms C. elegans to humans. It stands to the 
significance of the pathway that it is so conserved in so many species. 
Wnt pathways play a key role in normal and malignant development. Wnt 
signaling is involved in a large number of diverse and varied processes including 
embryonic development, cell polarity generation, cell fate determination, and cell 
division/proliferation (reviewed by Cadigan and Nusse, 1997; Moon et al., 1997; Wodarz 
and Nusse, 1998; Gradl et al., 1999; Moon et al., 2002; van de Wetering et al., 2002). 
The Wnt family of signaling ligands consists of a large number of secreted, 
cysteine-rich, glycoproteins that interact with Frizzled receptors at the cell membrane and 
activate downstream signaling pathways. There are at least four signaling pathways 
which includes the planar cell polarity (PCP), JNK, Wnt/Ca2+ and the most widely 
characterized canonical Wnt pathways (Reviewed by Veeman et al., 2003). Each 
pathway requires a separate Wnt ligand, has a different downstream signaling cascade, 
and has different target genes. 
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1.2.1 Canonical Wnt Signaling 
Tight control of the level of P-catenin plays a crucial role in regulating canonical 
Wnt signaling activity (reviewed by Wodarz and Nusse, 1998). In the absence ofWnt 
ligand, cytosolic P-catenin is phosphorylated by a complex containing the 
serine/threonine kinase Glygogen Synthase Kinase 3P (GSK-3p), the tumour suppressor 
adenomatous polyposis coli (APC), the scaffold protein Axin, along with Diversin and 
CK1 a (Behrens et al., 1998; Ikeda et al., 1998). The phosphorylated P-catenin is targeted 
by the P-TrCP 1 ubiquitin ligase for rapid degradation by the 26S proteosome, thus 
maintaining P-catenin at minimal levels (Aberle et al., 1997; Hart et al., 1998). 
Binding of Wnt to the Frizzled/LRP receptor complex activates the cytoplasmic 
protein Dishevelled (Dsh; Y anagawa et al., 1995) which, in association with Dapper 
(Dpr), inhibits the activity of the GSK-3P/APC/Axin/ CK1a/Diversin degradation 
complex (Noordermeer et al., 1994; Kishida et al., 1999; Lee et al., 1999; Smalley et al., 
1999). Stabilized P-catenin can then accumulate in the nucleus (Fagotto et al., 1998) 
where it derepressess Groucho and HDAC-dependent inhibition ofWnt target gene 
transcription (Cavallo et al., 1998; Roose et al., 1998; Brannon et al., 1999) by forming a 
complex with T cell factor (TCF), B Cell Lymphoma 9 (BCL9), and pygopus (Behrens et 
al., 1996; Molenaar et al., 1996; van Noort & Clevers, 2002; Kramps et al., 2002). This 
transcriptional regulatory complex functions by binding the promoters and recruiting the 
necessary transcription proteins which activate the expression of downstream target genes 
such as Myc (He et al., 1998), Cyclin D1 (Shtutman et al., 1999; Tetsu and McCormick, 
1999), matrix metalloproteinase MMP-7 (Brabletz et al., 1999; Crawford et al., 1999), 
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Figure 1.3 
Wnt signaling pathways 
(http://www.ambion.com/tools/pathway/loadlmage.php?pos=bl&im=images/WNT 
%20Signaling.jpg, accessed January 18, 2009). In the canonical Wnt pathway, 
secreted Wnt ligands initiate intracellular responses by binding to frizzled transmembrane 
receptors and to low-density lipoprotein (LRP5/6) co-receptors which, in turn, activate 
the cytoplasmic intermediate, Dishevelled. Dishevelled subsequently binds Axin to 
inhibit phosphorylation of B-Catenin by the Axin/adenomatous polyposis coli/glycogen 
synthase kinase-33 tumor suppressor complex (I 0). Unphosphorylated B-Catenin 
accumulates in the cytoplasm and nucleus where it interacts with T -cell factor/lymphoid 
enhancing factor (TCF/LEF), B-celllymphoma-9 (Bcl-9) and Pygopus (Pygo). Sequence-
dependent enhancer binding via TCFILEF initiates transcription oftarget genes involved 
in cell growth and proliferation, such as Cyclin D 1 and c-myc. 
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ITF-2 (Kolligs et al, 2002) and others (for a more complete listing see 
http://www.stanford.edu/-musse/pathways/targets.html). 
1.2.2 Noncanonical Wnt signaling 
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Originally it was thought that all Wnt signaling occurred through the stabilization 
and accumulation of P-catenin. Recently two additional Wnt signaling pathways have 
been discovered (reviewed in Montcouquiol et al. 2006, Strutt 2003, Veeman et al. 2003). 
In noncanonical Wnt signaling, Wnts still bind to the Fz receptor to activate Dvl, but the 
downstream signaling cascade does not involve GSK-3P or P-catenin. At least three 
distinct signaling pathways have been identified: Wnt/Ca2+ and Wnt/JNK in vertebrae 
and Wnt/PCP in Drosophilae. 
The first indications of the Wnt/Ca2+ pathway came with the observation that 
overexpression ofWnt5a or Wnt11 in Xenopus embryos increased intracellular calcium 
levels while having no effect on P-catenin levels (Kuhl et al. 2000, Slusarski et al. 1997). 
The elevated intracellular calcium levels activated protein kinase C (PKC) and 
calcium/calmodulin-dependent kinase (CamKII) (Kuhl et al. 2000, Sheldahl et al. 1999). 
The exact mechanism of the pathway's actions is still unclear. The Wnt/Ca2+ pathway is 
necessary for ventral formation of the Xenopus laevis embryo and in inhibiting the 
convergent extension of the embryo, which are the morphogenetic movements mediated 
by the Canonical Wnt pathway (Kuhl 2002). 
Polarity of the cell along its apical/basal axis is intrinsic to all cells whether they 
grow in vitro or in vivo. In essence, all cells have the ability to orientate in the vertical 
axis. In vivo cells composing most organs must also be organized in a plane 
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perpendicular to the apical/basal axis. This Planar Cell Polarity (PCP) plays an essential 
role in the formation of multiple organ systems regulating directed cell migrations, 
polarized cell division and proper differentiation. The Wnt pathway has been implicated 
in Drosophila (Wnt!PCP) and in vertebrae (Wnt/JNK). Although PCP signaling is not as 
well understood as the intensively studied canonical pathway it is thought that 
downstream ofDvl the small GTPases, Rho, Rae and Cdc42 are activated and this leads 
to regulation of the JNK cascade (Kamer et al, 2006; Habas et al, 2003; Habas and He, 
2006; Kahn and Moon, 2005). 
1.2.3 The role of Pygopus in Canonical Wnt signaling 
Pygopus is one of the most recently identified proteins in the Canonical Wnt 
pathway. Humans have two alternately-spliced pygopus mRNAs, both of which are 
needed for TCF-mediated transcription (Thompson et al., 2002). In Drosophila, mutation 
of pygopus causes phenotypes virtually identical to that of wingless (W g; the homolog of 
Wnt) and armadillo (Arm; ~-catenin's homolog) knockouts. The Pygopus protein family 
share two conserved regions, a Plant Romeo Domain (PHD) which binds, through four 
conserved residues, the Homology Domain 1 (HD 1) sequence of BCL9, connecting it to 
the transcription complex (Townsley et al., 2003; Kramps et al., 2002) and the Pygopus-
specific N-homology domain (NHD). PHDs contain a zinc-finger motif which, in other 
proteins, has been implicated in modulation of chromatin structure, DNA binding and 
protein-protein interactions (Aasland et al., 1995; Jacobson and Pillus, 1999; Matthews 
and Sunde, 2002). TheN-terminal Homology Domain (NHD) is proposed to recruit 
cofactors and act as a transcriptional activator (Kramps et al., 2002; Belenkaya et al., 
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Figure 1.4 
Wnt signaling pathways (Montcouquiol et al, 2006). Vertebrate nomenclature and 
interactions are listed. (A) The canonical Wnt signaling pathway. In the canonical 
pathway, binding of Wnt to a Frizzled (Fz) receptor, in association with a coreceptor, 
either LRP5 or LRP6, leads to activation of Disheveled (Dvl). Dvl inhibits the ability of 
GSK-3P to target P-catenin (P-eat) for degradation, leading to an increase in cytoplasmic 
P-eat. Increased cytoplasmic P-eat is translocated to nucleus, where it complexes with 
members of the TCF/LEF family, leading to changes in transcription. (B) The Wnt-
calcium pathway. Binding ofWnt to Fz leads to activation ofDvl, an increase in 
intracellular calcium and activation of PKC. Increased intracellular calcium can then lead 
to a secondary activation of PKC as well as to activation of calmodulin kinase II 
(CamKII). Each of these factors can then mediate various intracellular responses. (C) The 
Wnt-PCP pathway. Activated Fz receptors lead to activation ofDvl, which then signals 
through small GTPases and C-Jun N-terminal kinase (JNK) to modulate cytoskeletal 
elements including actin and microtubules. The PCP pathway also includes a number of 
other components, such as Vangl, Celsr, and PTK7. The specific roles of these factors 
have not been fully determined yet, but data from Drosophila suggest that V angl plays a 
role in the inhibition or degradation ofDvl. Finally, as indicated by the"?" above Wnt, 
the specific role of Wnt in activation of the PCP pathway in vertebrates is not fully 
understood yet. 
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Figure 1.5 
The Wnt transcription complex (A) and 3D representation of human pygopus 2 
PHD (B). A. ~-catenin forms a complex with T cell factor (TCF), B Cell Lymphoma 9 
(BCL9), and pygopus (Behrens eta/., 1996; Molenaar eta/., 1996; van Noort & Clevers, 
2002; Kramps eta/., 2002). Figure adapted from Kramps eta/, 2002. B. 3D 
representation ofhPygo2 PHD. 
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Table 1.5 
Wnt- and J3-catenin-pathway genes that are involved in diseases and syndromes 
(adapted from Moon et al, 2004 and 
http://www.stanford.edu/-rnusse/diseases/Humangeneticdis.htm, accessed 
December 21, 2008). Loss of Function (LOF); Gain of Function (GOF). 
Chapter 1 : Introduction Wells; page 52 
Gene Condition/Disease Mutation or Activity/ Reference Expression Chan2e 
WNTI Schizophrenia Elevated Miyaoka et a/, 1999 
WNT3 Tetra-amelia LOF Niemann eta/, 2004 
WNT4 Intersex GOF Jordan et a/, 2003 
WNT4 Kidney damage Elevated Terada eta/, 2003 Surendran & Simon, 2003 
WNT4 Polycystic Kideney Variable Rodova et a/, 2002 Disease 
WNT4 SERKAL Syndrome LOF Mandel et a/, 2008 
WNT5a Leukemia LOF; Reduced Liang et a/, 2003 
WNT5a Metastasis Elevated Weeraratna eta/, 2002 
WNT5B Type II diabetes LOF Kanazawa et a/, 2004 
WNT7A Fuhrmann syndrome LOF Woods et a/, 2006 
WNTIOA Odonto-onycho-dermal LOF Adaimy et a/, 2007 dysplasia 
WNTIOB Obesity LOF Christodoulides et a/, 2006 
WNTIOB Split-Hand/Foot LOF Ugur and Tolun, 2008 Malformation 
sFRP3 Osteoarthritis SNP; Reduced Loughlin et a/, 2004 
FZ4 FEVR LOF Robitaille et a/, 2002 
Norrin FEVR Xu et a/, 2004 
LRP5 FEVR LOF Toomes eta/, 2004 Low bone mass Gong et a/, 200 I 
LRP5 High Bone Mass GOF Little et a/, 2002 Boyden et a/, 2002 
LRP6 early_ coronary disease LOF Mani et al, 2007 
LRP6 Late onset Alzheimer LOF De Ferrari 2007 
DSHIDVL Lung Cancer Elevated Uematsu eta/, 2003 
APC Cancer LOF van de Wetering, 2002 
AXIN Cancer LOF Giles et a/, 2003 
AXINI caudal duplication Undetermined Oates, 2006 
AXIN2 Cancer LOF Lammi et a/, 2004 Tooth Agenesis 
[3-catenin Cancer GOF Giles et a/, 2003 
[3-catenin Aggressive fibromatosis Elevated Cheon et a/, 2004 
13-catenin Pulmonary Fibrosis Elevated Chilosi et a/, 2003 
TCF7L2 Grant et a/, 2006 
(TCF4) Type II diabetes LOF Florez et a/, 2006 O'Rahilly and Wareham, 2006 
WTX Wilms tumor LOF Major et a/, 2007 Rivera et a/, 2007 
Wang et a/, 2007 
PORCI Focal dermal hypoplasia LOF Grzeschik et a/, 2007 
Leoyklang et a/, 2008 
RSP04 autosomal recessive LOF Bergmann et a/, 2006 
anonychia Blaydon et a/, 2006 
VANGLI Neural tube defects LOF Kibar, 2007 
- ---- ----
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2003; Lake and Kao, 2003; Thompson, 2004). 
Since its discovery, pygopus has been suggested to have a transactivation function 
(Kramps et al., 2002). For example, when fused to Gal4, pygopus was able to activate 
transcription from a reporter vector containing a Gal4 binding site (Belenkaya et al., 
2002). When overexpressed in Xenopus embryos, the NHD ofPygopus activated 
expression of the Wnt marker Engrailed-2 and also induced partial secondary body axis 
development, two results consistent with Wnt activation (Lake and Kao, 2003). When 
fused to TCF, the NHD was able to activate TOPflash reporter expression (Thompson, 
2004). Therefore, pygopus can act as a transcriptional activator with the transactivation 
function dependent on the NHD. 
1.2.4 Wnt Signaling and Disease 
Along with being involved in normal development, components of the Wnt 
pathway have been linked to various diseases (see Table 1.5 for a complete list). 
1.2.4.1 Gastrointestinal Disease 
APC is an enormous protein that has muliple roles in the cell. In the Wnt 
pathway, it binds to f3-catenin in a complex with GSK-3f3/ Axin/ CKla/Diversin and is 
necessary for f3-catenin's down-regulation. Human APC is a major tumor suppressor 
gene. Mutations to APC can cause both familial adenomatous polyposis (F AP) and 
Gardner's syndrome (GS) (Kinzler et al1991 , Nishisho et al1991 ; Nakamura et al, 1992). 
F AP and GS are autosomal dominant genetic disorders, which predispose patients to the 
development of hundreds to thousands of adenomatous polyps in colon and rectum, one 
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or more of which progress to carcinoma if not surgically treated. Gardner's syndrome is a 
related disorder in which multiple lipomas, fibromas, osteomas, and desmoid tumors 
develop as well as a large number of polyps of the colon and rectum. Germ line 
mutations in APC are responsible for familial F AP and GS (Nakamura et al, 1992). APC 
is somatically altered by point mutation, deletion or insertion in approximately 85% of 
sporadic colorectal cancer (Nakamura et al, 1992; Kinzler and Vogelstein, 1996). In all 
cases, the loss of APC is associated with stabilization of the ~-catenin protein in the 
cytoplasm. 
1.2.4.2 Urinary Tract Disease 
Several studies have linked alterations in ~-catenin regulation to normal kidney 
development and to kidney disease (Vainio and Uusitalo, 2000; Rodova et al, 2002; 
Wilson, 2004; Koesters et al, 1999; Zhu, 2000; Kim, 2000) and proper regulation of Wnt 
signaling is necessary for normal renal development (Vainio and Uusitalo, 2000). For 
example, there are studies that link ~-catenin to proper regulation of the PKDJ promoter 
(Rodova et al, 2002). P KD 1 is mutated in ""85% of patients with autosomal dominant 
polycystic kidney disease (ADPKD) (Wilson, 2004). Qian et al (2005) created mice 
carrying a conditional deletion of the Ape tumor suppressor gene specifically in the renal 
epithelium. As expected, the loss of Ape leads to increased levels of ~-catenin protein in 
renal epithelium. Most of the mice died shortly after birth with multiple kidney cysts. In 
the rare mouse that survived to adulthood, it had severely cystic kidneys associated with 
the presence of renal adenomas. Similarly, expression of a form of ~-catenin in which the 
N -terminal131 amino acids are deleted induces early development of polycystic kidney 
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disease in a mouse model (Saadi-Kheddouci et al, 2001). These studies confirm an 
important role for proper regulation ofWnt/~-catenin signaling in renal development and 
provide evidence that dysregulation of the pathway can initiate tumorigenesis in the 
kidney 
Mutations in the ~-catenin gene have been identified in renal cell carcinomas and 
Wilms' tumors (Koesters et al, 1999; Zhu, 2000; Kim, 2000; Rivera et al, 2007; Major et 
al, 2007). Wilms tumor is a pediatric kidney cancer. Rivera et al (2007) used a high-
resolution screen for DNA copy-number alterations in Wilms tumors and identified 
somatic deletions targeting a previously uncharacterized gene on the X chromosome, 
which they called WTX. WTX is inactivated in approximately one-third of Wilms 
tumors ( 15 of 51 tumors). In contrast to biallelic inactivation of autosomal tumor-
suppressor genes, WTX is inactivated by a monoallelic "single-hit" event targeting the 
single X chromosome in tumors from males and the active X chromosome in tumors 
from females. Major et al (2007) used tandem-affinity protein purification and mass 
spectrometry to define the protein interaction network of the beta-catenin destruction 
complex in Wilms' tumours. They found that WTX, a protein encoded by a gene mutated 
in Wilms tumors, forms a complex with ~-catenin, AXINl, beta-TrCP2 (~-transducin 
repeat-containing protein 2), and APC (adenomatous polyposis coli). Functional analyses 
in cultured cells, Xenopus, and zebrafish demonstrate that WTX promotes ~-catenin 
ubiquitination and degradation, which antagonize WNT/~-catenin signaling. 
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1.2.4.3 Hepatobiliary Disease 
Hepatocellular carcinoma (HCC) is the most frequent primary malignancy of the 
liver. The genetic events responsible for HCC initiation or progression are not clear, but 
they involve at least three carcinogenesis pathways: the p53, RB, and Wnt/~-catenin 
signaling pathways (Buendia, 2000). Oncogenic mutations in the ~-catenin gene were 
evident in human and mouse liver tumors (de La Coste, 1998; Miyoshi et al, 1998). ~­
catenin mutations have been found in 19-41% (average 22%) of human HCCs of 
different etiologic origin (de La Coste, 1998; Miyoshi et al, 1998; Terris et al, 1999; Tran 
van Nhieu et al, 1999; Huang et al, 1999; Legoix et al, 1999). The strong correlation 
between nuclear ~-catenin staining and somatic mutations of the ~-catenin gene in tumor 
cells indicates that activation of the Wnt/~-catenin pathway in HCC occurs 
predominantly through mutations in the ~-catenin gene itself (Tran van Nhieu et al, 
1999). It differs from colorectal cancers in which APC mutations are responsible for ~­
catenin stabilization in 70-80% of the cases. HCCs harboring intense nuclear expression 
of ~-catenin are characterized by high proliferative rate, and their prognosis might be 
more severe (Tran van Nhieu et al, 1999). In benign liver sections, ~-catenin 
immunostaining is restricted to the cell membrane. It has been shown that ~-catenin 
mutations are more prevalent in HCCs that are not related to HBV infection. In APC-
knockout mice, 67% of mice developed HCC (Colnot et al, 2004). ~-Catenin signaling 
was strongly activated in these APC-inactivated HCCs. 
1.2.4.4 Cardiovascular Disease 
Patients with coronary artery disease (CAD) often have accompanying 
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Table 1.6 
Comparison of phenotypes in carriers and noncarriers of LRPR611c (Mani et al, 
2007). Means ± standard deviation are shown for quantitative traits. All kindred 
members with measured values were included for LDL, triglyceride, HDL, and BMI 
measurements. For blood pressure, fasting blood glucose, and diabetes, results for 
subjects over age 40 are shown. 
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Trait LRPR611C carriers Noncarriers Pvalue 
LDL (mg/dl) 170 ± 12 98 ± 5 6 x w-6 
Triglycerides (mg/dl) 209 ± 71 68±20 1 x w-5 
HDL (mg/dl) 57± 8 56± 7 0.4 
BMI (kg/m2) 24.3 ± 2.6 24.4 ± 1.6 0.13 
Systolic BP (mmHg) 168 ± 21 116 ± 5 s x w-5 
Diastolic BP (mmHg) 100 ± 14 81 ± 7 0.0025 
Fasting blood glucose (mg/dl) 159 ± 43 80± 3 0.001 
Diabetes (yes/no) 11/4 0/5 0.005 
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hypertension, diabetes, and aberrant levels of cholesterol and triglycerides. This diverse 
group of risk factors is collectively known as "metabolic syndrome," but the underlying 
molecular mechanisms that link these disorders are still poorly understood. Mani eta/. 
(2007) have identified the causative mutation in a family afflicted with a rare, inherited 
autosomal dominant form of early-onset CAD with many features of metabolic syndrome 
and osteoporosis. The culprit was a missense mutation, R611C, in a gene encoding low-
density lipoprotein receptor-related protein 6 (LRP6), a co-receptor in the Wnt cellular 
signaling pathway. R61llies in an epidermal growth factor (EGF}-like domain (fig. 82) 
and is conserved among LRP6 orthologs ranging from Xenopus to human. 
Analysis revealed complete linkage of LRP6R6I 1c and high LDL, with a lod score 
of5.5 (odds of316,000:1 in favor of linkage). The difference in mean LDL 
levels between mutation carriers and noncarriers is significant (170 ± 12 mg/dl versus 98 
± 5 mg/dl, P = 6 x 1 0--6; Table 1.4) .. Because high LDL levels are found in all mutation 
carriers, regardless of age, this trait can serve as a bio-marker of the mutation in subjects 
too young to manifest CAD. Similarly, LRP6R6IIC imparts significant effects on 
triglyceride levels, blood pressure, fasting blood glucose, and prevalence of diabetes 
(Table 1.4). No significant effects were seen on HDL levels or body mass index. All 
mutation carriers studied had low bone densities, with values below the 12.5 percentile (P 
< 0.001). 
Mani et al (2007) used NIH3T3 cells to determine the functional significance of 
the LRP6R6IIC mutation. In the absence of added Wnt 3a, LRP6R6IIC showed a 49% 
reduction of induced signaling compared with that of wild-type LRP6 (P < 0.01). The 
addition of low doses of Wnt 3a also showed markedly reduced signaling with LRP6R6IIC 
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( 42% reduction, p <1 o-5). At high doses ofWnt 3a Wnt signaling through LRP6R6IIC 
does not differ significantly from that ofthe wild type (P = 0.48). Measurementoftotal 
LRP6 expression by Western blotting and cell surface expression demonstrate similar 
levels of wild-type and mutant LRP6. All these findings are consistent with an impaired 
biochemical function ofLRP6R611c and implicate altered Wnt signaling as a 
cardiovascular risk factor. 
Other studies have demonstrated associations between components of the Wnt 
pathway with cardiac risk factors. WNT5B (Kanazawa et al, 2004) and transcription 
factor 7-like 2 (TCF7L2, formerly TCF4; Grant et al, 2006; Florez et al, 2006; O'Rahilly 
and Wareham, 2006) conferred risk for type 2 diabetes. Kanazawa et al (2004) 
demonstrated that the WNT5B gene was strongly associated with type 2 diabetes 
Ci=15.6; P=.00008; odds ratio=l.74; 95% confidence intervall.32-2.29). Expression of 
the WNT5B gene was detectable in several tissues, including adipose, pancreas, and liver. 
In vitro experiments identified the fact that expression of the Wnt5b gene was increased 
at an early phase of adipocyte differentiation and overexpression of the Wnt5b gene in 
preadipocytes resulted in the promotion of adipogenesis. 
Grant et al (2006) demonstrated that a microsatellite, DG 1084 78, within intron 3 
of the transcription factor 7-like 2 gene (TCF7L2; formerly TCF4) was associated with 
type 2 diabetes (P = 2.1 x 10"9). Heterozygous and homozygous carriers of the at-risk 
alleles had increased risk of Type 2 diabetes as compared to non-carriers (3 8% and 7% of 
the population, respectively; RR of 1.45 and 2.41 ). This corresponds to a population 
attributable risk of21%. Common variants in TCF7L2 are associated with an increased 
risk of diabetes among persons with impaired glucose tolerance with the risk-conferring 
----------
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genotypes in TCF7L2 being associated with impaired beta-cell function but not with 
insulin resistance (Florez et a/, 2006). The TCF7L2 gene product is a transcription factor 
previously implicated in blood glucose homeostasis and is thought to act through 
regulation of proglucagon gene expression in enteroendocrine cells via the Wnt signaling 
pathway. 
WNTI OB has been postulated to play a role in the negative regulation of 
adipocyte differentiation in vitro and in vivo. One proband with early-onset obesity was 
found to be heterozygous for a missense C256Y mutation (Christodoulides et al, 2006). 
With the C256Y mutation WNTI OB was unable to activate the canonical WNT signaling 
pathway and block adipogenesis. All relatives of the proband who carried this allele 
were either overweight or obese. The significance of aberrant Wnt signaling in obesity is 
still unclear. 
1.2.4.5 Neurological and Psychiatric Disease 
Alzheimer's disease (AD) is the most common form of age-associated dementia. 
It is a progressive neurodegenerative disorder characterized by a deficit in cognitive 
processes manifested as alterations in memory, judgment, and reasoning (Hardy and 
Selkoe, 2002). Although the etiology of AD remains to be fully understood, it is well 
accepted that, along with age, family history is the most prominent risk factor for the 
development of the disease. Inheritance of the apolipoprotein E-€4 (APOE-€4) allele is a 
risk factor for AD (Corder eta/, 1993; Strittmatter eta/, 1993), however epidemiological 
studies estimate that 42-68% of AD patients do not present the APOE-e4 allele, 
suggesting that additional genetic or environmental factors could play essential roles in 
----------
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the disease (Warwick eta/, 2000). It has been proposed that altered function ofWnt 
signaling components may be involved in AD (De Ferrari and Inestrosa, 2000; Mudher 
and Lovestone, 2002; Caricasole et al, 2003; Moon eta/, 2004; De Ferrari and Moon, 
2006). Consequently LRP6 gene has been studied in association with this disease. De 
Ferrari eta/ (2007) observed that SNP 18e, encoding a C---+ T missense mutation in 
LRP6, was strongly associated with AD in the APOE-fA -negative patients (P = 0.0075). 
Individuals carrying at least one copy had a 69-80% greater risk of getting AD compared 
with individuals being 18e homozygotes. 
Most WNTs and FZ receptors are expressed during development of the central 
nervous system and many are expressed in the adult brain. It has been proposed that 
increased expression of WNT1 might lead to altered cell adhesion, synaptic 
rearrangement and plasticity in the brains of people with schizophrenia (Miyaoka et a/, 
1999). Consistent with the possible involvement of WNT signalling in schizophrenia, 
Katsu eta/ (2003) reported FZ3 SNPs are associated with susceptibility to schizophrenia 
and Kozlovsky eta/ (2002) have suggested that GSK3~ activity is altered in 
schizophrenia. Similarly, deletion ofDsh1/Dvll in mice produces behavioural defects 
(Lijam eta/. 1999), further linking the WNT pathway to the modulation of brain activity. 
Inhibition of the Wnt antagonist GSK-3~ by lithium or GSK-3~ antisense short hairpin 
RNA (shRNA) provides protects neurons from death (Hongisto eta/, 2008). 
Neural-tube defects such as anencephaly and spina bifida (myelomeningocele) are 
common congenital malformations affecting 1-2 babies per 1000 (Copp eta/, 2003). 
Neural tube defects occur because of partial or complete failure of the neural tube to close 
during embryogenesis. Pathogenesis includes complex genetic and environmental 
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factors. Although no causative gene has been identified in humans, mutated Vang/2 is 
present in the Loop-tail (Lp) mouse mutant (Kibar eta/, 2001; Murdoch eta/, 2001) with 
a severe defect known as craniorachischisis (Stein and Rudin, 1953). Vang/2 is the 
mammalian homologue of the drosophila gene Stbm/Vang, which is required for 
establishing planar cell polarity in the developing eye, wing, and leg tissues (Taylor eta/, 
1998; Wolff and Rubin, 1998). Kibar et a/ (2007) studied V ANGL 1 and identified three 
mutations in the V ANGLl gene in patients with familial types (V239I and R274Q) and a 
sporadic type (M328T) of the disease. In a protein-protein interaction assay V239I 
abolished interaction of V ANGL1 protein with its binding partners, disheveled-! , -2, and 
-3. Along with previous studies (Kibar eta/, 2001; Murdoch eta/, 2001; Curtin eta/, 
2003; Hamblet eta/, 2002; Torban eta/, 2004; Wang eta/, 2006), the findings ofKibar et 
a/ (2007) indicate the critical role of core planar-cell-polarity genes (Vang/2, Celsr 1, Dvl, 
and Fz) in controlling convergent extension, a process necessary for neural-tube closure, 
and implicate V ANGLl mutations as a risk factor in human neural-tube defects. 
1.2.4.6 Musculoskeletal Disease 
Osteoporosis-pseudoglioma syndrome (OPPG; alternatively known as OPS and 
osteogenesis imperfecta, ocular form) is an autosomal recessive disorder generally 
characterized by congenital or infancy-onset visual loss and skeletal fragility recognized 
during childhood. Mutations in the low-density lipoprotein receptor-related protein 5 
(encoded by LRP5) cause OPPG (Gong et al, 2001). OPPG is a rare disorder, with an 
estimated population incidence of 1 per 2,000,000 and a carrier frequency of 1 per 700. 
Heterozygous carriers of OPPG-causing mutations have reduced bone-mineral density 
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(BMD) compared with age- and sex-matched controls (Gong eta/, 2001; Lev eta/, 2003) 
and LRP 5 mutations have been found among individuals with "idiopathic" osteoporosis 
and/or skeletal fragility (Hartikka et al, 2005). Two other phenotypes have been 
attributed to a mutation in LRP 5. Heterozygous missense mutations in the receptor's first 
six-bladed propeller domain can cause autosomal dominant disorders of high bone mass 
(HBM), in which BMD is several SDs above the mean (Boyden eta/, 2002; Little et al, 
2002; Van Wesenbeeck eta/, 2003). These mutations may cause a gain of function in the 
receptor by altering a binding site for the receptor's endogenous inhibitors (Boyden et a/, 
2002; Ai et a/, 2005). Heterozygous and homozygous mutations have also been 
described in some patients with the eye disease familial exudative vitreoretinopathy 
(FEVR; Jiao eta/, 2004; Toomes eta/, 2004; Qin eta/, 2005). FEVR can also be caused 
by mutations in a secreted ligand, Norrin (NDP; Chen eta/, 1993; Xu eta/, 2004), and an 
LRP5 coreceptor, Frizzled 4 (FZD4; Robitaille eta/, 2002; Qin eta/, 2005; Xu eta/, 
2004). 
WNT signaling plays a role in vertebrate limb development (Yang, 2003). In the 
developing vertebrate limb, Wnt signaling is required for limb bud initiation, early limb 
patterning (which is governed by several well-characterized signaling centers), and late 
limb morphogenesis events. Split-hand/split-foot malformation (SHFM) is a limb 
malformation involving the central rays of the autopod and presenting with syndactyly, 
median clefts of the hands and feet, and aplasia and/or hypoplasia of the phalanges, 
metacarpals, and metatarsals. Some patients with SHFM1 have been found to have 
mental retardation, ectodermal and craniofacial findings, and orofacial clefting (Elliott 
and Evans, 2006). A definite autosomal recessive inheritance for isolated SHFM has 
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been reported for one family only (Gul and Oktenli, 2006; Ugur and Tolun, 2008). Ugur 
and Tolun (2008) studied a large consanguineous family afflicted with autosomal 
recessive SHFM. Twelve affected members had central feet reductions with or without 
hand involvement. They identified a homozygous C toT missense WNTJOb mutation 
(p.R332W) in all affected individuals but the atypical case plus in an asymptomatic 
female. 
Anonychia is an autosomal recessive disorder characterized by the congenital 
absence of fingernails and/or toenails. It is a rare entity that may present either as a so-
called partial autosomal dominant form that affects only the thumbs (Strandoskow, 1939) 
or, in its most severe, autosomal recessively inherited variant, with involvement of all 
digits and toes (Littman and Levin, 1964). Bergmann et al (2006) studied a large 
German nonconsanguineous family with four affected and five unaffected siblings with 
isolated total congenital anonychia. They performed genomewide mapping and showed 
linkage to 20p13. Analysis of the RSP04 gene within this interval revealed a frameshift 
and a nonconservative missense mutation in the highly conserved exon 2. Both 
mutations were not present among controls. Slaydon et al (2006) studied eight affected 
families and identified homozygous or compound heterozygous mutations in the gene 
encoding R-spondin 4 (RSP04). RSP04 expression was specifically localized to 
developing mouse nail mesenchyme at embryonic day 15.5, suggesting a crucial role in 
nail morphogenesis. RSP04 is a member of the recently described R-spondin family of 
secreted proteins that play a major role in activating the Wnt/ beta -catenin signaling 
pathway (Kim et al, 2006; Nam et al, 2006). 
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Tetra-amelia is a rare human genetic disorder characterized by complete absence 
of all four limbs and other anomalies. Niemann eta/ (2004) studied a consanguineous 
family with four affected fetuses displaying autosomal recessive tetra-amelia and 
craniofacial and urogenital defects. They identified a homozygous nonsense mutation 
(Q83X) in the WNT3 gene in affected fetuses of the family. The Q83X mutation 
truncates WNT3 at its amino terminus, suggesting that loss of function is the most likely 
cause of the disorder. The identification of a WNT3 mutation in tetra-amelia indicates 
that WNT3 is required at the earliest stages of human limb formation and for craniofacial 
and urogenital development. 
In a Turkish-Arabian family, Fuhrmann eta/ (1980) initially described a 'new' 
syndrome consisting of bowing of the femurs, aplasia or hypoplasia of the fibula, and 
poly-, syn-, and oligodactyly. Other findings included hypoplasia of pelvis, congenital 
dislocation of hips, absence or coalescence of tarsal bones, absence of various 
metatarsals, hypoplasia offmgers and fingernails, and postaxial polydactyly. In a 
Jordanian family, Al-Awadi eta/ (1985) described a more severe syndrome with 
deficiency of all 4 extremities. Two family members had hypoplastic femora and absent 
ulnae and fibulae. Although 'thoracic dystrophy,' pelvic deformity, and unusual facies 
were mentioned, these did not seem as impressive as the limb malformations. In the 
Pakistani Muslim family described by Kumar eta/ (1997), Woods eta/ (2006) found that 
affected individuals had 3 homozygous changes, all in ex on 3 of the WNT7 A gene: a 
missense mutation, 630G-A, that led to an alanine-to-threonine substitution (Al09T), and 
2 known synonymous SNPs. The results suggest that a partial loss of WNT7 A function 
causes Fuhrmann syndrome (and a phenotype similar to mouse Wnt7a knockout), 
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whereas the more-severe limb truncation phenotypes observed in Al-Awadi/Raas-
Rothschild/Schinzel phocomelia syndrome (AARRS) result from null mutations (and 
cause a phenotype similar to mouse Shh knockout). 
Lammi et al (2004) studied a Finnish family in which severe permanent tooth 
agenesis (oligodontia) and colorectal neoplasia segregate with dominant inheritance. 
Eleven members of the family lacked at least eight permanent teeth, two of whom 
developed only three permanent teeth. Colorectal cancer or precancerous lesions of 
variable types were found in eight of the patients with oligodontia. They found that 
affected family members had a nonsense mutation, Arg656Stop, in the Wnt-signaling 
regulator AXIN2. They also identified a de novo frameshift mutation 1994-1995insG in 
AXIN2 in an unrelated young patient with severe tooth agenesis. As Axin is an inhibitor 
ofWnt signaling, both mutations are expected to activate the signaling pathway. The 
results suggest Wnt signaling is important for the development of dentition. 
1.2.4.7 Genital and Reproductive Anomalies 
At 6 weeks of human development, the male and female genital systems are 
indistinguishable in appearance. It consists of two sets of paired ducts: the 
paramesonephric (miillerian) ducts and the mesonephric (wolffian) ducts. In the absence 
of the testis-determining factor of the Y chromosome, the mesonephric ducts begin to 
degenerate. At the same time the paramesonephric ducts develop proximally to form the 
fallopian tubes and distally give rise to the uterus and upper four-fifths of the vagina. 
WNT4 suppresses male sexual differentiation by means of the regulation ofmiillerian-
duct formation and control of ovarian steroidogenesis (Vainio eta/, 1999; Jordan eta/, 
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2001; Jeays-Ward eta/, 2003). In a mouse model in which Wnt4 is ablated, both male 
and female Wnt4-knockout mice have defects in kidney development and adrenal 
function. The female mice exclusively had deficiencies in gonadal development and 
steroidogenic function (Vainio eta/, 1999; Stark eta/, 1994). Biason-Lauber eta/ (2004) 
presented a case report of an 18-year-old woman presented with primary amenorrhea. 
Further examination revealed miillerian agenesis, unilateral renal agenesis, and clinical 
signs of androgen excess-a phenotype resembling the Mayer-Rokitansky-Kilster-Hauser 
syndrome and remarkably similar to that of female Wnt4-knockout mice. A genetic 
evaluation revealed a loss-of-function mutation in the WNT4 gene. 
Mandel eta/ (2008) studied a consanguineous kindred of Arab Muslim origin. 
The family had been followed since the birth of an infant who died of type 1 citrullinemia 
at age 4 days. The parents were second cousins. Three affected fetuses showed largely 
overlapping features including female sex reversal and dysgenesis of kidneys, adrenals, 
and lungs, given the acronym of SERKAL syndrome (SEx Reversal, female, with 
dysgenesis of Kidneys, Adrenals and Lungs). In the case of all 3 affected fetuses, 
pregnancy was terminated because of the finding of renal agenesis. Given the similarities 
between the findings in these cases and a WNT4 knockout mouse model (Vainio eta/, 
1999; Heikkila eta/, 2005), Mandel eta/ (2008) genotyped all available family members 
for microsatellite markers spanning the WNT4locus. The affected fetus from which 
DNA was available displayed a homozygous haplotype, which was found to be carried in 
heterozygous state by all parents and unaffected sibs, suggesting the existence of a 
homozygous mutation in WNT4 in the affected fetus. The mutation was found to be a 
homozygous transition resulting in the amino acid substitution A114V. The mutation 
-------- -------- ---------
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resulted in markedly reduced WNT4 mRNA levels in vivo and in vitro and 
downregulated WNT4-dependent inhibition ofbeta-catenin degradation. 
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Caudal duplication anomaly was initially coined by Dominguez eta/ (1993) to 
describe the occurrence of duplications of different organs in the caudal region. They 
reported 6 affected patients and reviewed 8 similar previously published cases. Caudal 
duplication anomaly is similar to an anomaly seen in Axin(Fu) mice, which carry a 
mutation in the Axin locus (Vasicek eta/, 1997). Affected mice display bifurcated tails 
as a result of caudal duplication in the distal region. Axin encodes an inhibitor of the 
Wnt-signaling pathway and has been shown to regulate embryonic axis formation in 
mouse and in Xenopus (Zeng et a/, 1997). Suppression of wild type Axin in Xenopus 
embryos results in the duplication of the body axis. Using bisulfite sequencing, Oates et 
a/ (2006) examined methylation at the promoter region of the AXIN1 gene in the MZ 
twins discordant for a caudal duplication anomaly in whom no causative AXIN1 
mutation was found (Kroes eta/, 2002). Methylation of the promoter region in peripheral 
blood mononuclear cells was variable among individuals, including MZ pairs. In the MZ 
pair discordant for the caudal duplication, this region of the affected twin was 
significantly more methylated than that of the unaffected twin (Pless than 0.0001), which 
was significantly more methylated than those of the controls (P = 0.02). Oates eta/ 
(2006) confirmed that this CpG island functions as a promoter in vitro and that its activity 
is inversely proportional to the extent of methylation. This finding raised the possibility 
that hypermethylation of the AXIN 1 promoter, by mechanisms as yet undetermined, is 
associated with the malformation. 
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1.2.4.8 Dermatologic Disease 
Focal Dermal Hypoplasia (FDH) is inherited as an X-linked dominant 
multisystem birth disorder affecting tissues of ectodermal and mesodermal origin. 
Affected males die in utero. Affected female patients have features including atrophy 
and linear pigmentation of the skin, herniation of fat through the dermal defects, and 
multiple papillomas of the mucous membranes or skin. In addition, patients can also 
present with digital anomalies consisting of syndactyly, polydactyly, camptodactyly, and 
absence deformities; oral anomalies; lip papillomas; hypoplastic teeth; ocular anomalies 
(coloboma of iris and choroid, strabismus, microphthalmia); mental retardation; and 
striated bones (Larregue and Duterque, 1975; Happle and Lenz, 1977). 
Wang et al (2007) performed a genomewide oligonucleotide comparative 
genomic hybridization (CGH) array and identified a 219-kb deleted region in 2 affected 
individuals. This region encompassed 5 genes· including PORCN. Grzeschik eta/ (2007) 
used CGH to study 6 affected members of 1 family segregating FDH and 10 unrelated 
affected individuals. They identified a similar deletion in Xp 11.23 that overlapped by 
approximately 80 kb and included 4 genes, including PORCN. Wang eta/ (2007) 
amplified and sequenced all coding exons of the PORCN gene and identified 
heterozygous mutations in 10 FDH-affected women. In 8 individuals with FDH, 
Grzeschik et a/ (2007) identified several heterozygous nonsense mutations and 1 splice 
site mutation. Leoyk.lang et al (2008) reported 3 unrelated Thai girls with sporadic FDH 
in whom they identified mutations in the PORCN gene, confirming that PORCN is the 
gene responsible for FDH across different populations. 
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Odonto-onycho-dermal dysplasia (OODD) is a rare autosomal recessive 
syndrome in which the presenting phenotype is dry hair, severe hypodontia, smooth 
tongue with marked reduction of fungiform and filiform papillae, onychodysplasia, 
keratoderma and hyperhidrosis of palms and soles, and hyperkeratosis of the skin. 
OODD was originally reported in 3 consanguineous Lebanese Muslim Shiite sibships by 
Fadhil eta/ (1983). Arnold et al. (1995), Zirbel et al. (1995), and Megarbane et al. 
(2004) have described 11 additional affected patients. Adaimy et al (2007) studied 3 
consanguineous Lebanese Muslim Shiite families that included 6 individuals affected 
with odontoonychodermal dysplasia. They found homozygosity for the same nonsense 
mutation in the WNT1 OA gene (E233X). The mutation was predicted to result in a 
prematurely truncated protein of232 amino acids instead of 417 amino acids. 
1.3 Thesis Rationale 
Ovarian cancer is called "the silent killer". Current therapies have had limited 
success with increasing survival and curing these patients. Previous research in our 
laboaratory demonstrated overexpression of Pygopus in several EOC cell lines (Popadiuk 
eta/, 2006). Immunoblots ofTOV-112D and TOV-21G demonstrated a large increase in 
pygopus expression compared to the Immortalized Ovarian Surface Epithelial cell line 
(lOSE 397; a kind gift from Dr. Nelly Auersberg, University of British Columbia, 
Canada; McNeish eta/, 2005; Xu eta/, 2006). In contrast, P-catenin was only 
overexpressed in TOV-112D cells and was expressed minimally in TOV-21G cells. The 
co-overexpression of pygopus in TOV -112D cells is consistent with a requirement for 
these proteins in deregulated canonical Wnt signaling. TOV -21 G cells only 
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overexpressed pygopus. This indicates that pygopus may have a more central role in 
cancer development and proliferation, and that this role is independent of P-catenin. In 
my research, I have explored the possibility of pygopus as a unique and novel therapeutic 
target for ovarian cancer. With pygopus overexpression limited to a select number of 
tissues, including the ovaries, pygopus suppression could target the ovarian cancer cells 
selectively with theoretically fewer side effects and effect on other organ systems. 
While current evidence suggests that Pygopus is dedicated to the Wnt pathway, it 
is possible that it also has Wnt-independent functions, as described (Song et al, 2007; de 
Ia Roche and Bienz, 2007). To demonstrate this possibility in cancer, I studied the role of 
Pygopus in two different epithelial ovarian cancer cell lines (TOV-112D and TOV-21G), 
only one of which (TOV -112D) expressed P-catenin. My results indicated that while 
canonical Wnt signaling could be demonstrated in only in the P-catenin-expressing cell 
line, both cell lines overexpressed and required pygopus for growth, clearly suggesting 
that, as in embryonic development, pygopus has activity independent of wnt signaling in 
EOC. 
--------------
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2.1 Cell Culture 
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MATERIALS AND METHODS 
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The previously characterized epithelial ovarian cancer (EOC) cell lines, TOV-
112D and TOV-21G (Provencher et al., 2000), SK-OV-3 (Fogh, 1975; Fogh et al, 1977) 
and the NIH:OVCAR-3 cell line (Hamilton et al 1983) were obtained from the American 
Tissue Culture Collection (ATCC; CRL-11730, CRL-11731, HTB-77 and HTB-161 , 
respectively). All three cell lines were cultured in Delbecco's Modified Eagle' s Mediwn 
(DMEM; Gibco BRL) containing 10% fetal calf serum (FCS), 100 U/mL of penicillin 
and 1 OOJ.lg/mL of streptomycin. Cells were passaged every three to four days. 
TOV-112D cells have a known activating mutation in P-catenin (Wu eta!, 2001) 
that results in overexpression of P-catenin and increased canonical Wnt activity. In 
comparison, TOV -21 G cells have minimal expression of P-catenin (Popadiuk eta!, 
2006). SK-OV-3 and OVCAR-3 cell lines have moderate P-catenin expression 
(Popadiuk et al, 2006). TOV-21G, SK-OV-3 and OVCAR-3 have baseline canonical 
Wnt activity (Popadiuk eta!, 2006). 
The SV 40 Immortalized Ovarian Surface Epithelial 397 (lOSE 397) cell line was 
a gift from Dr. Nelly Auersperg on behalf of the Canadian Ovarian Tissue Bank. Cells 
were cultured in a 1:1 combination oftwo media, 199 (Sigma) and MCDB105 (Sigma) 
with 5% FCS, 100 U/mL of penicillin and 1 OOJ.!g/mL of streptomycin. Cells were 
passaged every three to four days. 
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2.2 TCF -dependent Transcription Reporter Assays 
To measure canonical Wnt activity in the EOC cell lines, TCF-dependent 
transcription reporter assays were performed as previously described (Morin et al., 1997). 
2 x 105 cultured cells were seeded in 6-well plates 24 hours prior to transfection. Cells 
were transfected with 0.4 Jlg of either pTOPflash or pFOPflash (Upstate Biotechnology) 
using Effectene® Transfection Reagent (Qiagen). Forty-eight hours post-transfection, 
cells were washed with PBS and lysed with the supplied Luciferase Cell Culture Lysis 
Buffer (Promega). Luciferase Assay Reagent was added and the light produced was 
measured with a Monolight® 2010 Luminometer (Analytical Luminescence Laboratory, 
San Diego, CA). Each experiment was performed in triplicate. 
To normalize transfection efficiency 0.4 Jlg of the RSV ~-gal vector was co-
transfected into the cells. 200 JlL of Z buffer (16.1 g/L Na2HP04 · 7H20 , 5.5 g/L 
NaH2P04 · H20, 0. 75 giL KCl, 0.25 g/L MgS04 · 7H20 , and 0.27% ~-mercaptoethanol) 
was added to 20 JlL of cell lysate and incubated at 3 7°C for 15 minutes. 100 JlL of 1 M 
Na2C03 was added to stop the reaction. ~-galactosidase levels were relative to the 
optical density obtained at 420 nm using an Ultrospec 2000 UV Nisible 
Spectrophotometer (Pharmacia Biotech). 
2.3 Plasmids 
Mammalian hPygo2 expression constructs were produced by subcloning hPygo2 
from p<;:>TB7/hPygo2 (engineered by Dr. B. Lake) and insertion into pCS2+ (a gift from 
Dave Turner). The full length hPygo2 construct (pCS2+/hPygo2) was prepared by 
releasing the hPygo2 insert from pOTB7/hPygo2 and ligating it into the EcoRI andXhol 
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Figure 2.1 
TOPflash Mechanism. To determine the amount of endogenous Wnt signaling in the 
ovarian cancer cell lines a TOPflash assay was performed. The ovarian cancer cells had 
either the TOPflash or the control FOPflash vector transfected into them. The TOPflash 
vector had six TCF binding sites allowing endogenous TCF to bind and recruit the 
remainder of the Wnt transcription complex. This complex activates the expression of 
luciferase. Luciferase Assay Reagent was added and the light produced was measured 
with a Monolight® 2010 Luminometer (Analytical Luminescence Laboratory, San Diego, 
CA). The FOPflash vector was used as a control. It had six mutated TCF binding sites. 
TCF is not able to bind. Therefore it is not able to recruit the transcription complex and 
luciferase is not expressed. Each experiment was performed in triplicate. 
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restriction sites of pCS2+. The full length antisense construct (pCS2+/a.s-hPygo2) was 
prepared by the digestion of pCS2+/hPygo2 with BamHI and Cia! restriction enzymes 
and ligating the released fragment into the BamHI and Cia! sites of pCS2+. All plasmids 
were sequenced with the USB Sequencing Kit (Amersham) to confirm specificity. 
Gal-4-hPygo2 fusion proteins were constructed by PCR amplification of different 
regions of hPygo2 (see Figure 3.3A) followed by the insertion into the EcoRI and Xhol 
restriction sites of pCMV-Tag2b (Stratagene). hPygo2 inserts were then subcloned from 
pCMV-Tag2b into the EcoRI and Hindlll restriction sites of pMG4 to make N-terminal 
Gal-4-hPygo2 fusion proteins. All plasmids were sequenced with the USB Sequencing 
Kit (Amersham) to confirm correct insert sequences. 
2.4 Ga14-fusion Transcription Assays 
2 x 105 cultured cells were seeded in 6-well plates 24 hours prior to transfection. 
Using the Effectene® Transfection Reagent (Qiagen) 0.15 J.lg of each of the pFR luc 
reporter, a pM pygopus vector, and the RSV ~-gal control plasmid were transfected into 
TOV-210 and TOV-112D cells. After 48 hours cells were washed with PBS and protein 
was extracted in Luciferase Cell Culture Lysis Buffer (Promega). Luciferase and~­
galactosidase reporter expression was measured as previously described. Luciferase 
values were also normalized by total protein as determined by BioRad® assays. 
2.5 Protein Extraction and Western Immunoblots 
Protein was extracted directly in SDS PAGE sample buffer from cells on 80% 
confluent plates and homogenized several times through a 21 G syringe. 20 J.lL of protein 
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Figure 2.2 
Gal4 Assays. To determine the amount oftransactivation activity ofhPygo2 in the 
presence and absence of the Wnt pathway, Gal4 Assays were performed. The hPygo2-
Gal4 Binding Domain fusion protein binds the Gal4 binding sites, and the transactivation 
activity of hPygo2 is measured by luciferase expression. 
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Table 2.1 
Primer Sequences and PCR Conditions for Gal-4-hPygo2 Constructs. 
TA = Primer annealing temperature. N = Number of annealing/elongation cycles. 
Synthetic nuclear localization sequence is in bold. Synthetic stop codon is underlined 
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Construct Upstream primer (5'-3') Downstream primer (5'-3') TA* N** 
Gal-4- GTCCCCCACTCCAT- TCAGCCAGGGGGTG- 60 35 
hPygo2-1 GGCCGCCTCG CCAAGCTGTTG 
Gal-4- ATGGCTCCAAAGAAG- TCACCCATCGTT AGC- 60 35 
hPygo2-2 AAGCGT AAGGTACAG- AGCC 
CCTCCCCCAGGCTTGG 
Gal-4- ATGGCTCCAAAGAAGA- TCAGCCAGGGGGTG- 60 35 
hPygo2-3 AGCGTAAGGTAGCATCC- CCAAGCTGTTG 
AACCCTTTTGAAGATGAC 
Gal-4- GTCCCCCACTCCATG- CCAAGGAA TGGAGG- 65 35 
hPygo2-4 GCCGCCTCG GGCTGCAAC 
Gal-4- ATGAAGAGTCCAGAA- CCAAGGAA TGGAGG- 65 35 
hPygo2-5 AAGAAGC GGCTGCAAC 
Gal-4- ATGAAGAGTCCAGAAA- TCACCCATCGTTAGC- 60 35 
hPygo2-6 AGAAGC AGCC 
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lysate was run on 10% SDS-PAGE protein gels and transferred to Hybond™ ECL™ 
nitrocellulose membranes under semi-dry conditions. Western immunoblots were 
performed essentially as previously described (Popadiuk eta/, 2006). Proteins were 
immunodetected using the ECL ™ Western Blotting Detection System and Hyperfilm TM 
(Ambersham Pharmacia Biotech). Rabbit polyclonal anti-pygopus antisera was 
developed previously (Popadiuk eta/, 2006). Mouse monoclonal anti-~-catenin 
antibodies and rabbit polyclonal anti-ERK antisera were purchased from Santa Cruz. 
Mouse monoclonal anti-~-actin antibodies were purchased from Sigma. 
2.6 Co-immunopreciptations 
Cells were grown on 6-well plates until 80% confluent. Cells were washed with 
cold PBS. Protein was extracted in lysis buffer (1 mg/mL aprotinin, 1 mg/mL leupeptin, 
5 mg/mL TLCK) and immunoprecipitated with anti-pygopus antisera overnight at 4°C. 
The primary antibody was bound to Protein A Sepharose beads. Immunoprecipitated 
protein was washed with Triton Media and 150 mM NaCI. Sample buffer was added and 
co-immunoprecipiated protein was detected by Western immunoblotting, as previously 
described. 
2. 7 Double labeling Immunocytochemistry (ICC) 
2 x 104 TOV-112D, TOV-21G, lOSE 397, or NIH-OVCAR-3 cells were seeded 
in eight-well Lab-Tek® chamber slides (Nalge Nunc International, USA) sixteen hours 
prior to fixation. Cells were washed with cell culture PBS and fixed with 4% 
paraformaldehyde. Cells are treated with 0.2% Triton X-1 00 in ICC PBS, washed with 
,-------------------------------------- ---
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ICC PBS, and then blocked with 10% normal donkey serum (NDS). Antibodies for 
hPygo2 and B-catenin or hPygo2 with CENP-E were diluted in 1.5% NDS in ICC PBS 
and incubated with the cells in a hwnid chamber overnight at 4°C. Cells were again 
treated with 0.2% Triton X-1 00/ICC PBS and washed with ICC PBS. The biotinylated 
donkey anti-rabbit and cy3 donkey anti-mouse secondary antibodies were diluted in 1.5% 
NDS in ICC PBS and incubated with the cells for 30 minutes at room temperature. After 
the secondary antibody incubation, cells were washed, and strepavidin-FITC was 
conjugated to the biotin molecules. Fluorescent cells were viewed under a Olympus® 
BX50WI confocal microscope and photographs were taken using the Olympus® 
Fluoview FV3000 imaging software. 
For CENP-E and hPygo2 double immunocytochemical staining, TOV -112D cells 
were synchronized with 2 mM thymidine and then immunocytochemically stained using 
hPygo2 and CENP-E antibodies. TOV-112D cells were first synchronized to have the 
maximum number of cells undergoing mitosis simultaneously. 4 x 104 TOV -112D cells 
were seeded in 4-well chamber slides. One day later they were treated with 2 mM 
thymidine. 36 hours later the thymidine was removed and the cells were washed with 
PBS and fresh DMEM was added. Eight hours later the cells were fixed, stained and 
viewed. 
2.8 Antisense Knockdowns 
Antisense oligonucleotides or siRNA was used to knockdown pygopus and B-
catenin protein expression with the TOV-112D and TOV-21G cell lines. Both strategies 
were employed in each cell line with the most effective strategy presented in this thesis. 
.~------------ - ---
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An antisense phophorothioated oligonucleotide (5'-GGCTGAGCAAATCGTTOG0-3') 
was complimentary to the intermediary coding region (nucleotides 635-654 of 
hPygopus2, OenBank number AF457208). Control oligonucleotide sequences were the 
J3-catenin mismatch (G*C*C*TOAGCTAATCATT*G*O*T where* represents 
phosphothioate bonds) and the human non-specific Xenopus Pygopus2 
(T*T*T*OCOCCOTTTCTT*C*T*C). The hPygopus2 siRNA sequence 
(CCAGCCUCUGOOUCAAAAC; target nucleotides 40 1-420) was designed and 
purchased using the online Qiagen online ordering system. J3-catenin and non-specific 
siRNA was purchased as a siRNA/siAB ™ Assay Kit from Upstate Biotechnology. 
4 x 104 TOV-112D or TOV-210 cells were seeded in 24-well plates 16 hours 
prior to transfection. Using Oligofectamine Transfection Reagent (Invitrogen, USA), 250 
nM of oligonucleotide was transfected into the TOV-210 cells. 0100 nM siRNA was 
transfected into the TOV -112D cell line using the RNAiF ect TM transfection reagent 
(Qiagen). Media was changed 24 hours post-transfection. Cells were counted 48 and 72 
hours post-transfection using a hemacytometer. To confirm the reduction in J3-catenin 
and hPygo2 protein levels, Western imrnunoblots were performed as per the protocol 
described in Section 2.5. 
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Figure 2.3 
hPygo2, (3-catenin and BCL9 antisense oligonucleotide and siRNA sequences. 
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Name Seguence Target Location 
11 1221 
Pygopus siRNA CCAGCCUCUGGGUCAAAAC 401-20 
Pygopus Oligo GGCTGAGCAAATCGTTGGG 635-54 
Non-specific Oligo T*T*T*GCGCCGTTTCTT*C*T*C No complimentary sequence 
-
Ann motif 3697 
13-catenin Oligo T*G* A *GAGCTTAACCACAA *C*T*G - 1685-1704 
Mismatch Oligo G*C*C*TGAGCTAATCATT*G*G*T No complimentary sequence 
13-catenin siRNA Unavailable Unspecified 
Non-specific siRNA Unavailable No complimentary sequence 
HDI,2&3 
Ill 6267 
BCL9siRNAc ACUGCAGCAGGAGUUUUAU 2159-78 
BCL9siRNAd AUCCCAGAUGGUCGAAAUU 2532-51 
* = Phosphothioate Bond 
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3.1 Pygopus localizes to the nucleus in EOC cell lines 
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I performed indirect double labeling immunocytochemistry to determine ~-
catenin and pygopus localization with the TOV-112D, TOV-21G, OVCAR-3, and lOSE 
397 cells (see Figure 3.1 ). Nuclear accumulation of ~-catenin is a hallmark of canonical 
Wnt pathway activation and was used to assess pathway activation status in these cell 
lines. Consistent with a ~-catenin activating mutation, overexpressed ~-catenin was 
found at high levels throughout TOV -112D cells, with pygopus co-localization occurring 
in the nucleus. Pygopus also localized in TOV-21G cells to the nuclei. For comparison, 
in NIH:OVCAR-3 cells (3-catenin localized primarily to the membrane and pygopus was 
concentrated in the nucleus. The lOSE 397 cell line had perinuclearly-located pygopus 
and membrane-associated (3-catenin. Because of its central role in Wnt-mediated 
transcription in other systems (Wright & Tijan, 2009; Mieszczanek eta/, 2008; Nair et a/, 
2008; Fiedler eta/, 2008; Jonckheere eta/, 2008; reviewed in Jessen et al, 2008), I 
expected that ifPygopus was involved in Wnt signaling in these cells, it would be 
co localized with ~-catenin. On the contrary, the lack of ~-catenin and pygopus nuclear 
co-localization within the TOV-21G cell line suggests that pygopus function in these 
cells is independent of ~-catenin. 
3.2 Endogenous Wnt activity is consistent with the presence of active J3-catenin 
We assayed TCF-dependent transcriptional activity to determine the presence and 
levels of endogenous canonical Wnt activity within the (3-catenin-postive and -negative 
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Figure 3.1 
Double immunocytochemistry of hPygo2 and ~-catenin. iOSE397 immortalized 
epithelial ovarian cells, as well as TOV-1120, TOV-210, and OVCAR-3 EOC cell lines 
were immunocytochemically stained using hPygo2 and ~-catenin antibodies. Pre-
immune sera was used as a control for the hPygo2 antibody. Scale bar equals 50 J.lm. 
hPygo2localized to the nucleus in the EOC cell lines and perinuclearly in the iOSE397 
cells. ~-catenin expression was variable, with it localizing to the cell membranes of 
iOSE397 and OVCAR-3 cells, expressed throughout the TOV-112D cells and is not 
detectable in the TOV-210 cells. 
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Figure 3.2 
Endogenous Wnt activity in Epithelial Ovarian Cancer cell lines. A. TCF -dependent 
transcriptional activity was determined by TOPflash assays. The presence and levels of 
endogenous canonical Wnt activity were determined in TOV-112D, TOV-21G, OVCAR-
3, and SK-OV-3 cells. B. hPygo2 immunoprecipitation in TOV-112D and TOV-21G 
cells, followed by P-catenin Western blotting. P-catenin was found to bind with hPygo2 
in the TOV-112D cells, but not in the TOV-21G cells. Total protein extracts are also 
shown. 
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EOC cell lines. TOPflash vectors contain consensus TCF-binding sites located in 
sequence with a luciferase reporter gene. The TOPflash vector expresses luciferase when 
bound by the TCF-mediated canonical Wnt transcription complex. FOPflash plasmids 
are identical to TOPflash with the exception that they contain a mutated TCF binding 
site. Cells were transfected with either the wildtype TCF-dependent luciferase reporter 
vector (pTOPflash) or the mutated control vector (pFOPflash). The ratio of pTOPflash 
luciferase activity to FOPflash reporter activity is a measure of endogenous canonical 
Wnt activity. TOV -112D cells demonstrated a significant amount of constituitive 
canonical Wnt activity (see Figure 3.2) consistent with a known activating mutation in its 
13-catenin as demonstrated previously (Wu et al., 2001 ). On the other hand, in 
comparison, TOV -210, OVCAR-3, and SKOV3 cells had baseline levels of canonical 
Wnt activity. 
3.3 Pygopus transactivation activity is independent of 13-catenin expression 
The hPygopus2-Gal4 fusion contructs and pFR luc reporter plasmid were 
transfected into the TOV-112D and TOV-210 cell lines, as described in Figure 3.3A. 
When transfected, the hPygopus2-0al4 fusion proteins were expected to bind the Oal4 
binding site on the pFR luc plasmid and initiate expression of the /uciferase reporter 
gene. The ability of the fusion proteins to activate transcription was measured by the 
level ofluciferase enzyme activity. Figure 3.3B shows that within TOV-112D cells, all 
portions of pygopus showed significant transactivation activity with the PHD having the 
highest fold increase over baseline. Interestingly, the TOV-210 cells, which contain 
minimal amounts of 13-catenin and have no discemable endogenous canonical Wnt 
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Figure 3.3 
Ga14 Assays. A. Schematic representation of the Gal4 constructs provided by Phillip 
Andrews, Terry Fox Laboratory, Memorial University. Constructs include the Gal4 
control (the empty pMG4 vector), aNHD + ~ (hPygo2 amino acids 1-312), PHD (amino 
acids 321-406), ~(amino acids 74-312), NHDa (amino acids 1-95), and NHDP (amino 
acids 38-95). B. The Gal4 assay performed in ovarian cancer cell lines TOV-112D and 
TOV-21G. 2 x 105 cultured cells were seeded in 6-well plates 24 hours prior to 
transfection. Using the Effectene® Transfection Reagent (Qiagen) 0.15 J.lg of each of the 
pFR luc reporter, a pM pygopus vector, and the RSV p-gal control plasmid were 
transfected into TOV -21 G and TOV -112D cells. After 48 hours cells were washed with 
PBS and protein was extracted in Luciferase Cell Culture Lysis Buffer (Promega). 
Luciferase and P-galactosidase reporter expression was measured as previously 
described. Luciferase values were also normalized by total protein as determined by 
BioRad® assays. The experiment was performed in triplicate and repeated three times. 
C. Expression of the Gal4-hPygo2 constructs in TOV-21G and TOV-112D cells. The 
Western blot is representative. The experiment was performed in triplicate. Protein 
extracts were normalized and the amount loaded was calculated based on total protein 
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concentration and P-actin Western immunoblot. D. Analysis of the transcription 
activation domain(s) in Pygo by Belenkaya eta/, 2002 demonstrating hPygo2 was able to 
activate transcription. Cells were transfected with the pG5El b-luciferase reporter 
construct (Hsu et al., 1994) and with vectors expressing GAL4 DNA-binding domain 
alone (pMl) (Sadowski et al., 1992) or with GAL4-Pygo fusion protein. A GAL4-Jun 
AC-containing Jun activation domain (amino acids 5 to 89) fused with GAL4 was used as 
a positive control. Luciferase acitivities are expressed as relative activities compared 
with cells transfected with the plasmid containing the GAL4 DNA-binding domain alone. 
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activity, also had significant amounts of transcriptional activitation from the pygopus 
fusion proteins. Although to a lesser extent, the PHD and L\ regions had the greatest fold 
mcreases. 
3.4 Pygopus expression is required for the proliferation of EOC 
To determine the requirements ofPygo and P-catenin, I reduced protein levels to 
approximately 50% of endogenous levels using antisense oligonucleotides in the TOV-
21G cells and antisense siRNA in the TOV-112D cells (see Figures 3.4 and 3.5). The 
specificity of the protein knockdown was determined by Western immunoblotting. Both 
TOV -112D and TOV -21 G EOC cell lines had significantly decreased proliferation in the 
hPygo-reduced samples as compared with the control mock transfected and non-specific 
siRNA and oligonucleotide transfected cells. This indicates that hPygo2 expression is 
required for the growth of these two EOC cell lines. 
P-catenin protein levels were significantly decreased by antisense siRNA in the 
TOV-112D cell line. The reduction in P-catenin protein expression resulted in a decrease 
in TOV-112D proliferation as compared with the cells transfected with non-specific 
siRNA and mock-transfected cells. This reduction in proliferation was similar to the 
reduction in the hPygo2-reduced TOV-112D cells. P-catenin was not detectable in the 
TOV-21G cell line. Anti-P-catenin oligonucleotides did not decrease the proliferation of 
TOV -21 G cells at either 48 or 72 hours post-transfection. BCL9 expression was reduced 
in the TOV-112D cells with BCL9 c and BCL9 d siRNA (see Figure 2.3 for a 
representation of the nucleotide changes). The reduction in proliferation of the TOV-
112D cells treated with either the BCL9 cor BCL9 d siRNA was comparable to the 
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Figure 3.4 
siRNA knockdown studies in TOV -112D EOC cells. A. Cell counts at 48 and 72 hours 
for TOV-112D cells transfected with nonspecific, hPygo2, P-catenin and BCL9 siRNA. 
Error bars represent standard error. B. Western analysis ofhPygo2, P-catenin and, as a 
control, ERK perfonned 48 hours after knockdown with nonspecific, hPygo2, P-catenin 
and BCL9 siRNA. Results are based on three experiments perfonned in triplicate. 
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Figure 3.5 
Antisense oligonucleotide knockdown studies in TOV-21G EOC cells. A. Cell counts 
at 48 and 72 hours ofTOV-21G cells transfected with nonspecific, hPygo2, 13-catenin and 
BCL9 antisense oligonucleotides. B. Western analysis ofhPygo2, 13-catenin and, as a 
control, ERK 48 hours after knockdown with nonspecific, hPygo2, 13-catenin and BCL9 
antisense oligonucleotides. Results are based on three experiments performed in 
triplicate. 
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reduction seen in the TOV-112D cells treated with anti-hPygo2 or anti-P-catenin siRNA. 
No equivalent BCL9 antisense oligonucleotide was available for use with the TOV -21 G 
cells. These results indicate that hPygo2 maybe acting differently in the Wnt-active 
TOV-112D cells than in the Wnt-inactive TOV-21G cells. hPygo2 is a known 
component of the Wnt transcription complex that includes P-catenin and BCL9. In the 
TOV-112D cells siRNA knockdowns ofhPygo2, P-catenin and BCL9 produced similar 
decreases in proliferation, consistent with Wnt and the Wnt transcription complex playing 
an instrumental role in the proliferation of these cells. However in the Wnt-inactive 
TO V-21 G cells, reductions in hPygo2 protein levels still resulted in decreased 
proliferation of the cells despite minimal Wnt activity, only faintly detectable expression 
of P-catenin and no significant effect of the anti-P-catenin oligonucleotide. This 
indicates that hPygo2 is required for the proliferation of the TOV-21G cells 
independently of P-catenin and the Wnt pathway. 
3.5 Localization ofhPygo2 in dividing TOV-112D cells 
During my immunocytochemical analysis of the localization ofhPygo2 within 
ovarian cancer cell lines, I observed discrete punctate areas of hPygo2 in cells that were 
dividing. It was hypothesized that Pygopus may have a role in mitosis. Cell cycle 
synchronization and double immunocytochemistry was performed with antibodies against 
Pygopus and the kinetochore protein, CENP-E. CENP-E associates with centromeres 
during congression where the chromosomes ultimately end up with their centromeres 
situated in middle of the spindle at the metaphase plate. It then relocates to the spindle 
midzone at anaphase, and is quantitatively discarded at the end of the cell division (Yen 
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eta/, 1992). CENP-E is a centromere-associated protein and required for progression 
from metaphase to anaphase (Yen et al, 1991). The double-ICC I performed used CENP-
E as a marker of mitosis, and showed discrete areas of hPygo2 staining during a period in 
the cell cycle where CENP-E staining was observed (see Figure 3.6). No CENP-E 
co localization was observed indicating that these discrete punctuate areas of hPygo2 are 
not at the centromeres. However, using CENP-E as a marker of the metaphase to 
anaphase portion of the cell cycle, the immunocytochemical results indicate that Pygopus 
localizes to discrete punstate areas during mitosis. Pygopus overexpression in the EOC 
cell lines I studied is consistent with it having a role in the uncontrolled mitosis that is 
occurring in these cells. Further study is needed to elucidate the non-Wnt functions of 
Pygopus. 
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Figure 3.6 
Double immunocytochemistry ofhPygo2 and CENP-E in synchronized TOV-112D 
cells. Thymidine-synchronized TOV-112D cells were immunocytochemically stained 
using hPygo2 and CENP-E antibodies. 
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DISCUSSION 
4.1 hPygo2 transactivation activity 
Wells;page 105 
TOV-112D cells demonstrated significant transactivation activity with the PHD 
and 11 having the highest fold increase over baseline. Interestingly, the TOV-21G cells, 
which contain minimal amounts of ~-catenin and have no discemable endogenous 
canonical Wnt activity, also had significant amounts of transcriptional activitation from 
the pygopus fusion proteins. Although to a lesser extent than in TOV -112D cells, the 
PHD and 11 regions had the greatest fold increase. 
The activation with the PHD in TOV-112D cells may be partly explained by its 
ability to recruit the canonical Wnt transcription complex. A possible explanation for the 
11 construct exhibiting transactivation activity is the recently discovered hPygo2 NPF 
motif. Stadeli and Basler (2005) demonstrated that single point mutations of the 
uncharged amino acids N, P, or Fat positions 76-78 resulted in an almost complete loss 
oftransactivattion activity in a UAS-luc assay where the hPygo2 NHD was tethered to 
DNA with the G4°80 in 82 cells. These important amino acids were present in the 11 
construct and possibly provide a portion of its transactivation activity. However they are 
also present in the two NHD constructs, which have lower transactivation activities, and 
therefore the NPF motif cannot account for all the transactivation occurring within the 11 
construct. 
As there is no significant Wnt activity and minimal levels of ~-catenin expression 
in TOV -21 G cells, the transactivation activity of pygopus in TOV -21 G cells is 
independent of ~-catenin expression. However, ~-catenin and the Wnt transcription 
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complex may be required for hPygo2 localization and DNA thethering. As the Gal4 
transcription assay artificially tethers the hPygo2 construct to the transcription vector, the 
experiment only measures hPygo2's ability to recruit and bind the necessary transcription 
machinery, but is not able to comment on its ability to bind the DNA promoter 
sequences. 
4.2 Wnt signaling and cancer 
Deregulation of the Wnt pathway leading to abnormal overexpression of 
mitogenic Wnt-target genes has been linked to many cancers (Bienz & Clevers, 2000; 
Pola.kis, 2000). 80% of all colorectal cancers show inactivation of APC which drastically 
reduces the phosphorylation and degradation of ~-catenin. In the remaining 20%, many 
have activating point mutations in ~-catenin that alter its GSK-3~ phosphorylation sites 
causing a constitutive increase in its stability. Similar mutations in ·other Wnt 
components also result in ~-catenin accumulation and ligand-independent target gene 
over-expression. Wnt components have been implicated in a number of cancers and 
diseases (see Table 1.3 and Section 1.2.4). There is much evidence, however, that the 
canonical Wnt pathway does not play a role in non-endometrioid EOC (Kildal eta!, 2005; 
Faleiro-Rodrigues eta!, 2004; Faleiro-Rodrigues et al, 2005, Popadiuk et al., 2006). 
My results are consistent with canonical Wnt signaling having a role in the 
proliferation of endometrioid EOC. TOV-112D cells were isolated from a 42 year old 
woman with a primary malignant adenocarcinoma of the ovary, specifically an 
endometrioid carcinoma, grade 3, stage IIIC (Provencher et al, 2000). In assays for TCF-
dependent transcriptional activity, TOV -112D cells demonstrated a significant amount of 
Chapter 4: Discussion Wells;page 107 
constituitive canonical Wnt activity (see Figure 3.2) consistent with a known activating 
mutation in ~-catenin as demonstrated previously (Wu et al., 2001). As well, protein 
knockdowns experiments with anti-~-catenin and anti-BCL9 siRNA resulted in decreased 
proliferation of the TOV -112D cells. 
4.3 Wnt-independent functions of pygopus 
Pygopus is a component of the Wnt transcription complex. It associates with 
Armadi11o/~-catenin and T cell factor (TCF) through the Legless/BCL9 adaptor, but its 
molecular function in TCF-mediated transcription is not completely described. Pygopus 
has been suggested to have a transactivation function (Kramps et al., 2002). For 
example, when fused to Gal4, Pygopus was able to activate transcription from a reporter 
vector containing a Gal4 binding site (Belenkaya et al., 2002). When overexpressed in 
Xenopus embryos, hPygo2 activated expression of the Wnt marker Engrailed-2 and 
induced secondary axis formation, two results consistent with Wnt activation (Lake and 
Kao, 2003). When fused to TCF, the pygopus NHD was able to activate TOPflash 
reporter expression (Thompson, 2004). This evidence suggests that pygopus acts as a 
transcriptional activator with the transactivation function dependent on the NHD. 
Mieszczanek et a/ (2008) used a groucho-null allele to show that Groucho 
represses Wingless target genes during Drosophila development. Interestingly, groucho 
pygo double-mutants revealed that Pygo is not obligatory for transcriptional and 
phenotypic Wingless signaling in the absence of Groucho and other transcriptional 
antagonists of Wingless signaling. This indicated an anti-repressor function of Pygo. 
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The authors proposed that Pygo predisposes Drosophila TCF target genes for rapid 
Wingless-induced transcription or that it protects them against premature shut-down. 
In the research that I have presented this thesis, I demonstrated that pygopus is 
required for proliferation of ovarian cancer cells both in the presence and absence of Wnt 
signaling. It is not unique, as other components of the Wnt pathway, such as B-catenin, 
a.xin, and APC, are engaged in cellular functions outside of canonical Wnt signaling 
(Bienz, 2002; Ciani eta/, 2004). Previous research in our labarotory demonstrated that 
Pygopus was overexpressed in EOC (Popadiuk et a/, 2006), despite the fact that there is 
much evidence that the canonical Wnt pathway does not play a role in non-endometrioid 
EOC (Kildal eta/, 2005; Faleiro-Rodrigues eta/, 2004; Faleiro-Rodrigues eta/, 2005). 
As well, the Pygopus knockdown studies I performed demonstrated that pygopus was 
required for proliferation in both the Wnt-active TOV-112D and Wnt-inactive TOV-21G 
cell lines, indicating non-canonical Wnt activity for pygopus. 
I went on to study one possibility of a non-canonical function of Pygopus. During 
my immunocytochemical analysis of the localization of Pygopus within ovarian cancer 
cell lines, I observed discrete punctate areas of Pygopus in cells that were dividing. It 
was hypothesized that Pygopus may have a role in mitosis. Cell cycle synchronization 
and double immunocytochemistry was performed with antibodies against Pygopus and 
the kinetochore protein, CENP-E. CENP-E associates with centromeres during 
congression, where the chromosomes ultimately end up with their centromeres situated in 
middle of the spindle at the metaphase plate. It then relocates to the spindle midzone at 
anaphase, and is quantitatively discarded at the end of the cell division (Yen eta/, 1992). 
CENP-E is centromere-associated protein and required for progression from metaphase to 
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anaphase (Yen eta!, 1991). The ICC I performed showed punctate staining ofPygopus 
on or around the CENP-E staining (see Figure 3.6). Using CENP-E as a marker of 
mitosis, the ICC staining indicates that Pygopus localizes to discrete areas during mitosis 
and may play a role in the cell cycle. Pygopus overexpression in the EOC cell lines I 
studied is consistent with it having a role in the uncontrolled mitosis that is occurring in 
these cells. Further study is needed to elucidate the non-Wnt functions ofPygopus. 
4.4 Pygopus as a novel therapeutic target 
With the prognosis of EOC remaining poor despite aggression surgical 
cytoreduction and chemotherapy, it is important to identify novel markers and therapeutic 
targets (See eta!, 2003). A variety of mRNAs are now being used as targets for antisense 
therapy in early phase clinical trials (Wang eta!, 2008; Xu eta!, 2008; Gleave & Monia, 
2005; See & Kavanagh, 2004), including vascular endothelial growth factor (Levine et al, 
2006), protein kinase C alpha (Advani eta!, 2004; Yuen eta!, 1999), c-rafkinase (Oza et 
a!, 2003; Cunningham eta!, 2000), raf-1 (Mullen eta!, 2004), p53 (Skilling et al, 1996), 
survivin (Ma eta!, 2005), X-linked inhibitor of apoptosis protein (Li eta!, 2000), and 
te1omerase (Yuan eta!, 2002; Kushner et al, 2002). The overexpression ofhPygo2 in 
epithelial ovarian cancer cell lines and tumors (Popadiuk et al, 2006) and the requirement 
of hPygo2 for EOC growth that I confirmed in this thesis , strongly suggests that hPygo2 
is a potential therapeutic target. 
Pygopus shows more potential as a therapeutic target than other components of 
Wnt signaling. The Pygopus knockdown studies I performed demonstrate that Pygopus 
was required for proliferation in both the Wnt-active TOV-112D and Wnt-inactive TOV-
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21 G cell lines. Canonical Wnt is not consistently active in ovarian cancer cell lines, but 
pygopus is consistently overexpressed in EOC histologic subtypes (Popadiuk et a/, 2006). 
Whereas canonical Wnt signaling appears to play a role in only endometriod EOC, my 
work indicates hPygo2 is required for both endometroid (TOV-112D) and non-
endometroid (TOV-210) EOC cells. The work I have performed along with the previous 
work described, indicate hPygo2 has greater potential as a therapeutic target in EOC than 
other Wnt components, as the Wnt pathway is not universally required for Epithelial 
Ovarian Cancer proliferation. 
hPygo2 is overexpressed in ovarian cancer cells, but in few other tissues. This 
specificity to EOC would limit the effect ofhPygo2 antisense therapy on other cell types. 
More study is needed, but hPygo2 has potential for being a unique therapeutic target for a 
variety of EOC histologic subtypes with potentially less effect on other tissues due to its 
lack of expression. 
Further research in our laboratory has shown that hPygo2 is required for 
anchorage-independent growth and growth in severe combined immunodeficient mice 
(Popadiuk eta/, 2006). hPygo2 antisense oligonucleotides reduced anchorage-
independent growth. There was a significant decrease in the size and number of colonies 
grown in soft agar formed by SK-OV-3 cells transfected with the pooled hPygo2 
antisense oligonucleotides, compared with those transfected with the mismatched control 
oligo. The in vitro growth inhibition findings were complemented with in vivo growth 
assays to determine whether the in vivo culture environment might reverse the initial 
effects ofhPygo2 antisense oligonucleotides. hPygo2 antisense oligonucleotides or 
mismatched control oligos were transiently transfected into SK-OV -3 cells and then 
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implanted subcutaneously into severe combined immunodeficient mice. Measurable 
tumors appeared later in the mice implanted with the hPygo2 antisense oligonucleotide-
treated cells as compared with the missense-oligonucleotide transfected cells (11 weeks 
versus 14 weeks). In all cases, antisense oligonucleotide-transfected cells formed smaller 
tumors than mismatched control transfected cells and after 18 weeks, there was a visible 
difference in tumor mass between mice implanted with cells transfected with hPygo2 
antisense oligonucleotides (0.21 g) and those implanted with cells transfected with the 
mismatched control oligos (0.62 g). These results indicated that in vivo culture of 
hPygo2-transfected cells does not reverse the effect of growth inhibition by antisense 
hPygo2 antisense oligonucleotides. 
hPygo2 may also be a potential therapeutic target in other cancers. Andrews et a/ 
(2007) demonstrated that hPygo expression was required for proliferation in breast cancer 
cells. hPygo2 was highly expressed in breast cancer cell lines. The expression of 
hPygo2 mRNA was highest in the malignant breast cell lines and showed a lower 
expression level in normal breast cell lines (Hs-574, Hs-578-Bst). On the other hand, the 
expression of hPygo 1 mRNA was was not specifically overexpressed in the malignant 
cell lines and showed little correlation with the expression of hPygo2. 
Immunohistochemical analysis showed hPygo2localized to the nuclei of64% of the 
malignant tumours tested. While hPygo2 was absent from normal connective (stroma) 
tissue and adipose tissue of the breast, it did accumulate weakly but asymmetrically in the 
cytoplasm of ductal epithelium. In addition hPygo2, but not hPygo 1, knockdowns in 
MCF-7 cells and MDA-MB-468 cells produced a reduction in cell number and a decrease 
in the Wnt target gene Cyclin D1. As an instrumental component of the Wnt 
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transcription complex and with minimal expression in normal breast tissue, hPygo2 has 
potential as a therapeutic target in breast malignancies. 
Deregulation ofWnt signalling is linked to colorectal cancer (Polakis, 2000; 
Bienz and Clevers, 2000). 80% of all colorectal cancers show inactivation of APC. 
Furthermore, many colorectal tumours that are wild type for APC have activating 
mutations in ~-catenin. Typically, they are point mutations that affect its GSK3 
phosphorylation site, rendering ~-catenin refractory to degradation. Colorectal cancer 
cells that are mutant for APC or ~-catenin have high levels ofTCF-mediated 
transcription (Morin et a/, 1997), which is thought to be the basis for tumorigenesis. 
Thompson eta/ (2002) used double-stranded (ds) RNA interference on colorectal 
cancer cells that have high levels of ~-catenin-TCF -mediated transcription, to test the 
function and requirement of endogenous Pygo proteins. This transcriptional activity was 
measured with a luciferase reporter (TOPFLASH) that contains multiple TCF binding 
sites. TOPFLASH activity was high in colorectal cancer cells that are mutant for APC 
(for example, SW480 cells) or that have an oncogenic ~-caten1n mutation (for example, 
HCT116 cells). They designed RNA oligomers specific for ~-catenin, hPygol and 
hPygo2, and co-transfected SW480 and HCT116 cells with the ds RNAi oligomers, 
TOPFLASH and an internal reference plasmid. They found that in both the SW480 and 
HCT116 cells, the ~-catenin, hPygol and hPygo2 oligomers all caused a substantial 
reduction ofTOPFLASH activity, to 35% of controls (Fig. 6g,h). hPygo2 oligomers are 
less effective; they roughly halve TOPFLASH activity (Fig. 6g,h). The combined 
application of both oligomers, simultaneously or in succession, results in reductions to 
35- 40% of controls (Fig. 6h and data not shown). There are no specific effects of the 
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Pygo oligomers on FOPFLASH activity (Fig. 6h, middle). Therefore, the effects of the 
Pygo oligomers on the TOPFLASH activity are significant and specific. Finally, 
cotransfection of cells with mPygo 1 rescues the effects of both hPygo2 and hPygo 1 
oligomers, but does not rescue the effects of P-catenin depletion. They concluded that 
both human Pygo proteins are required for Wnt-dependent TCF-mediated transcription in 
colo rectal cancer cells. While not assayed, growth of these cells is predicted to be 
inhibited by Pygo knockdown consistent with that shown for B-Catenin (Rob et al, 2001 ; 
Verma et al, 2003; Sekiya et al, 2002). 
hPygo2 may also play a role in chemotherapeutic resistance. In a recent study, De 
et al (2009) generated human carcinoma (HeLa) cell lines stably expressing Pygo2, 
which counteracted vinblastine-induced apoptosis. The anti-apoptotic function was 
determined by various techniques including DNA fragmentation, sub-G 1 appearance, 
loss of mitochondrial membrane potential (Deltapsim) and the activation of caspase-9 
and caspase-3. In addition, they found that Pygo2 effectively blocks vinblastine-induced 
c-Jun and AP-1 activation, maintains the anti-apoptotic protein Bcl-2 in an 
unphosphorylated state, and therefore rendered cells resistant to apoptosis. They 
concluded the anti-apoptotic activity exerted by Pygo2 was through blocking activation 
of the JNK/AP-1 signaling pathway induced by vinblastine. This chemotherapeutic 
resistance is the first to be linked to hPygo2 and more research in this area is sure to 
follow. 
4.5 Conclusions 
In conclusion I have confirmed the hypothesis that hPygo2 overexpression 
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contributes to the growth of ovarian cancer cells. I have shown this through hPygo2 
expressional knockdown experiments where hPygo2-knocked-down ovarian cancer cells 
had decreased proliferation. Decreased hPygo2 levels decreased ovarian cancer cell 
proliferation independent of Wnt activity, as seen in the Wnt-inactive TOV -21 G cells. 
This indicates that hPygo2 would make a more suitable therapeutic target than other Wnt 
proteins. More research into hPygo2's Wnt-independent and Wnt-dependent functions is 
required to understand its role in ovarian cancer proliferation. 
4.6 Future directions 
My results indicate that hPygo2 is involved in in the pathogenesis of ovarian 
cancer. A study with a large patient population would be needed to confirm this. 
Prognosis, disease-free survival, and response to treatment could be correlated to hPygo2 
expression to determine if it is a valid prognostic marker. 
There has been little work done on the Wnt-independent functions ofhPygo2. As 
my results confirm that hPygo2 is important in ovarian cancer cell proliferation 
independent of Wnt activity, it is important to determine the functions that are important 
in cancer pathogenesis. Proteomics is a potential tool that can be used to further elucidate 
the role ofhPygo2, both within the Wnt transcription complex and in the absence ofWnt. 
hPygo2 and its interacting proteins could be immunoprecipitated using the antibody 
developed within our labarotory. Candidate proteins would then have to be identified, 
confirmed to interact with hPygo2 and then evaluated for their functional significance. 
After hPygo2 immunoprecipitation, interacting proteins could be identified by a 
couple techniques. First interacting proteins would be separated by a high resolution, 
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two-dimensional gel electrophoresis. Protein bands could be viewed by a non-specific 
stain such as Coomassie Blue. The different banding patterns between the Wnt-active 
(TOV-112D) and Wnt-inactive (TOV-210) cells would be indicative of proteins that 
bind to hPygo2 in the presence and absence of the Wnt pathway. Bands present in the 
TOV-210, but not TOV-112D cell precipitates would represent proteins that are possibly 
important for hPygo2's Wnt-independent functions. Similarly, bands present in the 
TOV-112D, but not the TOV-210 immuoprecipitates would possibly represent proteins 
important for hPygo2's functions in the Wnt pathway. The bands could be cut out of the 
gel, purified and analysed by matrix-assisted laser desorption/ionization time of flight 
(MALDI-TOF) mass spectrometry. MALDI is a soft ionization technique used to 
analyze biomolecules that are otherwise too fragile to be ionized by conventional 
techniques. Commonly a pulsed nitrogen laser is used to initiate the ionization. The 
laser is first passed through a crystallized matrix that protects the molecule from being 
destroyed as would be the case with direct laser ionization. The TOF mass spectrometer 
accelerates the ionized particles using an electromagnetic field. The velocity of the ion 
depends on the mass-to-charge ratio. The time that it subsequently takes for the particle 
to reach a detector is measured. This time will depend on the mass-to-charge ratio of the 
particle (heavier particles reach lower speeds). From this time one can find the mass-to-
charge ratio of the ion which can be compared to a database to identify the protein. 
An alternative to MALDI-TOF is Tandem mass Spectrometry, also known as 
MS/MS (Hardouin, 2007; Shadforth eta/, 2005; M0rtz eta/, 1996). A tandem mass 
spectrometer can be thought of as two mass spectrometers in series connected by a 
collision cell. A protein sample is sorted in the first mass spectrometer, broken into 
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smaller peptides in the collision cell, and a single peptide or a small number of peptides 
are sorted and analyzed in the second mass spectrometer. The mass spectrometers can be 
a sector MS that utilizes a static electric or magnetic sector or some combination of the 
two as a mass analyzer, a transmission quadrupole MS that separates ions based on the 
stability of their trajectories in oscillating electric fields applied to four parallel circular 
rods., or time-of-flight as discussed above. The first MS would select out proteins and 
peptides of interest. The second MS could identify the amino acid sequences of those 
peptides that could be then compared to genome sequences to identify previously 
unknown proteins that interact with hPygo2. Tandem MS is useful in samples that 
contain dozens or hundreds of compounds as the first MS will allow for the analysis of a 
just a few by the second MS. It may not be practical to identify every compound in the 
samples, so this would allow for the analysis of a smaller number of proteins of interest 
that may have significance. It would eliminate some of the purification steps after the 
initial immunoprecipitation and the possible loss of important proteins. 
Appendices 
CHAPTERS 
REFERENCES 
Wells; page 117 
Aarnio M, Mecklin JP, Aaltonen LA, Nystrom-Lahti M, Jarvinen HJ (1995). Life-time 
risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) 
syndrome. Int J Cancer 64(6):430-3. 
Aasland, R., Gibson, T., & Stewart A. (1995). The PHD finger: implications for 
chromatin-mediated transcriptional regulation. Trends Biochem. Sci. 20: 56-59. 
Abeliovich D, Kaduri L, Lerer I, Weinberg N, Amir G, Sagi M, Zlotogora J, Heching N, 
Peretz T. (1997). The founder mutations 185delAG and 5382insC in BRCA1 and 
6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast 
cancer patients among Ashkenazi women. Am J Hum Genet. 1997 Mar;60(3):505-14. 
Aberle, H., Bauer, A, Stappert, J., Kinspert, A., and Kemler, R. (1997). ~-catenin is a 
target for the ubiquitin-proteosome pathway. EMBO J. 16: 3797-3804. 
ACOG Committee Opinion Number 280 (2002). The role of the Generalist Obstetrician-
Gynecologist In The Early Detection of Ovarian Cancer. Obstet Gyneco/100: 1413. 
Adaimy L, Chouery E, Megarbane H, Mroueh S, Delague V, Nicolas E, Belguith H, de 
Mazancourt P, Megarbane A (2007). Mutation in WNT10A is associated with an 
autosomal recessive ectodermal dysplasia: the odonto-onycho-dermal dysplasia. Am. J. 
Hum. Genet. 81: 821-828. 
Adami HO, Hsieh CC, Lambe M, Trichopoulos D, Leon D, Persson I, Ekbom A, Janson 
PO. (1994). Parity, age at first childbirth, and risk of ovarian cancer. Lancet 344:1250-4 
Advani R, Peethambaram P, Lum BL, Fisher GA, Hartmann L, Long HJ, Halsey J, 
Holmlund JT, Dorr A, Sikic BI (2004). A Phase II trial of aprinocarsen, an antisense 
oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to 
patients with advanced ovarian carcinoma. Cancer. 100(2):321-6. 
AiM, Holmen SL, Van Hul W, Williams BO, Warman ML (2005). Reduced affinity to 
and inhibition by DKK1 form a common mechanism by which high bone mass-
associated missense mutations in LRP5 affect canonical Wnt signaling. Mol Cell Bioi 
25:4946-4955. 
Al-A wadi SA, Teebi AS, Farag TI, Naguib KM, El-Khalifa MY (1985). Profound limb 
deficiency, thoracic dystrophy, unusual facies, and normal intelligence: a new syndrome. 
J. Med Genet. 22: 36-38. 
Alberts OS; Marth C; Alvarez RD; Johnson G; Bidzinski M; Kardatzke DR; Bradford 
WZ; Loutit J; Kim DH; Clouser MC; Markman M (2008). Randomized phase 3 trial of 
interferon gamma-1 b plus standard carboplatinlpaclitaxel versus carboplatinlpaclitaxel 
Appendices Wells; page 118 
alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: 
results from a prospectively designed analysis of progression-free survival. Gyneco/ 
Onco/. 109(2):174-81. 
Anderson GL, Judd HL, Kaunitz AM, Barad DH, Beresford SA, Pettinger M, Liu J, 
McNeeley SG, Lopez AM; Women's Health Initiative Investigators (2003). Effects of 
estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the 
Women's Health Initiative randomized trial. JAMA. 290(13): 1739-48. 
Anderson JP, Ross JA, Folsom AR. (2004). Anthropometric variables, physical activity, 
and incidence of ovarian cancer: The Iowa Women's Health Study. Cancer 100:1515- 21. 
Andrews PG, Lake BB, Popadiuk C, Kao KR (2007). Requirement ofPygopus 2 in 
breast cancer. Int J Oncol. 30(2):357-63. 
Arnold WP, Merkx MAW, Steijlen PM (1995). Variant of odontoonychodermal 
dysplasia? Am. J. Med. Genet. 59: 242-244. 
Arzimanoglou II, Lallas T, Osborne M, Barber H and Gilbert F (1996). Microsatellite 
instability differences between familial and sporadic ovarian cancers. Carcinogenesis 
17: 1799- 1804. 
Bain C, Purdie D, Green A, et al. (1996). Exercise may protect against ovarian cancer. 
Am J Epidemio/143:72. 
Balkwill, FR (2000). Re: Possible Role of Ovarian Epithelial Inflammation in Ovarian 
Cancer. JNCI Journal of the National Cancer Institute 92(2): 162-163 
Barker, N., Hurlstone, A., Musisi, H., Miles, A., Bienz, M., and Clevers, H. (2001). The 
chromatin remodeling factor Brg-1 interacts with B-catenin to promote target gene 
activation. EMBO J. 20: 4935-4943. 
Bast RC, Klug TL, StJohn E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T~ 
Griffiths CT, Parker L, Zurawski VR, Knapp RC (1983). A radioimmunoassay using a 
monoclonal antibody to monitor the course of epithelial ovarian cancer. N Eng/ J Med 
309:883- 887 
Bauer, A., Huber, 0., and Kemler, R. (1998). Pontin52, an interaction partner of B-
catenin, binds the TATA box binding protein. Proc. Nat!. Acad Sci. USA 95: 14787-
14792. 
Behrens, J., von Kries, J.P., Kuhl, M., Bruhn, L., Wedlich, D., Grosschedl, R., and 
Birchmeier, W (1996). Functional interaction of ~-catenin with the transcription factor 
LEF-1. Nature 382: 638-642. 
Appendices Wells; page 119 
Behrens, J., Jerchow, B. A., Wurtele, M., Grimm, J., Asbrand, C., Wirtz, R., Kuhl, M., 
Wedlich, D., and Birchmeier, W. (1998). Functional interaction of an axin homolog, 
conductin, with ~-catenin, APC, and GSK3~. Science 280: 596-599. 
Belenkaya, T.Y., Han, C., Standley, H. J., Lin, X., Houston, D. W., Heasman, J., and Lin, 
X. (2003). pygopus encodes a nuclear protein essential for wingless/Wnt signaling. 
Development 129: 4089-4101. 
Berchuck A, Heron KA, Carney ME, Lancaster JM, Fraser EG, Vinson VL, eta/. (1998). 
Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clin Cancer 
Res 4:2433-7. 
Bergfeldt K, Rydh B, Granath F, Gronberg H, Thalib L, Adami HO, Hall P. (2002). Risk 
of ovarian cancer in breast-cancer patients with a family history of breast or ovarian 
cancer: a population-based cohort study. Lancet 360(9337):891-4. 
Bergmann C, Senderek J, AnhufD, Thiel CT, Ekici AB, Poblete-Gutierrez P, van 
Steensel M, Seelow D, Niimberg G, Schild HH, Niirnberg P, Reis A, Frank J, Zerres K 
(2006). Mutations in the gene encoding the Wnt-signaling component R-spondin 4 
(RSP04) cause autosomal recessive anonychia. Am J Hum Genet. 79(6):1105-9. 
Bertone ER, Newcomb PA, Willett WC, Stampfer MJ, Egan KM. (2002). Recreational 
physical activity and ovarian cancer in a population-based case-control study. Int J 
Cancer 99:431-6. 
Bertone ER, Willett WC, Rosner BA, et al. (200 1 ). Prospective study of recreational 
physical activity and ovarian cancer. J Nat/ Cancer Inst 93:942-8. 
Biason-Lauber A, Konrad D, Navratil F, Schoenle EJ (2004). A WNT4 mutation 
associated with Miillerian-duct regression and virilization in a 46,XX woman. N Eng/ J 
Med 351(8):792-8. 
Bidoli E; LaVecchia C; Talamini R; Negri E; Parpinel M; Conti E; Montella M; Carbone 
MA; Franceschi S (200 1 ). Micronutrients and ovarian cancer: a case-control study in 
Italy. Ann Onco/ 12(11):1589-93. 
Biesma RG, Schouten LJ, Dirx MJ, Goldbohm RA, van den Brandt PA. (2006). Physical 
activity and risk of ovarian cancer: results from the Netherlands cohort study (the 
Netherlands). Cancer Causes Contro/11:109-15. 
Bienz M (2002). The subcellular destinations of APC proteins. Nat Rev Mol Cell Bioi 3: 
328-38 
Bienz, M. & Clevers, H. (2002). Linking colorectal cancer to Wnt signaling. Ce//103: 
311-320. 
- ------ - - - - - ----- ---------- --
Appendices Wells; page 120 
Blaydon DC, Ishii Y, O'Toole EA, Unsworth HC, Teh MT, RiischendorfF, Sinclair C, 
Hopsu-Havu VK, Tidman N, Moss C, Watson R, de Berker D, Wajid M, Christiano AM, 
Kelsell DP (2006). The gene encoding R-spondin 4 (RSP04), a secreted protein 
implicated in Wnt signaling, is mutated in inherited anonychia. Nat Genet. 38(11):1245-
7. 
Bolis G, Colombo N, Pecorelli S, Torri V, Marsoni S, Bonazzi C, Chiari S, Favalli G, 
Mangili G, Presti M, Zanaboni F, Mangioni C and G.I.C.O.G.: Gruppo Interregionale 
Collaborativo in Ginecologia Oncologica (1995). Adjuvant treatment for early epithelial 
ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further 
treatment or chromic phosphate (32P). Ann Oncol. 6(9):887-93. 
Bookman, MA for the Gynecologic Cancer InterGroup (GCIG) (2006). GOG0182-
ICON5: 5-arm phase III randomized trial ofpaclitaxel (P) and carboplatin (C) vs 
combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) 
in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal 
(PPC) carcinoma. Journal of Clinical Oncology, 2006 ASCO Annual Meeting 
Proceedings Part 1 24(18S): 5002 
Bosetti C; Negri E; Franceschi S; Pelucchi C; Talamini R; Montella M; Conti E; La 
Vecchia C (2001). Diet and ovarian cancer risk: a case-control study in Italy. Int J 
Cancer 93(6):911-5. 
Boyd, J (2003). Specific keynote: Hereditary ovarian cancer: what we know. Gynecol 
Onco/ 88:S8. 
Boyd J, Sonoda Y, Federici MG, Bogomolniy F, Rhei E, Maresco DL, Saigo PE, 
Almadrones LA, Barakat RR, Brown CL, Chi DS, Curtin JP, Poynor EA, Hoskins WJ 
(2000). Clinicopathologic features ofBRCA-linked and sporadic ovarian cancer. JAMA 
283(17):2260-5. 
Boyden LM, Mao JH, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu DQ, Insogna K, 
Lifton RP (2002). High bone density due to a mutation in LDL-receptor-related protein 
5. N Engl. J. Med 346: 1513- 1521. 
Brabletz, T., Jung, A., Dag, S., Hlubek, F., and Kirchner, T. (1999). ~-catenin regulates 
the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am J 
Pathol. 155:1033-1038. 
Brannon, M., Brown, J. D., Bates, R., Kimelman, D., and Moon, R. T. (1999). XCtBP is 
a XTcf-3 co-repressor with roles throughout Xenopus development. Development 126: 
3159-3170. 
Brooks, SE (1994). Preoperative evaluation of patients with suspected ovarian cancer. 
Gynecol Onco/55: S80. 
Appendices Wells; page 121 
Buendia, M.A. (2000). Genetics of hepatocellular carcinoma. Semin. Cancer Bioi. 10: 
185-200. 
Buermeyer AB, Deschenes SM, Baker SM and Liskay RM (1999). Mammalian DNA 
mismatch repair. Annu Rev Genet 33: 533-564. 
Cadigan, K. M. and Nusse, R. (1997). Wnt signaling: a common theme in animal 
development. Genes Dev. 11: 3286-3305. 
Canney PA, Moore M, Wilkinson PM, James RD (1984). Ovarian cancer antigen CA125: 
A prospective clinical assessment of its role as a tumour marker. Br J Cancer. 50:765-
769 
Cannistra SA (2004). Cancer of the ovary. N Eng/ J Med 351: 2519. 
Capib, A., Scultz, D., Rauscher, T., & Borden, K. (2001). Solution structure of the PHD 
domain from the KAP-1 co-repressor: structural determinants for PHD, RING, and LIM 
zinc-binding domains. EMBO J. 20: 165-177. 
Caricasole A, Copani A, Caruso A, Caraci F, Iacovelli L, Sortino MA, Terstappen GC, 
Nicoletti F (2003). The Wnt pathway, cell-cycle activation and beta-amyloid: novel 
therapeutic strategies in Alzheimer's disease? Trends Pharmacal Sci 24:233- 238. 
Casagrande JT, Louie EW, Pike MC, Roy S, Ross RK, Henderson BE. (1979). 
"Incessant ovulation" and ovarian cancer. Lancet 2:170-3. 
Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY (2003). Improved 
survival in women with BRCA-associated ovarian carcinoma. Cancer. 97(9):2187-95. 
Cavallo, R. A., Cox, R. T., Moline, M. M., Roose, J., Polevoy, G. A., Clevers, H., Peifer, 
M., and Bejsovec, A. (1998). Drosophila Tcfand Groucho interact to repress Wingless 
signaling activity. Nature 395: 604-608. 
Chang ET; Lee VS; Canchola AJ; Clarke CA; Purdie DM; Reynolds P; Anton-Culver H; 
Bernstein L; Deapen D; Peel D; Pinder R; Ross RK; Stram DO; West DW; Wright W; 
Ziogas A; Hom-Ross PL (2007). Diet and risk of ovarian cancer in the California 
Teachers Study cohort. Am J Epidemiol. 165(7):802-13. 
Chen ZY, Battinelli EM, Fielder A, Bundey S, Sims K, Breakefield XO, Craig IW 
(1993). A mutation in the Norrie disease gene (NDP) associated with X-linked familial 
exudative vitreoretinopathy. Nat Genet 5:180-183 
Cheon, S. S., Nadesan, P., Poon, R. & Alman, B. A. (2004). Growth factors regulate P-
catenin-mediated TCF-dependent transcriptional activation in fibroblasts during the 
proliferative phase of wound healing. Exp. Cell Res. 293: 267-274. 
Appendices Wells; page 122 
Chilosi M, Poletti V, Zamo A, Lestani M, Montagna L, Piccoli P, Pedron S, Bertaso M, 
Scarpa A, Murer B, Cancellieri A, Maestro R, Semenzato G, Doglioni C (2003). 
Aberrant Wnt/~-catenin pathway activation in idiopathic pulmonary fibrosis. Am. J. 
Pathol. 162: 1495-1502. 
Christodoulides C, Scarda A, Granzotto M, Milan G, Dalla Nora E, Keogh J, De Pergola 
G, Stirling H, Pannacciulli N, Sethi JK, Federspil G, Vidal-Puig A, Farooqi IS, O'Rahilly 
S, Vettor R (2006). WNTIOB mutations in human obesity. Diabetologia 49(4):678-84. 
Ciani L, Krylova 0, Smalley MJ, Dale T, and Salinas PC (2004). A divergent canonical 
WNT -signaling pathway regulates microtubule dynamics: dishevelled signals locally to 
stabilize microtubules. J Cell Bioi 164:243-53 
Colnot S, Decaens T, Niwa-Kawakita M, Godard C, Hamard G, Kahn A, Giovannini M, 
Perret C (2004). Liver-targeted disruption of Ape in mice activates beta-catenin 
signaling and leads to hepatocellular carcinomas. Proc Nat/ Acad Sci USA 
101(49):17216-21. 
Copp AJ, Greene NDE, Murdoch JN (2003). The genetic basis of mammalian 
neurulation. Nat Rev Genet 4:784-793. 
Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, 
Roses AD, Haines JL, Pericak-Vance MA (1993). Gene dose of apolipoprotein E type 4 
allele and the risk of Alzheimer's disease in late onset families. Science 261:921- 923. 
de La Coste A, Romagnolo B, Billuart P, Renard CA, Buendia MA, Soubrane 0, Fabre 
M, Chelly J, Beldjord C, Kahn A, Perret C. (1998). Somatic mutations of the beta-
catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc. Nat!. 
Acad. Sci. USA 95: 8847-8851. 
Cramer, DW, Welch, WR (1983). Determinants of ovarian cancer risk. II. Inferences 
regarding pathogenesis. J Nat/ Cancer Inst. 71( 4): 717-21. 
Cramer DW, Welch WR, Scully RE, Wojciechowski CA. (1982). Ovarian cancer and 
talc: a case-control study. Cancer. 50(2):372-6. 
Crawford, H. C., Fingleton, B. M., Rudolph-Owen, L. A., Goss, K. J., Rubinfeld, B., 
Polakis, P., and Matrisian, L. M. (1999). The metalloproteinase matrilysin is a target of 
beta-catenin transactivation in intestinal tumors. Oncogene. 18: 2883-2891. 
Cunningham CC, Holmlund JT, Schiller JH, Geary RS, Kwoh TJ, Dorr A, Nemunaitis J 
(2000). A phase I trial of c-Rafkinase antisense oligonucleotide ISIS 5132 administered 
as a continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res. 
6(5):1626-31. 
Appendices Wells; page 123 
Curtin JA, Quint E, Tsipouri V, Arkell R, Cattanach B, CoppA, Henderson D, Spurr N, 
Stanier P, Fisher E (2003). Mutation ofCelsr1 Disrupts Planar Polarity of Inner Ear Hair 
Cells and Causes Severe Neural Tube Defects in the Mouse. Current Biology 13(13): 
1129- 1133. 
Daly M, Obrams GI.(1998). Epidemiology and risk assessment for ovarian cancer. 
Semin Onco/. 25(3):255-64. 
De D, Chen A, Wu Z, Lv S, He G, Qi Y (2009). Overexpression ofPygopus2 protects 
HeLa cells from vinblastine-induced apoptosis. Bioi Chern. 390(2):157-65. 
De Ferrari GV, Inestrosa NC (2000). Wnt signaling function in Alzheimer's disease. 
Brain Res Brain Res Rev 33:1-12. 
De Ferrari GV, Moon RT (2006). The ups and downs ofWnt signaling in prevalent 
neurological disorders. Oncogene 25:7545- 7553. 
De Ferrari GV, Papassotiropoulos A, Biechele T, Wavrant De-Vrieze F, Avila ME, 
Major MB, Myers A, Saez K, Henriquez JP, Zhao A, Wollmer MA, Nitsch RM, Hock C, 
Morris CM, Hardy J, Moon RT (2007). Common genetic variation within the low-density 
lipoprotein receptor-related protein 6 and late-onset Alzheimer's disease. Proc Natl Acad 
Sci US A. 104(22):9434-9. 
de Ia Roche M, Bienz M (2007). Wingless-independent association of Pygopus with 
dTCF target genes. Curr Bioi. 17(6):556-61. 
Dominguez R, Rott J, Castillo M, Pittaluga RR, Corriere JN Jr (1993). Caudal 
duplication syndrome. Am. J. Dis. Child. 147: 1048-1052. 
Dosemeci M, Hayes RB, Vetter R, et al. (1993). Occupational physical activity, 
socioeconomic status, and risks of 15 cancer sites in Turkey. Cancer Causes Control 
4:313-21. 
duBois A; Weber B; Rochon J; Meier W; Goupil A; Olbricht S; Barats JC; Kuhn W; 
Orfeuvre H; Wagner U; Richter B; Lueck HJ; Pfisterer J; CostaS; Schroeder W; Kimmig 
R; Pujade-Lauraine E (2006). Addition of epirubicin as a third drug to carboplatin-
paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized 
gynecologic cancer intergroup trial by the Arbeitsgemeinscha:ft Gynaekologische 
Onkologie Ovarian Cancer Study Group and the Groupe d'lnvestigateurs Nationaux pour 
!'Etude des Cancers Ovariens. J Clin Oncol. 24(7): 1127-35. 
Einzig AI, Wiernik PH, Sasloff J, Runowicz CD, Goldberg GL (1992). Phase II trial of 
paclitaxel in patients with progressive ovarian carcinoma after platinum-based 
chemotherapy: a Gynecologic Oncology Group study. J Clin Onco/10(11 ): 1748-53. 
- ------ - -------
Appendices Wells; page 124 
Eitan, R, Levine, DA, Abu-Rustum, N, Sonoda, Y, Huh, JN, Franklin, CC, Stevens, TA, 
Barakat, RR, & Chi, DS (2005). The clinical significance of malignant pleural effusions 
in patientswith optimally debulked ovarian carcinoma. Cancer 103: 1397-1401. 
Elliott AM, Evans JA (2006). Genotype-phenotype correlations in mapped split hand 
foot malformation (SHFM) patients. Am. J. Med Genet. 140A: 1419-1427. 
Fadhil M, Ghabra TA, Deeb M, Der Kaloustian VM (1983). Odontoonychodermal 
dysplasia: a previously apparently undescribed ectodermal dysplasia. Am. J. Med. Genet. 
14: 335-346. 
Fagotto, F., Gluck, U., and Gumbiner, B. M. (1998). Nuclear localization signal-
independent and importinlkaryopherin-independent nuclear import of ~-catenin. Curr. 
Bioi. 8: 181-190. 
Fairfield KM; Hankinson SE; Rosner BA; Hunter DJ; Colditz GA; Willett WC (2001). 
Risk of ovarian carcinoma and consumption of vitamins A, C, and E and specific 
carotenoids: a prospective analysis. Cancer 92(9):2318-26. 
Faleiro-Rodrigues C, Macedo-Pinto I, Pereira D, eta/ (2004). Loss of B-catenin is 
associated with poor survival in ovarian carcinomas. Int J Gynecol Pathol 23:337-46. 
Faleiro-Rodrigues C, Macedo-Pinto IM, Maia SS, eta/ (2005). Biological relevance of 
E-cadherin-catenin complex proteins in primary epithelial ovarian tumors. Gynecol 
Obstet Invest 60:75-83. 
Fathalla, MF (1971). Incessant ovulation--a factor in ovarian neoplasia? Lancet 2(7716): 
163 
Fiedler M, SAnchez-Barrena MJ, Nekrasov M, Mieszczanek J, Rybin V, MUller J, Evans 
P, Bienz M (2008). Decoding of methylated histone H3 tail by the Pygo-BCL9 Wnt 
signaling complex. Mol Cell. 30(4):507-18. 
Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, Murphy J, Ghadirian P, 
Friedman E, Foulkes WD, Kim-Sing C, Wagner T, Tung N, Couch F, Stoppa-Lyonnet D, 
Ainsworth P, Daly M, Pasini B, Gershoni-Baruch R, Eng C, Olopade 01, McLennan J, 
Karlan B, Weitzel J, Sun P, Narod SA; Hereditary Ovarian Cancer Clinical Study Group 
(2006). Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal 
cancers in women with a BRCA1 or BRCA2 Mutation. JAMA. 296(2): 185-92. 
Florez JC, Jablonski KA, Bayley N, Pollin TI, de Bakker PI, Shuldiner AR, Knowler 
WC, Nathan DM, Altshuler D; Diabetes Prevention Program Research Group (2006). 
TCF7L2··polymorphisms and progression to diabetes in the Diabetes Prevention Program. 
N Eng/ J Med 355(3):241-50. 
Fogh J, editor (1975). Human tumor cells in vitro. New York: Plenum Press; 115-159. 
Appendices Wells; page 125 
Fogh J, Wright WC, Loveless JD (1977). Absence ofHeLa cell contamination in 169 
cell lines derived from hwnan twnors. J. Nat/. Cancer Inst. 58: 209-214. 
Ford D, Easton DF, Peto J. (1995). Estimates of the gene frequency ofBRCA1 and its 
contribution to breast and ovarian cancer incidence. Am J Hum Genet. 57(6):1457-62. 
Foster KA, Harrington P, Kerr J, Russell P, DiCioccio RA, Scott IV, eta/. (1996). 
Somatic and gerrnline mutations of the BRCA2 gene in sporadic ovarian cancer. Cancer 
Res 56:3622- 5. 
Fuhrmann W, Fuhrmann-Rieger A, de Sousa F (1980). Poly-, syn- and oligodactyly, 
aplasia or hypoplasia of fibula, hypoplasia of pelvis and bowing of femora in three sibs--a 
new autosomal recessive syndrome. Europ. J. Pediat. 133: 123-129. 
Gleave ME, Monia BP (2005). Antisense therapy for cancer. Nat Rev Cancer 5:468- 79. 
Gertig DM; Hunter DJ; Cramer DW; Colditz GA; Speizer FE; Willett WC; Hankinson 
SE (2000). Prospective study of talc use and ovarian cancer. J Nat/ Cancer /nsf 
92(3):249-52. 
Giles, R. H., van Es, J. H. & Clevers, H. (2003). Caught up in a Wnt storm: Wnt 
signaling in cancer. Biochim. Biophys. Acta 1653: 1- 24. 
Goff, B, Mandell, L, Muntz, H, & Melancon, C (2000). Ovarian carcinoma diagnosis: 
Results of a national ovarian cancer survey. Cancer 89: 2068-2075. 
GoffBA, Matthews BJ, Larson EH, Andrilla CH, Wynn M, Lishner DM, Baldwin LM 
(2007). Predictors of comprehensive surgical treatment in patients with ovarian cancer. 
Cancer. 109(1 0):2031-42. 
GoffBA, Matthews BJ, Wynn M, Muntz HG, Lishner DM, Baldwin LM (2006). 
Ovarian cancer: patterns of surgical care across the United States. Gyneco/ Onco/. 
1 03(2):383-90. 
Gong YQ, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, Wang HW, 
Cundy T, Glorieux FH, Lev D, Zacharin M, Oexle K, Marcelino J, Suwairi W, Heeger S, 
Sabatakos G, Apte S, Adkins WN, Allgrove J, Arslan-Kirchner M, Batch JA, Heighton P, 
Black GCM, Boles RG, Boon LM, Borrone C, Brunner HG, Carle GF, Dallapiccola B, 
De Paepe A, Floege B, Halfhide ML, Hall B, Hennekam RC, Hirose T, JansA, Juppner 
H, Kim CA, Keppler-Noreuil K, Kohlschuetter A, LaCombe D, Lambert M, Lemyre E, 
Letteboer T, Peltonen L, Ramesar RS, Romanengo M, Somer H, Steichen-GersdorfE, 
Steinmann B, Sullivan B, Superti-Furga A, Swoboda W, van den Boogaard MJ, Van Hul 
V, Vikkula M, Votruba M, Zabel B, Garcia T, Baron R, Olsen BR, Warman ML (2001). 
LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 
107: 513- 523. 
----- ---- -------------------
Appendices Wells; page 126 
Gordon AN, Granai CO, Rose PG, Hainsworth J, Lopez A, Weissman C, Rosales R, 
Sharpington T (2000). Phase II study of liposomal doxorubicin in platimun- and 
paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol. 18(17):3093-1 00. 
Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J, 
Helgason A, Stefansson H, Ernilsson V, Helgadottir A, Styrkarsdottir U, Magnusson KP, 
Walters GB, Palsdottir E, Jonsdottir T, Gudmundsdottir T, Gylfason A, Saemundsdottir J, 
Wilensky RL, Reilfy MP, Rader DJ, Bagger Y, Christiansen C, Gudnason V, Sigurdsson 
G, Thorsteinsdottir U, Gulcher JR, Kong A, Stefansson K (2006). Variant of 
transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet. 
38(3):320-3. 
Grzeschik K-H, Bornholdt D, Oeffner F, Konig A, Boente M del C, Fritz B, Hertl M, 
GrasshoffU, Hofling K, Oji V, Paradisi M, Schuchardt C, Szalai Z, Tadini G, Traupe H, 
Happle R (2007). Deficiency ofPORCN, a regulator ofWnt signaling, is associated with 
focal dermal hypoplasia. Nature Genet. 39: 833-835. 
Gul D., Oktenli C (2002). Evidence for autosomal recessive inheritance of split 
hand/split foot malformation: a report of nine cases. Clin. Dysmorphol. 11: 183- 186. 
Habas R, Dawid IB and He X (2003). Coactivation ofRac and Rho by Wnt/Frizzled 
signaling is required for vertebrate gastrulation. Genes Dev 17: 295- 309. 
Habas Rand He X (2006). Activation of Rho and Rae by Wnt/frizzled signaling. 
Methods Enzymol 406: 500-511 . 
Hamblet NS, Lijam N, Ruiz-Lozano P, et al (2002). Dishevelled 2 is essential for cardiac 
outflow tract development, somite segmentation and neural tube closure. Development 
129:5827-5838. 
Hamilton, T. C., Young, R. C., McKoy, W. M., Grotzinger, K. R., Green, J. A., Chu, E. 
W., Whang-Peng, J., Rogan, A.M., Green, W. R., and Ozols R. F., (1983). 
Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen 
and estrogen receptors. Cancer Res. 43: 5379-5389 
Hankinson SE, Colditz GA, Hunter DJ, Willett WC, Stampfer MJ, Rosner B, Hennekens 
CH, Speizer FE. (1995). A prospective study of reproductive factors and risk of 
epithelial ovarian cancer. Cancer 76:284-90. 
Hankinson SE, Hunter DJ, Colditz GA, Willett WC, Stampfer MJ, Rosner B, Hennekens 
CH, Speizer FE. (1993). Tubal ligation, hysterectomy, and risk of ovarian cancer. A 
prospective study. JAMA. 270(23):2813-8. 
Hannan LM, Leitzmann MF, Lacey N , Jr., et al. (2004). Physical activity and risk of 
ovarian cancer: a prospective cohort study in the United States. Cancer Epidemiol 
Biomarkers Prev 13:765- 70. 
Appendices Wells; page 127 
Happle R, Lenz W (1977). Striation of bones in focal dermal hypoplasia: manifestation 
of functional mosaicism? Brit. J Derm. 96: 133-138, 1977. 
Hardy J, Selkoe DJ (2002). The Amyloid Hypothesis of Alzheimer's Disease: Progress 
and Problems on the Road to Therapeutics Science 297:353- 356. 
Harlow BL, Cramer DW, Bell DA, Welch WR. (1992). Perineal exposure to talc and 
ovarian cancer risk. Obstet Gyneco/. 80( 1 ): 19-26. 
Harrison ML, Hoskins P, duBois A, Quinn M, Rustin GJ, Ledermann JA, Baron-HayS, 
Friedlander ML (2006). Small cell of the ovary, hypercalcemic type-- analysis of 
combined experience and recommendation for management. A GCIG study. Gynecol 
Onco/. 100(2): 233-8. 
Hart, M. J., de loa Santos, R., Albert, I. N., Rubinfeld, B., and Polakis, P. (1998). Down-
regulation of b-catenin by human axin and its association with the APC tumor suppressor, 
~-catenin and GSK3~. Curr. Bioi. 8: 573-581. 
Hartikka H, Makitie 0, Mannikko M, Doria AS, Daneman A, Cole WG, Ala-Kokko L, 
Sochett EB (2005). Heterozygous mutations in the LDL receptor-related protein 5 
(LRP5) gene are associated with primary osteoporosis in children. J Bone Miner Res 
20:783-789. 
Hatsell S, Rowlands T, Hiremath M, Cowin P (2003). Beta-catenin and Tcfs in 
mammary development and cancer. J Mammary Gland Bioi Neoplasia 8(2):145-58. 
He, T. C., Sparks A. B., Rago C., Hermeking H., Zawel L., da CostaL. T., Morin P. J., 
Vogelstein B., and Kinzler K. W. (1998). Identification of c-MYC as a target of the APC 
pathway. Science 281:1509-1512. 
Hecht, A., Litterst, C. M., Huber, 0., and Kemler, R. (1999). Functional characterization 
of multiple transactivating elements in ~-catenin, some of which interact with the TAT A-
binding protein in vitro. J Bioi. Chern. 274: 18017-18025. 
Hecht, A., Vleminckx, K., Stemmler, M.P., van Roy, F., and Kemler, R. (2000). The 
p300/CBP acetyltransferases function as transcriptional coactivators of ~-catenin in 
vertebrates. EMBO J 19: 1839-1850. 
Heikkila M, Prunskaite R, Naillat F, Itaranta P, Vuoristo J, Leppaluoto J, Peltoketo H, 
Vainio S (2005). The partial female to male sex reversal in Wnt-4-deficient females 
involves induced expression of testosterone biosynthetic genes and testosterone 
production, and depends on androgen action. Endocrinology 146: 4016-4023. 
Heintz AP, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, Ngan HY, 
Sideri M, Pecorelli S (2001). Carcinoma of the ovary. J Epidemiol Biostat 6: 107. 
Appendices Wells; page 128 
Heintz AP, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, Ngan HY, 
Pecorelli S. (2003). Carcinoma of the ovary: FIGO annual report. Int J Gynaeco/ Obstet 
83:135. 
Helzlsouer KJ, Bush TL, Alberg AJ, Bass KM, Zacur H, Comstock GW (1993). 
Prospective study of serum CA-125 levels as markers of ovarian cancer. JAMA. 
269:1123-1126. 
Hardouin J (2007). Protein sequence information by matrix-assisted laser 
desorption/ionization in-source decay mass spectrometry. Mass spectrometry reviews 26 
(5): 672-82. 
Hobmayer, B., Rentzsch, F., Kuhn, K., Happel, C.M., von Laue, C.C., Snyder, P., 
Rothbacher, U., and Holstein, T.W. (2000). WNT signalling molecules act in axis 
formation in the diploblastic metazoan Hydra. Nature 407: 186-189. 
Hogdall EV, Christensen L, Kjaer SK, Blaakaer J, Kjaerbye-Thygesen A, Gayther S, 
Jacobs IJ, !Wgdall CK (2007). CA125 expression pattern, prognosis and correlation with 
serum CA125 in ovarian tumor patients (From The Danish "MALOVA" Ovarian Cancer 
Study). Gyneco/ Onco/. 104:508-515. 
Hongisto V, Vainio JC, Thompson R, Courtney MJ, Coffey ET (2008). The Wnt pool of 
glycogen synthase kinase 3beta is critical for trophic-deprivation-induced neuronal death. 
Mol Cell Bioi. 28(5):1515-27. 
Howe LR, Brown AM (2004). Wnt signaling and breast cancer. Cancer Bioi Ther. 
3(1 ):36-41. 
Huang H, Fujii H, Sankila A, Mahler-Araujo BM, Matsuda M, Cathomas G, Ohgaki H 
(1999). Beta-catenin mutations are frequent in human hepatocellular carcinomas 
associated with hepatitis C virus infection. Am. J Patho/. 155: 1795-1801. 
Huncharek M; Kupelnick B (200 I). Dietary fat intake and risk of epithelial ovarian 
cancer: a meta-analysis of 6,689 subjects from 8 observational studies. Nutr Cancer 
40(2):87-91. 
Ikeda, S., Kishida, S., Yamamoto, H., Murai, H., Koyama, S., and Kikuchi, A. (1998). 
Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK3~ 
and ~-catenin and promotes GSK3~-dependent phosphorylation of ~-catenin. EMBO J. 
17: 1371-1384. 
Jacobs I, Davies AP, Bridges J, Stabile I, Fay T, Lower A, Grudzinskas JG, and Oram D 
(1993). Prevalence screening for ovarian cancer in postmenopausal women by CA 125 
measurement and ultrasonography. BMJ 306:1030-1034. 
Appendices Wells; page 129 
Jacobs IJ, Menon U. (2004). Progress and challenges in screening for early detection of 
ovarian cancer. Mol Cell Proteomics. 3:355- 366. 
Jacobson, S. and Pill us, L. (1999). Modifying chromatin and concepts of cancer. Curr. 
Opin. Genet. Dev. 9: 175-184. 
Jeays-Ward K, Hoyle C, Brennan J, Dandonneau M, Alldus G, Capel Band Swain A 
(2003). Endothelial and steroidogenic cell migration are regulated by WNT4 in the 
developing mammalian gonad. Development 130:3663-3670. 
Jemal, A, Siegal, R, Ward, E, Hao, Y, Xu, J, Murray, T, and Thun, M (2008). Cancer 
Statistics. CA Cancer J C/in 58:71. 
Jessen S, Gu B, Dai X (2008). Pygopus and the Wnt signaling pathway: a diverse set of 
connections. Bioessays. 30(5):448-56. 
Jiao X, Ventruto V, Trese MT, Shastry BS, Hejtmancik JF (2004). Autosomal recessive 
familial exudative vitreoretinopathy is associated with mutations in LRP 5. Am J Hum 
Genet 75:878- 884. 
Jonckheere N, Mayes E, Shih HP, LiB, Lioubinski 0 , Dai X, Sander M (2008). Analysis 
of mPygo2 mutant mice suggests a requirement for mesenchymal Wnt signaling in 
pancreatic growth and differentiation. Dev Bioi. 318(2):224-35. 
Jordan BK, Mohammed M, Ching ST, Delot E, Chen XN, Dewing P, Swain A, Rao PN, 
Elejalde BR, Vilain E (2001). Up-regulation ofWNT-4 signaling and dosage-sensitive 
sex reversal in humans. Am J Hum Genet 68:1102-1109. 
Jordan, B. K. , Shen, J. H., Olaso, R., Ingraham, H. A. & Vilain, E (2003). Wnt4 
overexpression disrupts normal testicular vasculature and inhibits testosterone synthesis 
by repressing steroidogenic factor liP-catenin synergy. Proc. Nat/ Acad. Sci. USA 100: 
10866-10871. 
Jordan SJ; Whiteman DC; Purdie DM; Green AC; Webb PM (2006). Does smoking 
increase risk of ovarian cancer? A systematic review. Gynecol Oncol. 103(3): 1122-9. 
Epub 2006 Sep 26. 
Junor EJ, Hole DJ, McNulty L, Mason M, Young J (1999). Specialist gynaecologists and 
survival outcome in ovarian cancer: a Scottish national study of 1866 patients. Br J 
Obstet Gynaeco/ 106: 1130-1136. 
Kabawat SE, Bast RC, Bhan AK, Welch WR, Knapp RC, Colvin RB. (1983). Tissue 
distribution of a coelomic-epithelium-related antigen recognized by the monoclonal 
antibody OC125. Int J Gyneco/ Pathol. 2:275- 285. 
Appendices Wells; page 130 
Kaku T, Ogawa S, Kawano Y, Ohishi Y, Kobayashi H, Hirakawa T, Nakano H. (2003). 
Histological classification of ovarian cancer. Med Electron Microsc. 36(1):9-17. 
Kanazawa A, Tsukada S, Sekine A, Tsunoda T, Takahashi A, Kashiwagi A, Tanaka Y, 
Babazono T, Matsuda M, Kaku K, Iwamoto Y, Kawamori R, Kikkawa R, Nakamura Y, 
Maeda S (2004). Association of the gene encoding wingless-type mammary tumor virus 
integration-site family member 5B (WNT5B) with type 2 diabetes. Am J Hum Genet. 
75(5):832-43. 
Karla BY, Boyd J, Strong Let al (2003). Discussion: Hereditary ovarian cancer. 
Gyneco/ Onco/ 88: S 11. 
Karner C, Wharton JKA and Carroll TJ (2006). Planar cell polarity and vertebrate 
organogenesis. Semin Cell Dev Bioi 17: 194-203. 
Katsu T, Ujike H, Nakano T, Tanaka Y, Nomura A, Nakata K, Takaki M, Sakai A, 
Uchida N, Imamura T, Kuroda S (2003). The human frizzled-3 (FZD3) gene on 
chromosome 8p21, a receptor gene for Wnt ligands, is associated with the susceptibility 
to schizophrenia. Neurosci Letters 353: 53-56 
Kerlikowske K, Brown JS, Grady DG (1992). Should women with familial ovarian 
cancer undergo prophylactic oophorectomy? Obstet Gynecol. 80(4):700-7. 
Khoo US, Ngan HY, Cheung AN, Chan KY, Lu J, Chan VW, eta/ (2000). Mutational 
analysis ofBRCA1 and BRCA2 genes in Chinese ovarian cancer identifies 6 novel 
germline mutations. Hum Mutat 16:88-9. 
Kibar Z, Torban E, McDearmid JR, Reynolds A, Berghout J, Mathieu M, Kirillova I, De 
Marco P, Merello E, Hayes JM, Wallingford JB, Drapeau P, Capra V, Gros P (2007). 
Mutations in V ANGL1 associated with neural-tube defects. N Eng/ J Med. 
356(14):1432-7. 
Kibar Z, Vogan KJ, Groulx N, Justice MJ, Underhill DA, Gros P (2001). Ltap, a 
mammalian homolog of Drosophila StrabismusN an Gogh, is altered in the mouse neural 
tube defect mutant Loop-tail. Nat Genet 28:251-255. 
Kildal W, Risberg B, Abeler VM, et al (2005). B-catenin expression, DNA ploidy and 
clinicopathological features in ovarian cancer: a study in 253 patients. Eur J Cancer 
41:1127-34 
Kim, Y. S., Kang, Y. K., Kim, J. B., Han, S. A., Kim, K. I., and Paik, S. R. (2000). P-
Catenin expression and mutational analysis in renal cell carcinomas. Pathol. Int. 50: 
725-730. 
Appendices Wells; page 131 
Kim KA, Zhao J, Andarmani S, Kakitani M, Oshima T, Binnerts ME, Abo A, Tomizuka 
K, Funk WD (2006). R-spondin proteins, a novel link to ~-catenin activation. Cell Cycle 
5:23-26. 
Kinzler KW, Nilbert MC, SuLK, Vogelstein B, Bryan TM, Levy DB, Smith KJ, 
Preisinger AC, Hedge P, McKechnie D, et al. (1991). Identification ofFAP locus genes 
from chromosome 5q21. Science. 253(5020):661-5. 
Kinzler KW, and Vogelstein B (1996). Lessons from Hereditary Colorectal Cancer. 
Cell 81: 159-170 
Kishida, S., Yamamoto, H., Hino, S., Ikeda, S., Kishida, M., and Kikuchi, A. (1999). 
DIX domains ofDvl and axin are necessary for protein interactions and their ability to 
regulate ~-catenin stability. Mol. Cell Bioi. 19: 4414-4422. 
Koesters, R., Ridder, R., Kopp-Schneider, A., Betts, D., Adams, V., Niggli, F., Briner, J., 
and von Knebel Doeberitz, M. ( 1999). Mutational Activation of the B-Catenin Proto-
Oncogene Is a Common Event in the Development of Wilms' Tumors. Cancer Res. 59: 
3880-3882 
Kohn AD & Moon RT (2005). Wnt and calcium signaling: beta-catenin-independent 
pathways. Cell Calcium 38: 439-446. 
Kohn EC; Sarosy G; Bicher A; Link C; Christian M; Steinberg SM; Rothenberg M; 
Adamo DO; Davis P; Ognibene FP; et al (1994). Dose-intense taxol: high response rate 
in patients with platinum-resistant recurrent ovarian cancer. J Nat/ Cancer Inst 86(1): 
18-24. 
Kolligs, F. T., Nieman, M. T., Winer, 1., Hu, G., Van Mater, D., Feng, Y., Smith, I. M., 
Wu, R., Zhai, Y., Cho, K. R., and Fearon E. R. (2002). ITF-2, a downstream target of the 
Wnt/TCF pathway, is activated in human cancers with beta-catenin defects and promotes 
neoplastic transformation. Cancer Cell. 1:145-55. 
Koushik A; Hunter DJ; Spiegelman D; Anderson KE; Suring JE.; Freudenheim JL; 
Goldbohm RA; Hankinson SE; Larsson SC; Leitzmann M; Marshall JR; McCullough 
ML; Miller AB; Rodriguez C; Rohan TE; Ross JA; Schatzkin A; Schouten LJ; Willett 
WC; Wolk A; Zhang SM; Smith-Warner SA (2006). Intake of the major carotenoids and 
the risk of epithelial ovarian cancer in a pooled analysis of 10 cohort studies. Int J 
Cancer. 119(9):2148-54. 
Kozlovsky, N., Belmaker, R. H. & Agam, G (2002). GSK-3 and the neurodevelopmental 
hypothesis of schizophrenia. Eur. Neuropsychopharmacol. 12: 13-25. 
Kramps, T., Peter, 0., Brunner, E., Nellen, D., Froesch, B., Chatterjee, S., Murone, M., 
Ziillig, S., & Basker, K. (2002). Wnt/Wingless signaling requires BCL-9/Legless-
~ ~-------------------------
Appendices Wells; page 132 
mediated recruitment ofpygopus to the nuclear P-cateninffCF complex. Cell 109: 47-
60. 
Kroes HY, Takahashi M, Zijlstra RJ, Baert JA, Kooi KA, Hofstra RMW (2002). Two 
cases of the caudal duplication anomaly including a discordant monozygotic twin. Am. J. 
Med. Genet. 112: 390-393. 
Kuhl M (2002). Non-canonical Wnt signaling in Xenopus: regulation of axis formation 
and gastrulation. Semin. Cell Dev. Bioi. 13: 243-249. 
Kuhl M, Sheldahl LC, Park M, Miller JR and Moon RT (2000). The Wnt/Ca2+ pathway: 
a new vertebrate Wnt signaling pathway takes shape. Trends Genet. 16: 279-83. 
Kumar D, Duggan MB, Mueller RF, Karbani G (1997). Familial aplasia/hypoplasia of 
pelvis, femur, fibula, and ulna with abnormal digits in an inbred Pakistani Muslim family: 
a possible new autosomal recessive disorder with overlapping manifestations of the 
syndromes ofFuhrmann, Al-Awadi, and Raas-Rothschild. Am. J. Med. Genet. 70: 107-
113. 
Kurian A, Balise R, McGuire V, Whittemore A (2005). Histologic types of epithelial 
ovarian cancer: have they different risk factors? Gynecologic Oncology 96: 520-530. 
Kushi LH; Mink PJ; Folsom AR; Anderson KE; Zheng W; Lazovich D; Sellers TA 
(1999). Prospective study of diet and ovarian cancer. Am J Epidemiol 149(1 ):21-31 
Kushner DM, Paranjape JM, Bandyopadhyay B, Cramer H, Leaman DW, Kennedy A W, 
Silverman RH, Cowell JK (2000). 2-5A antisense directed against telomerase RNA 
produces apoptosis in ovarian cancer cells. Gyneco/ Onco/ 76:183-92 
Lake, B. B. & Kao, K. R. (2003). Pygopus is required for embryonic brain patterning in 
Xenopus. Dev. Bioi. 261: 132-148. 
Lammi L, Arte S, Somer M, Jarvinen H, Lahermo P, Thesleffl, Pirinen S, Nieminen P 
(2004). Mutations in AXIN2 cause familial tooth agenesis and predispose to colorectal 
cancer. Am. J. Hum. Genet. 74: 1043-1050. 
Larregue M, Duterque M (1975). Striated osteopathy in focal dermal hypoplasia. Arch. 
Derm. 111: 1365. 
Larsson SC; Giovannucci E; Wolk A (2004). Dietary folate intake and incidence of 
ovarian cancer: the Swedish Mammography Cohort. J Nat/ Cancer Inst 96(5):396-402. 
Larsson SC; Holmberg L; Wolk A (2004). Fruit and vegetable consumption in relation to 
ovarian cancer incidence: the Swedish Mammography Cohort. Br J Cancer 90(11 ):2167-
70. 
Appendices Wells; page 133 
Larsson SC; Orsini N; Wolk A (2006). Milk, milk products and lactose intake and 
ovarian cancer risk: a meta-analysis of epidemiological studies. Int J Cancer. 
118(2):431-41. 
Lee, J. S., Ishimoto, A., and Yanagawa, S. (1999). Characterization of mouse disheveled 
(DVL) proteins in Wnt/Wingless signaling pathway. J Bioi. Chern. 274: 21464-21470. 
Legoix P, Bluteau 0, Bayer J, Perret C, Balabaud C, Belghiti J, Franco D, Thomas G, 
Laurent-Puig P, Zucman-Rossi J (1999). Beta-catenin mutations in hepatocellular 
carcinoma correlate with a low rate ofloss of heterozygosity. Oncogene 18: 4044-4046. 
Leiser A, Visintin I, Alvero A, Rutherford T, Schwartz P, Azodil M, Mor G (2007). 
Novel serum test for the early detection of ovarian cancer. Gynecol Onco/104: S2-S3. 
Leoyklang P, Suphapeetipom K, Wananukul S, Shotelersuk V (2008). Three novel 
mutations in the PORCN gene underlying focal dermal hypoplasia. Clin. Genet. 73: 
373-379. 
Lev D, Binson I, Foldes AJ, Watemberg N, Lerman-Sagie T (2003). Decreased bone 
density in carriers and patients of an Israeli family with the osteoporosis-pseudoglioma 
syndrome. Isr Med Assoc J 5:419-421. 
Levine AM, Tulpule A, Quinn DI, Gorospe G 3rd, Smith DL, Hornor L, Boswell WD, 
Espina BM, Groshen SG, Masood R, Gill PS (2006). Phase I study of antisense 
oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular 
endothelial growth factor with potential clinical efficacy. J Clin Oncol. 24(11 ): 1712-9. 
Li AJ, Karlan, BY (2001). Genetic factors in ovarian carcinoma. Curr Oncol Rep 3:27. 
Li J, Sasaki H, Sheng YL, Schneiderman D, Xiao CW, Kotsuji F, Tsang BK (2000). 
Apoptosis and chemoresistance in human ovarian cancer: is Xiap a determinant? Bioi 
Signals Recept 9:122-30. 
Li Y, Welm B, Podsypanina K, Huang S, Chamorro M, Zhang X, Rowlands T, Egeblad 
M, Cowin P, Werb Z, Tan LK, Rosen JM, Varmus HE (2003). Evidence that transgenes 
encoding components of the Wnt signaling pathway preferentially induce mammary 
cancers from progenitor cells. Proc Nat/ A cad Sci US A. 100(26): 15853-8. 
Liang, H, Chen Q, Coles A, Anderson S, Pihan G, Bradley A, Gerstein R, Jurecic R, 
Jones S (2003). Wnt5a inhibits B cell proliferation and functions as a tumor suppressor 
in hematopoietic tissue. Cancer Cell 4: 349-360. 
Lijam N, Paylor R, McDonald MP, Crawley JN, Deng CX, Herrup K, Stevens KE, 
Maccaferri G, McBain CJ, Sussman DJ, WynshawBoris A (1997). Social interaction and 
sensorimotor gating abnormalities in mice lacking Dvll. Cell 90: 895-905. 
Appendices Wells; page 134 
Liou WS, Hamilton CA, Cheung MK, Osann K, Longacre TA, Teng NN, Husain.A, 
Dirbas FM, Chan JK. (2006). Outcomes of women with metachronous breast and 
ovarian carcinomas. Gyneco/ On col. 1 03( 1): 190-4. 
Little RD, Carulli JP, Del Mastro RG, Dupuis J, Osborne M, Folz C, Manning SP, Swain 
PM, Zhao SC, Eustace B, Lappe MM, Spitzer L, Zweier S, Braunschweiger K, 
Benchekroun Y, Hu XT, Adair R, Chee L, FitzGerald MG, Tulig C, Caruso A, Tzellas N, 
Bawa A, Franklin B, McGuire S, Nogues X, Gong G, Allen KM, Anisowicz A, Morales 
AJ, Lomedico PT, Recker SM, Van Eerdewegh P, Recker RR, Johnson ML (2002). A 
mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant 
high-bone-mass trait. Am. J Hum. Genet. 70: 11-19. 
Littman A, LevinS (1964). Anonychia as a recessive autosomal trait in man. J Invest 
Derm 42:177-178. 
Lloyd KO, Yin BW, Kudryashov V. (1997). Isolation and characterization of ovarian 
cancer antigen CA 125 using a new monoclonal antibody (VK-8): Identification as a 
mucin-type molecule. Int J Cancer. 71:842- 850 
Llort G, Peris M, Blanco I (2007). [Hereditary breast and ovarian cancer: primary and 
secondary prevention for BRCA1 and BRCA2 mutation carriers]. Med C/in (Bare). 
128(12):468-76. 
Loughlin J, Dowling B, Chapman K, Marcelline L, Mustafa Z, Southam L, Ferreira A, 
Ciesielski C, Carson DA, Corr M (2004). Functional variants within the secreted 
frizzled-related protein 3 gene are associated with hip osteoarthritis in females. Proc. Nat/ 
Acad Sci. USA 101: 9757-9762. 
Lurie G, Thompson P, McDuffie KE, Carney ME, Terada KY, Goodman MT. (2007). 
Association of estrogen and progestin potency of oral contraceptives with ovarian 
carcinoma risk. Obstet Gyneco/. 109(3):597-607. 
Lynch HT, Lanspa S, Smyrk T, Boman B, Watson P, Lynch J (1991). Hereditary 
nonpolyposis colorectal cancer (Lynch syndromes I & II). Genetics, pathology, natural 
history, and cancer control, Part I. Cancer Genet Cytogenet. 53(2):143-60. 
MaX, Wang S, Zhou J, Xing H, Xu G, Wang B, ChenG, Lu YP, MaD (2005). Induction 
of apoptosis in human ovarian epithelial cancer cells by antisurvivin oligonucleotides. 
Oncol Rep 14:275-9. 
Major MB, Camp ND, Berndt JD, Yi X, Goldenberg SJ, Hubbert C, Biechele TL, 
Gingras AC, Zheng N, Maccoss MJ, Angers S, Moon RT (2007). Wilms tumor 
suppressor WTX negatively regulates WNT/beta-catenin signaling. Science 
316(5827): 1043-6. 
Mandel H, Shemer R, Borochowitz Z.U, Okopnik M, KnopfC, Indelman M, Drugan A, 
Tiosano D, Gershoni-Baruch R, Choder M, Sprecher E (2008). SERKAL syndrome: an 
Appendices Wells; page 135 
autosomal-recessive disorder caused by a loss-of-function mutation in WNT4. Am. J. 
Hum. Genet. 82: 39-47. 
ManiA, Radhakrishnan J, Wang H, ManiA, Mani MA, Nelson-Williams C, Carew KS, 
Mane S, Najmabadi H, Wu D, Lifton RP (2007). LRP6 mutation in a family with early 
coronary disease and metabolic risk factors. Science 315(5816):1278-82. 
Matsushima M, Kobayashi K, Emi M, Saito H, Saito J, Suzumori K, eta/. (1995). 
Mutation analysis of the BRCAJ gene in 76 Japanese ovarian cancer patients: four 
germline mutations, but no evidence of somatic mutation. Hum Mol Genet 4:1953-6. 
Matthews, J. and Sunde, M. (2002). Zinc fingers-folds for many occasions. IUBMB 
Life 54: 351-355. 
McCann SE; Freudenheim JL; Marshall JR; Graham, S (2003). Risk of human ovarian 
cancer is related to dietary intake of selected nutrients, phytochemicals and food groups. 
J Nutr 133(6):1937-42. 
McCann SE; Moysich KB; Mettlin C (200 1 ). Intakes of selected nutrients and food 
groups and risk of ovarian cancer. Nutr Cancer 39(1 ): 19-28. 
McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-
Pearson DL; Davidson M (1996). Cyclophosphamide and cisplatin compared with 
paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Eng/ J 
Med 334(1):1-6. 
McGuire WP; Rowinsky EK; Rosenshein NB; Grumbine FC; Ettinger DS; Armstrong 
DK; Donehower RC (1989). Taxol: a unique antineoplastic agent with significant 
activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111(4):273-9. 
McNeish IA, Lopes R, Bell SJ, McKay TR, Fernandez M, Lockley M, Wheatley SP, 
Lemoine NR (2005). Survivin interacts with Smac/DIABLO in ovarian carcinoma cells 
but is redundant in Smac-mediated apoptosis. Exp Cell Res. 302(1):69-82. 
Megarbane H, Haddad M, Delague V, Renoux J, Boehm N, Megarbane A (2004). 
Further delineation of the odonto-onycho-dermal dysplasia syndrome. Am. J. Med 
Genet. 129A: 193-197. 
Metcalfe KA, Lynch HT, Ghadirian P, Tung N, Olivotto IA, Foulkes WD, Warner E, 
Olopade 0, Eisen A, Weber B, McLennan J, Sun P, Narod SA (2005). The risk of 
ovarian cancer after breast cancer in BRCA 1 and BRCA2 carriers. Gynecol Oneal. 
96(1):222-6. 
Michaelson JS, Leder P (2001). beta-catenin is a downstream effector ofWnt-mediated 
tumorigenesis in the mammary gland. Oncogene. 20(37):5093-9. 
Appendices Wells; page 136 
Mieszczanek J, de la Roche M, Bienz M (2008). A role ofPygopus as an anti-repressor 
in facilitating Wnt-dependent transcription. Proc Nat/ Acad Sci US A. 105(49):19324-9. 
Miyaoka, T., Seno, H. & Ishino, H (1999). Increased expression of Wnt-1 in 
schizophrenic brains. Schizophr. Res. 38: 1-6. 
Miyoshi Y, Iwao K, Nawa G, Yoshikawa H, Ochi T, Nakamura Y (1998). Frequent 
mutations in the beta-catenin gene in desmoid tumors from patients without familial 
adenomatous polyposis. Oncol. Res. 10: 591-594. 
Molenaar, M., van de Wetering, M., Oosterwegel, M., Peterson-Maduro, J., Godsave, S., 
Korinek, V., Roose, J., Destree, 0., and Clevers, H. (1996). XTcf-3 transcription factor 
mediates P-catenin-induced axis formation in Xenopus embryos. Cell 86: 391-399. 
Mommers M; Schouten LJ; Goldbohm RA; van den Brandt P A (2006). Dairy 
consumption and ovarian cancer risk in the Netherlands Cohort Study on Diet and 
Cancer. Br J Cancer. 94(1 ): 165-70. 
Montcouquiol, M, Crenshaw III, Band Kelley, M (2006). Noncanonical Wnt Signaling 
and Neural Polarity. Annu. Rev. Neurosci. 29:363-86 
Moon, R. T., Bowerman, B., Boutros, M., and Perrimon, N. (2002). The promise and 
perils ofWnt signaling through P-catenin. Science 296: 1644-1646. 
Moon, R. T., Brown, J. D. and Torres, M. (1997). WNTs modulate cell fate and behavior 
during vertebrate development. Trends Genet. 13: 157-162. 
Moon RT, Kohn AD, De Ferrari GV, Kaykas A (2004). WNT and beta-catenin 
signalling: diseases and therapies. Nat Rev Genet. 5(9):691-701. 
Moorman PG, Schildkraut JM, Calingaert B, Halabi S, Vine MF, Berchuck A. (2002). 
Ovulation and ovarian cancer: a comparison of two methods for calculating lifetime 
ovulatory cycles (United States). Cancer Causes Control 13: 807- 11 
Morgan RJ Jr, Alvarez RD, Armstrong DK, Boston B, Chen LM, Copeland L, Fowler J, 
Gaffney DK, Gershenson D, Greer BE, Grigsby PW, Havrilesky LJ, Johnston C, 
Lancaster JM, Lele S, Matulonis U, O'Malley D, Ozols RF, Remmenga SW, Sabbatini P, 
Schink J, Teng N; National Comprehensive Cancer Network (2008). Ovarian cancer. 
Clinical practice guidelines in oncology. J Nat/ Compr Cane Netw. 6(8):766-94. 
Morin, P. J., Sparks, A. B., Korinek, V., Barker, N., Clevers, H., Vogelstein, B., and 
Kinzler, K. W. (1997). Activation of P-catenin-TCF signaling in colon cancer by 
mutations in b-catenin or APC. Science 275: 1787-1790. 
Appendices Wells; page 13 7 
M0rtz E, O'Connor PB, RoepstorffP, Kelleher NL, Wood TD, McLafferty FW, Mann M 
( 1996). Sequence tag identification of intact proteins by matching tanden mass spectral 
data against sequence data bases. Proc. Nat/. Acad Sci. USA. 93(16): 8264-7. 
Mudher A, Lovestone S (2002). Alzheimer's disease - do tauists and baptists fmally 
shake hands? Trends Neurosci 25:22- 26. 
Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, Roman L, Uziely B, 
Muderspach L, Garcia A, Burnett A, Greco FA, Morrow CP, Paradiso LJ, Liang LJ 
(1997). Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor 
activity and toxicity modification by liposomal encapsulation. J Clin Oncol. 15(3):987-
93. 
Mullen P, McPhillips F, MacLeod K, MoniaB, Smyth JF and Langdon SP (2004). 
Antisense oligonucleotide targeting of Raf-1: importance of raf-1 mRNA expression 
levels and raf-t-dependent signaling in determining growth response in ovarian cancer. 
Clin Cancer Res 10:2100--8. 
Murdoch JN, Doudney K, Patemotte C, Copp AJ, Stanier P (2001). Severe neural tube 
defects in the loop-tail mouse result from mutation of Lpp 1, a novel gene involved in 
floor plate specification. Hum Mol Genet 10:2593-2601. 
Nair M, Nagamori I, Sun P, Mishra DP, Rheaume C, LiB, Sassone-Corsi P, Dai X 
(2008). Nuclear regulator Pygo2 controls spermiogenesis and histone H3 acetylation. 
Dev Bioi. 320(2):446-55. 
Nakamura Y, Nishisho I, Kinzler KW, Vogelstein B, Miyoshi Y, Miki Y, Ando H, Horii 
A (1992). Mutations of the APC (adenomatous polyposis coli) gene in FAP (familial 
polyposis coli) patients and in sporadic colorectal tumors. Tohoku J Exp Med 
168(2):141-7. 
Nam JS, Turcotte TJ, Smith PF, Choi S, Yoon JK (2006). Mouse cristin!R-spondin 
family proteins are novel ligands for the Frizzled 8 and LRP6 receptors and activate beta-
catenin-dependent gene expression. J Bioi Chern 281:13247- 13257. 
Narod SA, Risch H, Moslehi R, D0rum A, Neuhausen S, Olsson H, Provencher D, 
Radice P, Evans G, Bishop S, Brunet JS, Ponder BA (1998). Oral contraceptives and the 
risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N 
Eng/ J Med 339(7):424-8. 
Narod SA, Sun P, Ghadirian P, Lynch H, Isaacs C, Garber J, Weber B, Karlan B, 
Fishman D, Rosen B, Tung N, Neuhausen SL. (2001). Tubal ligation and risk of ovarian 
cancer in carriers ofBRCA1 or BRCA2 mutations: a case-control study. Lancet. 
357(9267): 1467-70. 
Appendices Wells; page 138 
National Institutes of Health consensus conference (1995). Ovarian cancer (Screening, 
treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer). 
JAMA. 273:491-497. 
Ness RB, Cottreau C (1999). Possible role of ovarian epithelial inflammation inovarian 
cancer. J Nat/ Cancer lnst. 91(17): 1459-67. 
Ness RB, Grisso JA, Cottreau C, Klapper J, Vergona R, Wheeler JE, Morgan M, 
Schlesselman JJ. (2000). Factors related to inflammation of the ovarian epithelium and 
risk of ovarian cancer. Epidemiology 11(2): 111-7. 
Nhieu JT, Renard CA, Wei Y, Cherqui D, Zafrani ES, Buendia MA (1999). Nuclear 
accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with 
increased cell proliferation. Am. J Pathol. 155: 703-710. 
Niemann S, Zhao C, Pascu F, Stahl U, Aulepp U, Niswander L, Weber J, Miiller U 
(2004). Homozygous WNT3 mutation causes tetra-amelia in a large consanguineous 
family. Am. J Hum. Genet. 74: 558-563. 
Nishisho I, Nakamura Y, Miyoshi Y, Miki Y, Ando H, Horii A, Koyama K, Utsunomiya 
J, Baba S, Hedge P (1991 ). Mutations of chromosome 5q21 genes in F AP and colorectal 
cancer patients. Science 253(5020):665-9. 
Noordermeer, J., Klingensmith, J., Perrimon, N., and Nusse, R. (1994). disheveled and 
armadillo act in the wingless signaling pathway in Drosophila. 
Nustad K, Bast RC, Brien TJ, Nilsson 0, Seguin P, Suresh MR, Saga T, Nozawa S, 
B0rmer OP, de Bruijn HW, Nap M, Vitali A, Gadnell M, Clark J, Shigemasa K, Karlsson 
B, Kreutz FT, JetteD, Sakahara H, Endo K, PausE, Warren D, Hammarstrom S, 
Kenemans P, Hilgers J. (1996). Specificity and affinity of26 monoclonal antibodies 
against theCA 125 antigen: first report from the ISOBM TD-1 workshop (International 
Society for Oncodevelopmental Biology and Medicine). Tumour Bioi. 17:196-219 
O'Rahilly S, Wareham NJ (2006). Genetic variants and common diseases--better late 
than never. N Eng/ J Med 355(3):306-8. 
Oates NA, van Vliet J, Duffy DL, Kroes HY, Martin NG, Boomsma DI, Campbell M, 
Coulthard MG, Whitelaw E, Chong S (2006). Increased DNA methylation at the AXINl 
gene in a monozygotic twin from a pair discordant for a caudal duplication anomaly. Am. 
J Hum. Genet. 79: 155-162. 
Olsen CM, Green AC, Nagle CM, Jordan SJ, Whiteman DC, Bain CJ, Webb PM; on 
behalf of the Australian Cancer Study Group (Ovarian Cancer) and the Australian 
Ovarian Cancer Study Group (2008). Epithelial Ovarian Cancer: testing the 'androgens 
hypothesis'. Endocr Relat Cancer. 15(4):1061-1068. 
Appendices Wells; page 139 
Olsen CM, Green AC, Whiteman DC, Sadeghi S, Kolahdooz F, Webb PM (2007). 
Obesity and the risk of epithelial ovarian cancer: a systematic review and meta-analysis. 
EurJCancer. 43(4):690-709. 
Olsen CM, Nagle CM, Whiteman DC, Purdie DM, Green AC, Webb PM; Australian 
Cancer Study (Ovarian Cancer) and Australian Ovarian Cancer Study Group (2008). 
Body size and risk of epithelial ovarian and related cancers: a population-based case-
control study. Int J Cancer 123(2):450-6. 
Omura G, Blessing JA, Ehrlich CE, Miller A, Yordan E, Creasman WT, Homesley HD 
( 1986). A randomized trial of cyclophosphamide and doxorubicin with or without 
cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study. Cancer 
57(9): 1725-30. 
Oza AM, Elit L, Swenerton K, Faught W, Ghatage P, Carey M, Mcintosh L, Dorr A, 
Holmlund JT, Eisenhauer E; NCIC Clinical Trials Group Study (NCIC IND.116) (2003). 
Phase II study of COP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an 
NCIC clinical trials group study (NCIC IND.l16). Gynecol Oneal. 89(1):129-33. 
Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, LaPolla J, Hoffman 
M, Martino MA, Wakeley K, Wilbanks G, Nicosia S, Cantor A, Sutphen R. (2005). 
BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma 
cases. Cancer. 104(12):2807-16. 
PanSY, Ugnat AM, Mao Y. (2005). Physical activity and the risk of ovarian cancer: a 
case-control study in Canada. Int J Cancer 117:300-7. 
Parker, D. S., Hemison, J., and Cadigan, K. M. (2002). Pygopus, a nuclear PHD-finger 
protein required for Wingless signaling in Drosophila. Development 129: 2565-2576. 
Patel AV, Rodriguez C, Pavluck AL, Thun MJ, Calle EE. (2006). Recreational physical 
activity and sedentary behavior in relation to ovarian cancer risk in a large cohort of US 
women. Am J Epidemiol163:709-16. 
Peifer, M., and Polakis, P. (2000). Wnt signaling in oncogenesis and embryogenesis--a 
look outside the nucleus. Science 287: 1606-1609. 
Peltomaki P, Vasen HF (1997). Mutations predisposing to hereditary nonpolyposis 
colorectal cancer: Database and results of a collaborative study-The International 
Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology 
113: 1146-1158. 
Petitti DB, Porterfield D. (1992). Worldwide variations in the lifetime probability of 
reproductive cancer in women: implications of best-case, worst-case, and likely-case 
assumptions about the effect of oral contraceptive use. Contraception. 45(2):93-1 04. 
Appendices Wells; page 140 
Pharoah PD and Ponder BA (2002). The genetics of ovarian cancer. Best Pract Res C/in 
Obstet Gynaecol 16: 449--468. 
Phelan CM, Rebbeck TR, Weber BL, Devilee P, Ruttledge MH, Lynch HT, Lenoir GM, 
Stratton MR, Easton DF, Ponder BA, Cannon-Albright L, Larsson C, Goldgar DE, Narod 
SA (1996). Ovarian cancer risk in BRCAl carriers is modified by the HRAS1 variable 
number of tandem repeat (VNTR) locus. Nat Genet. 12(3):309-11. 
Piccart MJ; Bertelsen K; James K; Cassidy J; Mangioni C; Simonsen E; Stuart G; Kaye 
S; Vergote I; Blom R; Grimshaw R; Atkinson RJ; Swenerton KD; Trope C; Nardi M; 
Kaem J; Tumolo S; Timmers P; Roy JA; Lhoas F; Lindvall B; Bacon M; Birt A; 
Andersen JE; Zee B; Paul J; Baron B; Pecorelli S (2000). Randomized intergroup trial of 
cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced 
epithelial ovarian cancer: three-year results. J Nat/ Cancer Inst 92(9):699-708. 
Polakis, P. (2000). Wnt signaling & cancer. Genes Dev. 14: 1837-1851. 
Popadiuk CM, Xiong J, Wells MG, Andrews PG, Dankwa K, Hirasawa K, Lake BB, Kao 
KR (2006). Antisense suppression of pygopus2 results in growth arrest of epithelial 
ovarian cancer. C/in Cancer Res. 12(7 Pt 1):2216-23. 
Prentice RL; Thomson CA; Caan B; Hubbell FA; Anderson GL; Beresford SA; Pettinger 
M; Lane DS; Lessin L; Yasmeen S; Singh B; Khandekar J; Shikany JM; Satterfield S; 
Chlebowski RT (2007). Low-fat dietary pattern and cancer incidence in the Women's 
Health Initiative Dietary Modification Randomized Controlled Trial. J Nat/ Cancer Inst. 
99(20): 1534-43. 
Provencher, D. M., Lounis, H., Champoux, L., Tetrault, M., Manderson, E. N., Wang, J. 
C., Eydoux, P., Savoie, R., Tonin, P. N. (2000). Characterization of four novel epithelial 
ovarian cancer cell lines. In Vitro Cell Dev. Bioi. Anim. 36: 357-361. 
Purdie DM, Bain CJ, Siskind V, Webb PM, Green AC. (2003). Ovulation and risk of 
epithelial ovarian cancer. lnt J Cancer 104: 228-32. 
Qian CN, Knol J, Igarashi P, Lin F, Zylstra U, Teh BT, Williams BO (2005). Cystic 
renal neoplasia following conditional inactivation of ape in mouse renal tubular 
epithelium. J Bioi Chem. 280(5):3938-45. 
Qin M, Hayashi H, Oshima K, Tahira T, Hayashi K, Kondo H (2005). Complexity of the 
genotype-phenotype correlation in familial exudative vitreoretinopathy with mutations in 
the LRP5 and/or FZD4 genes. Hum Mutat 26:104-112 
Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van 't Veer L, Garber JE, Evans GR, 
Narod SA, Isaacs C, MatloffE, Daly MB, Olopade OI, Weber BL (2004). Bilateral 
prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation 
carriers: the PROSE Study Group. J Clin Onco/. 22(6):1055-62. 
Appendices Wells; page 141 
Risch, HA (1998). Hormonal etiology of epithelial ovarian cancer, with a hypothesis 
concerning the role of androgens and progesterone. J Nat/ Cancer Inst. 90(23): 1774-86. 
Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Fan I, Tang J, LiS, Zhang S, 
Shaw P A, Narod SA (2006). Population BRCA1 and BRCA2 mutation frequencies and 
cancer penetrances: a kin-cohort study in Ontario, Canada. J Nat/ Cancer Jnst. 98(23): 
1694-706. 
Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, Jack E, Vesprini DJ, 
Kuperstein G, Abrahamson JL, Fan I, Wong B, Narod SA. (2001). Prevalence and 
penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 
women with ovarian cancer. Am J Hum Genet. 68(3):700-1 0. 
Risch HA, Weiss NS, Lyon JL, Daling, JR, Liff, JM (1983). Events of reproductive life 
and the incidence of epithelial ovarian cancer. Am J Epidemio/117:128-39. 
Robitaille J, MacDonald MLE, Kaykas A, Sheldahl LC, Zeisler J, Dube MP, Zhang LH, 
Singaraja RR, Guernsey DL, Zheng B, Siebert LF, Hoskin-MottA, Trese MT, Pimstone 
SN, Shastry BS, Moon RT, Hayden MR, Goldberg YP & Samuels ME (2002). Mutant 
frizzled-4 disrupts retinal angiogenesis in familial exudative vitreoretinopathy. Nature 
Genet. 32: 326-330. 
Rodova, M., Islam, M. R., Maser, R. L., and Calvet, J.P. (2002). The Polycystic Kidney 
Disease-1 Promoter Is a Target of the P-Cateninff-cell Factor Pathway. J. Bioi. Chem. 
277: 29577-29583 
Rodriguez, C., Calle, E.E., Coates, R.J., Miracle-McMahill, H.L., Thun, M.J., Heath Jr., 
C.W. (1995). Estrogen replacement therapy and fatal ovarian cancer. Am J Epidemiol 
141: 828-835. 
Rodriguez C., Patel A.V., Calle E.E., Jacob E.J., Thun M.J. (2001). Estrogen 
replacement therapy and ovarian cancer mortality in a large prospective study of US 
women. JAMA 285: 1460-1465. 
Roh H, Green DW, BoswelJ CB, Pippin JA and Drebin JA (2001). Suppression ofbeta-
catenin inhibits the neoplastic growth of APC-mutant colon cancer cells. Cancer Res 61: 
6563-6568. 
Roman, LD, Muderspach, LI, Stein, SM, Laifer-Narin, S, Groshen, S, & Morrow, CP 
(1997). Pelvic examination, tumour marker level, and gray-scale and Doppler 
sonography in the prediction of pelvic. Obstet Gyneco/ 89: 493-500. 
Roose, J., Molenaar, M., Peterson, J., Hurenkamp, J., Brantjes, H., Moerer, P., van de 
Wetering, M., Destree, 0., and Clevers, H. (1998). The Xenopus Wnt effector XTcf-3 
interacts with Groucho-related transcriptional repressors. Nature 395: 608-612. 
Appendices Wells; page 142 
Rose PG, Blessing JA, Buller RE, Mannel RS, Webster KD (2003). Prolonged oral 
etoposide in recurrent or advanced non-squamous cell carcinoma of the cervix: a 
Gynecologic Oncology Group study. Gynecol Onco/. 89(2):267-70. 
Rosenblatt KA, Thomas DB. (1993). Lactation and the risk of epithelial ovarian cancer. 
The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Epidemiol 
22:192-7. 
Rubin SC, Blackwood MA, Bandera C, Behbakht K, Benjamin I, Rebbeck TR, Boyd J 
(1998). BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations 
in an unselected ovarian cancer population: relationship to family history and 
implications for genetic testing. Am J Obstet Gynecol 178( 4):670-7. 
Saadi-Kheddouci, S., Berrebi, D., Romagnolo, B., Cluzeaud, F., Peuchmaur, M., Kahn, 
A., Vandewalle, A., and Perret, C. (200 1 ). Early development of polycystic kidney 
disease in transgenic mice expressing an activated mutant of the P-catenin gene. 
Oncogene 20, 5972-5981 
Salazar-Martinez E; Lazcano-Ponce EC; Gonzalez Lira-Lira G; Escudero-De los Rios P; 
Hernandez-Avila M (2002). Nutritional determinants of epithelial ovarian cancer risk: a 
case-control study in Mexico. Oncology 63(2):151-7. 
Scarfone, G, Scambia, G, Raspagliesi, F, et al (2006). A multicenter, randomized, phase 
III study comparing paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in 
patients with stage III (residual tumor 2: 1 em after primary surgery) and IV ovarian 
cancer (abstract). J Clin Onco/ 24:256s. 
Schmeler KM, Lynch HT, Chen LM, Munsell MF, Soliman PT, Clark MB, Daniels MS, 
White KG, Boyd-Rogers SG, Conrad PG, Yang KY, Rubin MM, Sun CC, Slomovitz 
BM, Gershenson DM, Lu KH (2006). Prophylactic surgery to reduce the risk of 
gynecologic cancers in the Lynch syndrome. N Eng/ J Med 354(3):261-9. 
Schildkraut JM, Thompson WD (1988). Familial ovarian cancer: a population-based 
case-control study. Am J Epidemiol. 128(3):456-66. 
Schutter, EM, Sohn, C, Kristen, P, Mobus, V, Crombach, G, Kaufmann, M, Caffier, H, 
Kreienberg, R, Verstraeten, AA, & Kenemans, P (1998). Estimation of probability of 
malignancy using a logistic model combining physical examination, ultrasound, serum 
CA125, and serum CA-72-4 in postmenopausal women with a pelvic mass; an 
international multicenter study. Gyneco/ Onco/ 69: 56-63 
Schwartz PE (2008). What is the role of neoadjuvant chemotherapy in the management 
of ovarian cancer? Oncology (Williston Park) 22(10):1118-25. 
See HT, Kavanagh JJ (2004). Novel agents in epithelial ovarian cancer. Cancer Invest. 
22 Suppl 2:29-44. 
Appendices Wells; page 143 
See HT, Kavanagh JJ, Hu W, Bast RC (2003). Targeted therapy for epithelial ovarian 
cancer: current status and future prospects. Int J Gynecol Cancer 13:701- 34. 
Sekiya T, Nakamura T, Kazuki Y, et al (2002). Overexpression of I cat induces G(2) 
arrest and cell death in tumor cell mutants for adenomatous polyposis coli, beta-catenin, 
or axin. Cancer Res 62: 3322-3326. 
Serov SF, Scully RE, Sobin IH ( 1973 ). International histological classification of tumors 
no. 9. histological typing of ovarian tumours. Geneva: World Health Organization. 
Shadforth I, Crowther D, Bessant C (2005). Protein and peptide identification algorithms 
using MS for use in high-throughput, automated pipelines. Proteomics 5(16): 4082- 95. 
Sheldahl LC, Park M, Malbon CC, and Moon RT (1999). Protein kinase Cis 
differentially stimulated by Wnt and Frizzled homologs in a G-protein-dependent 
manner. Curr. Bioi. 9:695-98. 
Shtutman, M., Zhurinsky, J., Simcha, I., Albanese, C., D'Amico, M., Pestell, R., Ben-
Ze'ev, A. (1999). The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. 
Proc Nat/ Acad Sci US A. 96: 5522-5527. 
Shu XO; Brinton LA; Gao YT; Yuan JM (1989). Population-based case-control study of 
ovarian cancer in Shanghai. Cancer Res 49(13):3670-4. 
Skates SJ, Menon U, MacDonald N, Rosenthal A, Orarn D, Knapp R, Jacobs I (2003). 
Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical 
detection in postmenopausal women. J Clin Oncol. 21:206s- 210s 
Skilling JS, Squatrito RC, Connor JP, Niemann T, Buller RE (1996). p53 gene mutation 
analysis and antisense-mediated growth inhibition of human ovarian carcinoma cell lines. 
Gynecol Oncol 60:72- 80. 
Slusarski DC, Yang-Snyder J, Busa WB, and Moon RT (1997). Modulation of 
embryonic intracellular Ca2+ signaling by Wnt-5A. Dev. Bioi. 182:114-120. 
Smalley, M. J., Sara, E., Paterson, H., Naylor, S., Cook, D., Jayatilake, H., Fryer, L. G., 
Hutchinson, L., Fry, M. J., and Dale, T. C. (1999). Interaction of axing and Dvl-2 
proteins regulates Dvl-2-stimulated TCF-dependent transcription. EMBO J. 18: 2823-
2835. 
Song N, Schwab KR, Patterson LT, Yamaguchi T, Lin X, Potter SS, Lang RA (2007). 
pygopus 2 has a crucial, Wnt pathway-independent function in lens induction. 
Development. 134(10):1873-85. 
Appendices Wells; page 144 
Stadeli R, Basler K (2005). Dissecting nuclear Wingless signalling: recruitment of the 
transcriptional co-activator Pygopus by a chain of adaptor proteins. Mech Dev. 
122(11):1171-82. 
Stark K, Vainio S, Vassileva G, McMahon AP (1994). Epithelial transformation of 
metanephric mesenchyme in the developing kidney regulated by Wnt-4. Nature 
372:679-683. 
Steevens J; Schouten LJ; Verhage BA; Goldbohm RA; van den Brandt PA (2007). Tea 
and coffee drinking and ovarian cancer risk: results from the Netherlands Cohort Study 
and a meta-analysis. Br J Cancer. 97(9):1291-4. 
Stein KF, Rudin lA (1953). Development of mice homozygous for the gene for Looptail. 
J Hered 44:59-69. 
Strandoskow HH (1939). Inheritance of absence of thumbnails. J Hered 30:53-54. 
Stratton JF, Gayther SA, Russell P, Dearden J, Gore M, Blake P, eta/. (1997). 
Contribution of BRCAJ mutations to ovarian cancer. N Eng/ J Med 336:1125-30. 
Stratton, J.F., Pharoah, P., Smith, S.K., Easton, D., Ponder, B.A.J. (1998). A systematic 
review and meta-analysis of family history and risk of ovarian cancer. Br J Obstet 
Gynaeco/105: 493-499. 
Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, 
Roses AD (1993). Apolipoprotein E: high-avidity binding to beta-amyloid and increased 
frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Nat/ Acad Sci 
USA 90: 1977- 1981. 
Struewing JP, Abeliovich D, Peretz T, Avishai N, Kaback MM, Collins FS, Brody LC 
(1995). The carrier frequency of the BRCA1 185delAG mutation is approximately 1 
percent in Ashkenazi Jewish individuals. Nat Genet. 11(2): 198-200. 
Strutt D. (2003). Frizzled signaling and cell polarisation in Drosophila and vertebrates. 
Development 130:4501- 13 
Su F, Lang J, Kumar A eta/. (2007). Validation of candidate serum ovarian cancer 
biomarkers for early detection. Biomark Insights 269- 375. 
Surendran, K. & Simon, T. C. (2003). CNP gene expression is activated by Wnt 
signaling and correlates with Wnt4 expression during renal injury. Am. J. Physiol. Renal 
Physiol. 284: F653- F562. 
Sun, Y., Kolligs, F. T., Hottiger, M. 0., Mosavin, R., Fearon, E. R., and Nabel, G. J. 
(2000). Regulation of J3-catenin transformation by the p300 transcriptional coactivator. 
Proc. Nat/. Acad Sci. USA 97: 12613-12618. 
Appendices Wells; page 145 
Takahashi H, Behbakht K, McGovern PE, Chiu H-C, Couch FJ, Weber BL, et al. (1995). 
Mutation analysis of the BRCAJ gene in ovarian cancers. Cancer Res 55:2998-3002. 
Takahashi H, Chiu H-C, Bandera CA, Behbakht K, Liu PC, Couch FJ, et al. (1996). 
Mutations of the BRCA2 gene in ovarian carcinomas. Cancer Res 56:2738--41. 
Takemaru, K. I. And Moon, R. T. (2000). The transcriptional coactivator CBP interacts 
with f3-catenin to activate gene expression. J Cell Bioi. 149: 249-254. 
Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, Joenje H, Mok 
SC, D'Andrea AD (2003). Disruption of the Fanconi anemia-BRCA pathway in 
cisplatin-sensitive ovarian tumors. Nat Med. 9(5):568-74. 
Tavani A, Gallus S, LaVecchia C, et al. (2001). Physical activity and risk of ovarian 
cancer: an Italian case-control study. Int J Cancer 91:407-11. 
Taylor J, Abramova N, Charlton J, Adler PN (1998). Van Gogh: a new Drosophila tissue 
polarity gene. Genetics 150:199-210. 
Terada Y, Tanaka H, Okado T, Shimamura H, Inoshita S, Kuwahara M, Sasaki S (2003). 
Expression and function of the developmental gene Wnt-4 during experimental acute 
renal failure in rats. JAm. Soc. Nephrol. 14: 1223-1233. 
Terris B, Pineau P, Bregeaud L, Valla D, Belghiti J, Tiollais P, Degott C, Dejean A 
(1999). Close correlation between beta-catenin gene alterations and nuclear 
accumulation of the protein in human hepatocellular carcinomas. Oncogene 18: 6583-
6588. 
Tetsu, 0. and McCormick, F. (1999). f3-catenin regulates expression ofcyclin D1 in 
colon carcinoma cells. Nature 398: 422-426. 
Thigpen JT; Blessing JA; Ball H; Hummel SJ; Barrett RJ (1994). Phase II trial of 
paclitaxel in patients with progressive ovarian carcinoma after platinum-based 
chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol 12(9): 1748-53. 
Thompson, B. (2004). A complex of armadillo, legless, and pygopus coactivates dTCF 
to activate wingless target genes. Curr. Bioi. 14: 458-466. 
Thompson, B., Townsley, F., Rosin-Arbesfeld, R., Musisi, H., & Nienz, M. (2002). A 
new nuclear component of the Wnt signaling pathway. Nature Cell Bioi. 4: 367-373. 
Thibodeau SN, Bren G, and Schaid D (1993). Microsatellite instability in cancer of the 
proximal colon. Science 260: 816-819. 
Appendices Wells; page 146 
Toomes C, Bottomley HM, Jackson RM, Towns KV, ScottS, Mackey DA, Craig JE, 
Jiang L, Yang ZL, Trembath R, WoodruffG, Gregory-Evans CY, Gregory-Evans K, 
Parker MJ, Black GCM, Downey LM, Zhang K, Ingleheam CF (2004). Mutations in 
LRP5 or FZD4 underlie the common familial exudative vitreoretinopathy locus on 
chromosome 11q. Am. J Hum. Genet. 74: 721-730. 
Torban E, Kor C, Gros P (2004). Van Gogh-like 2 (Strabismus) and its role in planar cell 
polarity and convergent extension in vertebrates. Trends Genet 20:570-577. 
Tserkezoglou, A, Kontou, S, Hadjieleftheriou, G, Apostolikas, N, Vassilomanolakis, M, 
Sikiotis, K, Salamalekis, E, Tseke, P, and Magiakos, G (2006). Primary and metatstatic 
ovarian cancer in patients with prior breast carcinoma. Pre-operative markers and 
treatment results. Anticancer Res 26: 2339-2344. 
Tung K-H, Wilkens LR, Wu AH, et al. (2005). Effect of anovulation factors on pre- and 
postmenopausal ovarian cancer risk: revisiting the incessant ovulation hypothesis. Am J 
Epidemio/161: 321-9. 
Tworoger SS, Fairfield KM, Colditz GA, Rosner BA, Hankinson SE. (2007). 
Association of oral contraceptive use, other contraceptive methods, and infertility with 
ovarian cancer risk. Am J Epidemiol. 166(8):894-901. 
Tworoger SS; Gertig DM; Gates MA; Hecht JL; Hankinson SE (2008). Caffeine, 
alcohol, smoking, and the risk of incident epithelial ovarian cancer. Cancer 112(5): 
1169-77. 
Tworoger SS; Hecht JL; Giovannucci E; Hankinson SE (2006). Intake of folate and 
related nutrients in relation to risk of epithelial ovarian cancer. Am J Epidemiol. 
163(12):1101-11. 
Uematsu K, He BA, You L, Xu ZD, McCormick F, Jablons DM (2003). Activation of 
the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression. 
Oncogene 22, 7218-7221 (2003). 
Ugur SA, Tolun A (2008). Homozygous WNTJOb mutation and complex inheritance in 
Split-Hand/Foot Malformation. Hum Mol Genet. 17(17):2644-53. 
Vainio, H, Bianchini, F (Eds) (2003). !ARC Working Group on the Evaluation of 
Cancer-Preventive Strategies. IARC Handbook of Cancer Prevention: Fruit and 
vegetables, vol8. !ARC Press, Lyon. 
Vainio S, Heikkila M, Kispert A, ChinN, McMahon AP (1999). Female development in 
mammals is regulated by Wnt4 signalling. Nature 397:405-409. 
Appendices Wells; page 14 7 
Vainio, S. J., and Uusitalo, M.S. (2000). A road to kidney tubules via the Wnt pathway. 
Pediatr. Nephrol. 15: 151-156 
Van de Wetering, M., de Lau, W., and Clevers, H. (2002). WNT signaling and 
lymphocyte development. Cell 109: Sl3-S19. 
van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A, van der Hom 
K, Batlle E, Coudreuse D, Haramis AP, Tion-Pon-Fong M, Moerer P, van den Born M, 
Soete G, Pals S, Eilers M, Medema R, Clevers H (2002). The f3-catenin/TCF-4 complex 
imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 111: 241-250. 
Van Gorp T, Amant F, Neven P, Vergote I, Moerman P. (2004). Endometriosis and the 
development of malignant tumours of the pelvis. A review of literature. Best Pract Res 
Clin Obstet Gynaecol. 18(2):349-71. 
van Noort, M. and Clevers, H. (2002). TCF transcription factors, mediators of Wnt 
signaling in development and cancer. Dev. Bioi. 244: 1-8. 
Van Wesenbeeck L, Cleiren E, Gram J, Beals RK, Benichou 0, Scopelliti D, Key L, 
Renton T, Bartels C, Gong Y, Warman ML, de Vemejoul M-C, Bollerslev J, Van Hul W 
(2003). Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene 
in different conditions with an increased bone density. Am J Hum Genet 72:763-771 
Vasicek TJ, Zeng L, Guan X-J, Zhang T, Costantini F, Tilghman SM (1997). Two 
dominant mutations in the mouse fused gene are the result of transposon insertions. 
Genetics 147: 777-786. 
Veeman, M., Axelrod, J., and Moon, R. (2003). A second canon: functions and 
mechanisms of f3-catenin-independent Wnt signaling. Dev. Cell 5: 367-377 
Veeman MT, Slusarski DC, Kaykas A, Louie SH, Moon RT. (2003). Zebrafish prickle, a 
modulator of noncanonical Wnt/Fz signaling, regulates gastrulation movements. Curr. 
Bioi. 13:680--85 
Verma UN, Surabhi RM, Schmaltieg A, Becerra C and Gaynor RB (2003). Small 
interfering RNAs directed against betacatenin inhibit the in vitro and in vivo growth of 
colon cancer cells. Clin Cancer Res 9: 1291-1300. 
Visintin I, Feng Z, Longton G, Ward D, Alvero A, Lai Y, Tenthorey Y, Leiser A, Flores-
Saaib R, YuH, Azori M, Rutherford T, Schwartz P and Mor G (2008). Diagnostic 
markers for early detection of ovarian cancer. Clin Cancer Res 14: 1065-1072. 
Wang Y, Guo N, Nathans J (2006). The role ofFrizzled3 and Frizzled6 in neural tube 
closure and in the planar polarity of inner-ear sensory hair cells. J Neurosci 26:2147-
2156. 
Appendices Wells; page 148 
Wang Y, Saad M, Pakunlu RI, Khandare JJ, Garbuzenko OB, Vetcher AA, Soldatenkov 
VA, Pozharov VP, Minko T (2008). Nonviral nanoscale-based delivery of antisense 
oligonucleotides targeted to hypoxia-inducible factor 1 alpha enhances the efficacy of 
chemotherapy in drug-resistant tumor. Clin Cancer Res. 14(11):3607-16. 
Wang X, Sutton VR, Peraza-Llanes JO, Yu Z, Rosetta R, Kou Y-C, Eble TN, Patel A, 
Thaller C, Fang P, Van den Veyver IB (2007). Mutations in X-linked PORCN, a putative 
regulator of Wnt signaling, cause focal dermal hypoplasia. Nature Genet. 39: 836-838. 
Warwick Daw E, Payami H, Nemens EJ, Nochlin D, Bird TD, Schellenberg GD, 
Wijsman EM (2000). The number of trait loci in late-onset Alzheimer disease. Am J 
Hum Genet 66:196-204. 
Watson P, Riley B (2005). The tumor spectrum in the Lynch syndrome. Fam Cancer 
4(3):245-8. 
Watson P, Vasen HF, Mecklin JP, Bernstein I, Aarnio M, Jarvinen HJ, Myrlwj T, Sunde 
L, Wijnen JT, Lynch HT (2008). The risk of extra-colonic, extra-endometrial cancer in 
the Lynch syndrome. Int J Cancer 123(2):444-9. 
Weeraratna AT, Jiang YA, Hostetter G, Rosenblatt K, Duray P, Bittner M, Trent JM 
(2002). Wnt5a signaling directly affects cell motility and invasion of metastatic 
melanoma. Cancer Cell 1: 279-288. 
Wehner, AP (1994). Biological effects of cosmetic talc. Food Chern Toxico/32: 1173-
1184. 
Weiderpass E, Margolis KL, Sandin S, et al. (2006). Prospective study of physical 
activity in different periods of life and the risk of ovarian cancer. Int J Cancer 118: 
3153-60. 
West RJ, Zweig SF (1997). Meta-analysis of chemotherapy regimens for ovarian 
carcinoma: a reassessment of cisplatin, cyclophosphamide and doxorubicin versus 
cisplatin and cyclophosphamide. Eur J Gynaecol Oncol. 18(5):343-8. 
Whittemore, AS (1994). Characteristics Relating to Ovarian Cancer Risk: Implications 
for Prevention and Detection. Gyn One 55(3): S 15-S 19 
Whittemore AS, Harris R, Itnyre J. (1992). Characteristics relating to ovarian cancer 
risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian 
cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol. 
136(10):1184-203. 
Wilson, PD (2004 ). Polycystic Kidney Disease N Engl. J. Me d. 350, 151-164 
The Wnt Gene Hompage. Website: http://www.stanford.edu/- musse/wntwindow.html 
Appendices Wells; page 149 
Wodarz, A. & Nusse, R. (1998). Mechanisms ofWnt signaling in development. Cell 
Dev. Bioi. 14: 59-88. 
WolffT, Rubin GM (1998). Strabismus, a novel gene that regulates tissue polarity and 
cell fate decisions in Drosophila. Development 125:1149-1159. 
Woods CG, Stricker S, Seemann P, Stem R, Cox J, Sherridan E, Roberts E, Springell K, 
Scott S, Karbani G, Sharif SM, Toomes C, Bond J, Kumar D, Al-Gazali L, Mundlos S 
(2006). Mutations in WNT7 A cause a range of limb malformations, including Fuhrmann 
syndrome and Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome. Am. J. Hum. 
Genet. 79: 402-408. 
Wright KJ, Tjian R (2009). Wnt signaling targets ETO coactivation domain of 
TAF4/TFIID in vivo. Proc Nat/ Acad Sci US A. 106(1):55-60. 
Wu, R., Zhai, Y., Fearon, E. and Cho, K. (2001). Diverse mechanisms of ~-catenin 
deregulation in ovarian endometrioid adenocarcinomas. Cancer Res. 61: 8247-8255. 
www.seer.cancer.gov accessed September 23,2008 
www.stanford.edu/~musse/diseases/Humangeneticdis.htm accesed December 21, 2008 
Xu G, Zhou H, Wang Q, Auersperg N, Peng C (2006). Activin receptor-like kinase 7 
induces apoptosis through up-regulation ofBax and down-regulation ofXiap in normal 
and malignant ovarian epithelial cell lines. Mol Cancer Res. 4(4):235-46. 
Xu W, Cai B, Chen JL, Li LX, Zhang JR, Sun YY, Wan XP (2008). ATP7B antisense 
oligodeoxynucleotides increase the cisplatin sensitivity of human ovarian cancer cell line 
SKOV3ipl. Int J Gynecol Cancer. 18(4):718-22. 
Xu Q, Wang Y, Dabdoub A, Smallwood PM, Williams J, Woods C, Kelley MW, Jiang L, 
Tasman W, Zhang K, Nathans J (2004).Vascular development in the retina and inner ear: 
control by Norrin and Frizzled-4, a high-affinity ligand-receptor pair. Cell. 116(6):883-
95. 
Yanagawa, S., van Leeuwen, F., Wodarz, A., Klingensmith, J., and Nusse, R. (1995). 
The disheveled protein is modified by wingless signaling in Drosophila. Genes Dev. 9: 
1087-1097. 
Yang Y (2003). Wnts and wing: Wnt signaling in vertebrate limb development and 
musculoskeletal morphogenesis. Birth Def ects Res. C. Embryo. Today 69:305- 317. 
Yen TJ, Li G, Schaar BT, Szilak I & Cleveland D (1992). CENP-E is a putative 
kinetochore motor that accumulates just before mitosis. Nature 359 (6395): 53~9 
Appendices Wells; page 150 
Yen TJ, Compton DA, WiseD, et al. (1991). CENP-E, a novel human centromere-
associated protein required for progression from metaphase to anaphase. EMBO J 10 
(5): 1245-54. 
Young RC (1975). Chemotherapy of ovarian cancer: past and present. Semin Oncol 2: 
267. 
Young RC, Decker DG, Wharton JT, Piver MS, Sindelar WF, Edwards BK, Smith JP 
(1983). Staging laparotomy in early ovarian cancer. JAMA. 250(22):3072-6. 
Young RC, Walton LA, Ellenberg SS, Homesley HD, Wilbanks GD, Decker DG, Miller 
A, Park R, Major F Jr. (1990). Adjuvant therapy in stage I and stage II epithelial ovarian 
cancer. Results of two prospective randomized trials. N Eng! J Med. 322(15):1021-7. 
Yuan B, Mi R (2002). [Antisense oligodeoxynucleotides of human telomerse catalytic 
sub-unit inhibits telomerase activity and proliferation in SKOV3 and COC1]. Zhonghua 
Fu Chan Ke Za Zhi 37:198-201 
Yuen AR, Halsey J, Fisher GA, Holmlund JT, Geary RS, Kwoh TJ, Dorr A, Sikic BI 
(1999). Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 
3521/CGP 64128A) in patients with cancer. Clin Cancer Res. 5(11):3357-63. 
Zeng L, Fagotto F, Zhang T, Hsu W, Vasicek TJ, Perry WL III, Lee JJ, Tilghman SM, 
Gumbiner BM, Costantini F (1997). The mouse fused locus encodes axin, an inhibitor of 
the Wnt signaling pathway that regulates embryonic axis formation. Cell 90: 181-192. 
Zhang Z, Bast RC Jr, Yu Y, Li J, Sokoll L, Rai A, Rosenzweig J, Cameron B, Wang Y, 
Meng X, Berchuck A, van Haaften-Day C, Hacker N, de Bruijn H, van der Zee A, Jacobs 
I, Fung E and ChanD (2004). Three biomarkers identified from serum proteomic 
analysis for the detection of early stage ovarian cancer. Cancer Res 64: 5882-5890. 
Zhang M, Xie X, Lee AH, Binns CW. (2004). Sedentary behaviours and epithelial 
ovarian cancer risk. Cancer Causes Contro/15:83- 9. 
Zhang M; Yang ZY; Binns CW; Lee AH (2002). Diet and ovarian cancer risk: a case-
control study in China. Br J Cancer 86(5):712-7. 
Zhu, X., Kanai, Y., Saito, A., Kondo, Y., and Hirohashi, S. (2000). Aberrant expression 
of ~-catenin and mutation of ex on 3 of the ~-catenin gene in renal and urothelial 
carcinomas. Pathol. Int. 50: 945-952 
Zirbel GM, Ruttum MS, Post AC, Esterly NB (1995). Odonto-onycho-dermal dysplasia. 
Brit. J Derm. 133: 797-800. 




